var title_f25_44_26304="Ultrasound partial mole";
var content_f25_44_26304=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F52538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F52538&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Partial molar pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 200px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Transabdominal image at 15 weeks gestational age show (A) a heterogeneous placenta with multiple cysts and (B) a live fetus. Findings are compatible with partial molar pregnancy.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Deborah Levine, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26304=[""].join("\n");
var outline_f25_44_26304=null;
var title_f25_44_26305="Congenital emphysema right";
var content_f25_44_26305=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F70967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F70967&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Newborn with congenital lobar emphysema, right upper lobe",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 316px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAE8AWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwDu5p/MgkVAu/HHfjvT7R08lY2QqwGOnf3qeazj85xuVVI6jr+NZ920UYKpIFOM8kYOKANQJGUwz4I6YPNRX0QmiV42+ZTisu0u45WRZsA4wTjr7VppNHMrxrJ0HBBoAxdQiVyQjKQBkA8Vwl3bNa3hfZtZ+SSOn0r0WbTchmDls+p6GsPxPorS23mQlllzg4oA5qNcSpgEjOSRU6xZZyQcgnke/aoYbWeCIg855IHp61JGJFmwu4nIJx+lADdiKBkZfPOOgFWIUVcM6hsDg9x6AmicNsYebvJPJJ6mi3RixjZhJjkknhTmgCeJIyu5QHZjhmHb2qe3i3zgoXX6N19qZDE3m8YUPnK44OK0IyVOI8Nt7heB9fpQBEs0wmLIz7f4fw71DcTTO4KuzKScEmtCGxmmZn3Fc5yG71R1txCvlR5LBdxYnGPagChd6i1mjruyQvBODg1if8JRKkhVlGB0PSqepzO5AIJ45YisWZBsJAOTyvNAHoGk66JFBO0swzyfb9K6PT9UlkRQGUjH3GP8q8Thu57aZtgYZ4NbGm6zdQ3COmWK9FoA9fM5mjIcYOMjI71zt1aI6M3JbOD2NR6XrH2m2L3KlWI+6RxmpfPErFmYFc8be1AGfb2Czje7SKi54A/Wlm0hSocS7RweoHHpitdS4iZcqWwMDHJ56GnRxlSXiQbgQwA7H8aAMRdHXyFS4fccZGOcA0+20URfdLYHJHT8K3EtT5WCWbjofX/CnwwOu8NjaB1/woALQRR/KikEHGCc54/StSK8HKElkAAIVcYNYpniEwEQ3Nkru24AapkWR2Tg7SeBjk/0oAt3N5L5aiKMBVPIJ5JHaqtxO+5T5Zz0AznHtTkkJj3uAnG5QTkDtTJP3sRYuc7htZTyaAIMSuuEQAY+ZuhBppu4Y5FG8M3IPGcY/nT54g8ZZQCkYIXcenFVUs3ijDZwzdRg96ALi30RkbCuxIByvH50+TVxGxEVvg/3t2R9PrVU2SbXwrbuu8c/lUEyq3Ct0HKgY78f40AWm1e+u1WG34YHgLx+BNReW0o+d3aXO1gx5X8frTLdQhDtCXByFycfjxzUrBS2Y1kMZ6EA5BoAopAXYYbLE9VHP/6uKJIgSHJ4J5Oc4z/Wrs0WxhGqLxxkHPvzUUsYPmByPlwoz0X3460AV2h3IVRRjoWIPAqK+txx+8BVMc5Aq3HC52AZYE5BDfp9KDBh5BtATaSec5oA5+e2UxFnJCEcEj/D1qxZ6aWXe2GKjO1RwPYirnkPKxURsCOQSv8AOtsQvHwY8HbuLKM4+tAHNX9qsFkQCwkPHpk+lX7OwCrFC5VCEABB6j196dqMCmaOOQblJB5zz71tTwyQ20QUHbtAUgdB2oA5/UbGO3mZY0Lx+gGDmorHSmv23BH8tCMY4yPTmt+7ia8uY1beUfGZMZGBzW5baXkMONmcZzkmgDKstPEKOfLQQkHKg4JFFdB9hQExqTkAAlhjH4d6KANe+RDC+wBSQc8ZAI9K4a4JF8Rw5xld3X25rs9WuVEUgXYBgj6Vyk/lRyZcjkHLY+7mgBrFhIm1F46YPfvW1pLNLMoYKRjGSOlYtqiyIIlIYDBBzwR3INbVqPKi3xY7EDvQBp3sSb93kja3UYxzWVdaeJ7ZlZmUA/LxkmtuBhcqplOAR1xn8KmltQsbtIfnHT/doA8xFkiXEsfDAn5SSRmqLWbRS7hE2Rk5ycYruL7TDJI0gXKY+TB6e9VP7ILK+3LMRgk0AcfHbox+fnfz05qeOCJQSVyCMcdPrW1JZvCxbYCwPTGOe2KghRom3yxK6ZOc+v4UASaPZfaXQKpKAk7t3GK6+w0iILgIcKPTr71H4ZW3jZ9wVD2GAAK6N9QjFsRI0SZGCFIGRQBzmpi3sIWUAtJ6d68713UWkxIsTLgbTk10HjDWLQO2xtxGSNp5/GvKtY1yIs3z4brg9aAG3+poJSrKd3t6VVkmjlACnaxOeDXOajqqrK20kn8j0pttdlow2dvNAHQsIkGWYH8cmtLSzCZvkyrbePUmuWt5g4MhcEjjB61q2z4CgcALkEdaAO2tLxILWQSKj7jkFc/Sla4SSAPbSLG+MkY61hwsxgAbAX7xz9KqQ3EqXChXO1jkjHCjtQBstqlwMhdwP972rSi1KXZgyEc4JzgAnvUUZhkszwpZu5XORUoaBYQjJEMEtux0HagDSt7q4dMKWIB+Vs9akvPtbyKfO2rnAAz0+lQ6dOsKIqKGQnnIzWta3aSSKrhAM8EjoelADrGwQFHmbMueNv8AFn+tbYWJWQKDtAwUHU+vNVo0QkPkknpx+tG828LL8zNknnt9aAM66tYTI7o3zE/czx649qggIDCTONoGQemPSnysWZ1V0YkDJxx9KpODEWLbUOeM9fyoAuyGN4WI5DHAIHOKVfKETN5i7TnbsPI9yaoLE6hfNZgFzlOc/lTHkgjjWVRIfmIGVzn2xQBtQiIqWL4yu1Rnn8atfY4pAXUAoTyp57VzK3QZ0Hl7ACeNx/Wun0e4bKLIysvOcjrQBTbTHwvlDMuPuDgEemajVfKZ4pkMZX5SPvV3UOn/AGiESrgIfmAxzisDXNPVoWZAPMBwR0zQBzigISgU5JwB2x/WqqsFaYhlUHAyw9DxV65wpVB8pXB9ce2f6VVnGciJg+TzuG2gB+nKszqdp2k7dvYfjXXvpEP2IOyrkdxXPaVH5USmTiUEnluDW5Fcy3TCBeARzQBnw2CyKwJ++cAYzwKkktPLJJRgAMDJyDW/FYCBC2wgMB05/CoZ498bM2Ylx1znHFAHF3LxGaITjYEbgEZyf8D6Vca9V7Vlk4BGVI5rmrwzXGpXDybAFxtbYeB24q6VZoV+ZiqgDk4yfpQBracZJHABxnjAPA+ldjpqqEB3BHA2cDNcbaSKksQ3neg+UA8DjvXV2kp+zxkHLHgnOSRQBpTxgIXyhP8AFjGT9KKhLRIiggktjg+lFAGBe3TTMyBQcHqBk5rJurdnSV9jHPGQOnvXVNf2KYYNGq+u0GqEusWqAmRS3ByQOn1oAoaXYyfIyxODj5Qe9awgdxs2OoI4wOpq3Z6vCDGYg+Bg7iKuwapGGLFjsHA45Hf8KAF0+ExWybgSc9GFFyxKtllLDjdnr71pwXkLwsJCVGeR1NUtWeGSI7MDODkc49qAMiNRIr5Y7c5AAzSpN9nI8sZGcsMfzqNQcFNxGDyuakZzg7OjnrQBV1CL7RhoowS3f1qoNLZi2/5OcYzzXUW9oGsA54z0zxXO61fCzjlLHA5BCjr7UAU5nt7OBy0hdk4OBk4rA1vWJYLVwgCFlzljjisLUPEEsMrtDbqsRBJyx/P3rjdU8S3lwssUgXyyMEkZAHtQBW1/W53LlcuW5yRXEzXUrEEg596TVLy8jlZPNJHI4PGK56a6uC3+tY+nPFAG01wXcF0LfzrVsGVoyXGFxgZrj/tsyNknP1rW07U2EQU7SKAOtsraNvlWUjd3IyK2EtGj2oXLbTj61zuiX0fmKGYhhzye1b6anCl4WRSy8YJ7E0AdTYaS7xBGyz4yFHbiue1ffb3WxkZdpwVPH4mukj1JvLDQ5PGQyjpWdqk/2qPfLhnfPNAF3Sb2Oa1EZdS+fyNWxEEZgcMzdye3pXDWK7NROxmQHpj0rYMs8QCu7Hn5SRz/APqoA622URKS5yVGSCORz296kS7DFTHkMpyFA65rn4JZQ2N0nP3gf5Ves3PnAysVUc8UAd3pEskybVG5duSfT860RBvgLZPqwXuKwNLvFW3CBhtBzVtNSWCB5CrbcZU9uvagCSW1V1bcyKwO4DPOaih09PODHcf9oZIPtVqwu7e4VmLgHOOo/OpLmVYsjcoQHkg0AZN7BGsztGSx56dvqR3qmbaLYqnDM2CGByQP6VPeXCB9zP8Au884Pynvmq39oJ+8OyMrnoep/L2oARIFLltuB3Yk4ArW08yhiN6ORjO3oaxjqDIztJChTPJHH0GKu2epLGjEQ4ABIYUAd3puoK6bJJsbDg54zVbXZBMiLEplc9l4ArlbfVojKRIhHfrwK0LXXbbzCok4Y/xDGTQBXurSRZcFQVJ54OGOPWq2xVjxt3N1APP5CusiiS6iJRgwJ52ngGnvpUTuNqMu3j/EUAc9bJIW2p949OOPT8K6zSLE24jeRMvIBwOo9qpxacbOYM5JHUEdvrW1AwKZDFmAyCfegCxdR+bGEChVU8YPSsHxEnk+TCWyCcsh7j2NdBDlXAwdu0fMPX3rL1+JJrgswBHGOcbfegDhr2y89XWNE+9nr7+n0qnHCjSShwQVHP4V0bW6rLINwI/vgkdazriFIrhlC5BA4PHPrQAlvGEV9uMkYUsMkD6VdspXiMURcEk9R3psBywEhJAGd2MYpZU+4GC4xuHYkA+1ADry7YgMrsozgKOMmiq9wCg3BQFHfr+QooAznMmwZHHucce3rTEdGjYypnb0xx35J9aSRzJAP3Xy9ST2qWPYLbey4ZRgjPB9/agC9YyGVQjAEHjbngf/AFq3LfLOkZJWPs2M8VhaYYw27IB6Ent6c1uRSFkKnO5sdsfhQBdX5Ff77J1BOBUMzyPgbTleevT8aRjnIYdO4yR9KViWXK4UE4IoAlgt5JYlC4AJzn3q3FaIhXf35HFWNLQfZRuHzk/dxk8VQu5ZYJSz5OclRmgCfVbyOK0wG2gds8mvLvFd5IZd8jEoVwoNO8V6veQXhjWRnY/MQvauD1K+1DYPOferHPJoAq+ILs/Z1WIkRk885zXI6hdKI2wOf61c1d55kOJMbcjGc4FYNxatIq7peOhOaAKk7LIrHgnsKxbmMBWIxuz0HGBW61nHFGUMpJPpVOS1t1Zicq3qe9AGIA2SvPPXirlsPn3djzzxV6OytiR85Dfwn3q3Y6YWl+c9DnGKAG2kjRyKcDp3railIIP45HNMh0licopKZx1rXtbKJEVCjFj7UAbuiXReyMbhvLIzxU10YhFG5+UDgjvU/h7RmuV4YrHkZB/UCp/FOkT2ka+WAwJwnoaAMdGRb2JlUFOwz1P+NddK1u+JGVWDAY9fpXmxnmSVwyFccFa7PQbhb23jDoXZOD7elAHTA7ANmNrDJbqSe9Rv9nJVZUXcTgcfe9zTy7xrjywrGo7ZWFyskwBycqBzmgDXgidInYDOAfmJA6dsetULydmicEj5QSoHUe9dIllG1irvgYPAY1h6jYBY2JYyEHJBHagDLivpUjV1kIIHAx1z3qY69KuIpUyRzkcEfhUP2ONYS67mZeuDyKzLixUq2QQT3JoA2jeQSxHzcZfkZPJ/GnKkUkLGM8E8Bjg/hWLDAqwqWBJHRvbv/StSyKfIEYiRySSemP6UAXGgJ8lOSDnj/GpSqxBWVQvzYIBzx/Sr1vEh8mPdIqkZwerA9x7U+40wbQIpeB13dcUAY4DK7bypLEY2gce2aRYWZizbTgkAbQccVa+xyiYgMDt557fhStFLA2doZyc/KetAF7S4ZlTEMxAxgFW6Cu40K8kD28EqSSHdxIozj8a4O0dkYKyAkHAXNdP4e1Ly2XevJY/KeQKAO5urNEYAjcrZHrzWJcrJbXYUsWTkAYx+taKX/mW6qxBY46dqztVzmIKPmxjls4/+vQBciPmjbwiY2nFQXhAOUHbIIHJqC2m8lGxk7uc55pZd/wA20LsbG0MeF9aAMOZwHDcYJxtxjrUF1FHHMGU4IHOe5q7dxg3IYo3X1/rVaZCZBGwXC84PII9KAK8aMN+R8xIyM5596lUiJQNwIyWy3f6GkuWaKMRj5AO6dfoKokS+cocAkDhhQAy8cyRqQcKRyo5oqC5wBOQSJMc4B+X3PY0UAQ2jLIru7MVIIIPIH/16l4kjcx7doXv2+tOht3jhCfJtJyx6/h0pzP5cA2qvOR16D0NABpSj2BB7Dj61uqSgXoFPIHoaydFDNATgM3cnkf8A1627fEgibHUcAigCSPLAKxIQnr2zVvygox823jBHI/GorZThiMnYc49TXQ6Rpj3UiySpiLOcAcH2oAsWFmyWfmyqAgQniuS8SXIXcIxvmPAP90eld54ou007SixKjavIB6CvBPFniOe9fZbMIAc5wOvNAGb4guIbRWM0kYlPcnmvPdU1u2RSJZVbPQr6VLrzvM7GUhyDjJPNcDq2TK7McY9+KAJdR1+2kLKDIT0qkmpwiIseR6GsieHq5wuTxk96rAgKy8kHpzigDWn1stKSsK46A1XfVGcn90uDWbTv1oA1bXUFAJePnrkV0WnXcbZbIUkcZrlLSIGT0wMnParyMQ64OCOlAHcafdJvKbsIDn5j+lalzeQxmNgdxHHy9BXEadMMjdyc4PvWqk7O6qigr6UAem6PfwvZxTR4DK2Ao4x71D4iv5L2AYba6kkbDjBrntClMcL7FwA3XrWhcSedGjgbV6YFAHLzvLE7EkHJ64ya1fDGozx3ZhUgAgE5HpU/krnCISMnBIyfetjwtaxm/wB8kagkY6ZGP8+tAGzHezrAB5nzMPvdetWbVnR4XQqSvXcucfSto2caDCorbsgDjiqvkBHIfgqMj3oA0ra7zAI2AkXqWJ5ArI1PUoRIyBGbaTzuzgVohWhtcxgYJ5J52npXO6iGeRj8xH3RtHBNAFtJkFoQqtufkt6VmySW6Qv5oJbqoLZzTZ3YWwiGVKe+c+3FYd22Wxtww65NAFya9gywjVsjocnA9qdb6uqRKRCoc+tYcrLkeY2ewHP507zFPzklwOTnpmgDq7XxFsZMohYHGF5NdDb+IIXGGXGSMZ7k15lHKWUliAewzV2Odo2jxlVB545oA9LN5a5ZnUhjySOhqVZLaRVKyFQx6N+dcdYaiksR83APQqOfzrUbbJCFTg46g8k+hNAHUCJJ4v8AXBlJDYzU8TiKRVjVcng4/mRXFZkSPMdz84zwO3vVm31V7ZwjvlcEEtw2O9AHcQ3k6MfLABI+9U+Z958xiSo/Kuc0rU4LgxKHCMWDBT0+tdzZ2zTQgSEZQZDDuKAKm2R05O1wOfqabLMVk27WbtgenpVma3a1LeYS2Tnn+I1TmtS0gYE564oAckqyg7j8uMAVk3TyeaOCFOenUDvWhHCFklx9zHA61lagf3w3gEEcHmgBNieYRGVAZeMdfY9cA1RnkYxMYziTIXnJIqzCqRo2SNqAg85piojOSSUU9Mc9fagDLmik2eSWBBGee340VYvWcKgVD1wSOCPf8vSigDWMHmsy8BR0z8uapzw+fbsEUIB0OM59/WtKZMwAbgQvPrt+tVrtCioxdsHjPb6UAO0uIFG3vgZBOB0FasUPmKGiZlOenrVS02LAByyueK17dNqqcc44Oe1AE1lbSSTxxh9xbAJz0rvrGKKCP5OqjBArldBjK3aO4Uj+6T3rr5iURmwQAM5NAHmfxLuJWaRdp+7g9814dq9xI7sQoBXkcHOa+gfEFtDcSOxJcEk/LwPyrzXxFbW/n7EtwQDycYoA8V1JpXV9qvnOcmuYuoJZc5jwR2Neq6zb2LScui89m6fWuHvvsluzyece+QKAOLu7CVzsLrwcZ9ahOlqFw8uMDJOK07m8t5ZMxbjz0A4/OqU98A7BIN4X1NAFc2EC9ZG9zT47GBjwWyO2asQ6mFKj7MhLDBJqT+0PNO42yDnDBRQAJZxEKjMypnqDVu209Gk2q2Av61DDfQyyHfC68cEHgVpWdzb+YSAckYoAdFYZkwMBjnBBq/aaesDBZmIdhkA9h2p9pcRRMki4BVs4YZB+tW5fJMkVykxkSTlgo5HtQBsaHpdwHZdqMjcbie5q5r1lcacViIJkbpxVywaya1jeOU7Rzxy30Iq/4jvU1S3tTCSJIkwxHGaAOXMk62QBUgMcZrpfCluJY1IEgck8AZyKw7q/RVVZoQy42/L/AJ611Wgatb2kMZSAGXGd393PegDossInO3leAPp6VHaNPKI/PUlBwKkXUIwoYpwcnGcZ+tTw3akQhEC5yW57dzQBfOmmKzBUB1I4Djrk1z08SxktL8gIxtC579a6QXyS2xXeVjB+7xzjuTWBqk0b3LLG+9RyBjAz6UAY62GBkMcnvjA6+tZ93pw8tnjdDtOCT1xXRAxiPmVMgYyvRfYj86zXlj2yruG5l6HoaAOcnt4WIVh1yPfHb+VRx2ECxlSWPfBPOKtz3ESSHdGcDklT/I1Et9B5p8uAjd1YnqPQUAVGighAEUjLJ0AA4NSSWTld/mlm4zuHNMvNQiUs6RFm/wBmpLTV4JBtnhIzwxDZ49aANDTrGZQHTeSBztGMf/WrWglZEV33ecH2gbeF46/WqH2+08vyI53ReM542itfTJUE6CGSNxyP3hxnjnNAE00Il2PLE0ayEg59f/1/zqhcwsyrG0WSBtxjoexJ9a7CCOBwd0I+Y9R2qO70hGCNuYHBICnGfrQBzTQvbfKJFU/KSE5Hp+H4V3XgXWJFdLa+O5WOAxPSuan0eWOdmiBRuoULmr3hrT7h7xDcKIkRhknr0/lQB7Jdaet1Bs2jcF3KQMA1yk0RjlMRJDg8g11ek3SNFEJC2VG3B54rN1qEi8diEPmDcMDI60AYoiZSCucccqOAax9ThfzdwVSpHHHOfauhAMcRwC2Tg45FZeqoiuhCkKBn5jnH9KAMcw+bw1vhMYxkcn2PeqTxf6Qu35VHDKTwR/jmtiLBJwAVYnAPPFV5ogrh9o65GO59KAMi+tGjYKWxk87Dwv8A+uirF00hLAFQ7AMVXBGMUUAajp85whO4Y9qq30ZFv5brhVIXj19avps3fKsgXGCrHjFUr5uIkUMO+M0AW9P3x28Xy/MRtA6cVs2weVowME46Yzj2rNsgyxcggr0AGf1710/haAS3o3rwuW6dx2oA2tI04RKHkPKj9aPEepw2VsFmfaWAPPGK0tQuBa2zSbQT0APc14j4/wBaa5vZQ5JQDJBPB9qANXxB4jWO2drTcxBPPrXkfiXX55pHWWRk3cY6BfrVS51u4tScSb0LHgnjHpXN6rfLeSmaMghjnaecUAULyWUNId7BWHQHtXOanNu4HJ6Y7Vr383lxEkDH+eKxFV5mI8sseuAKAM1IsZcZHvTZohv27Tjrjvmth7G58pWSFth5BAqSPRLve5kAjIGTk0Ac4YjkIMq3I696kC7AVjOXwMjNbcmlCPkyr0zgDmq502IYZmbj260AZ9sTgqwLfh1q5EcEOi4X/PSpYbCIs3+sOOgPSrv2BCUVAM9gaAEi3GFwwyT79ansd29I2+6DyMnmra6e4zgfdxkDvVpNNlBBUAEj160Aa2gxuA45kyfuj1rctVYKYwAoB+bnr9Kj8HaZIHkMqk4HB7KfWr1/CbN23BWYNnDd6AI47G2kmXzd5QH5gB0rpLCys5EijjQAZwME8nPeuKOotLIkZRgoJPB5rp/DUokd4H3Bz/e4OPT60Adn/ZsHk/u44/l42/4VDN5MRL7gN4AOB+gqtLN5ccaxtIioSdvQnjio9O8+5uQzNlFGAce+aAJL0gKFJMa5ySo681hXUTkb9wADZCgYz9K7T+zHkhDkbhy2cYWsm5sXWVhM6qsh6Y7UAcpcnJG0kRjqM4qtcFFcNMWKg5YdwK6iOwAGBsILZzjJHtz1+tVNQ05Gt/8AVgEjII5I9zQBydxtDfLuYP07EVVkG2VctgEkYFak8aRTndHwMdqSYqrfdGzrtI49PyoA50xgnYBx1BJzipFAWWJwgwP4vxre2q7hfISVdvVR29cj8qvLp+nHajRFCDgt7fjQBzNzGSOOAwHOP0qxZI3mx9v4RzyOK15tKSRiLaR1UD5QwzmmwaNPbumzEjH5segoA6HTJbgxlImbeHGMkD/Oa6WPUpFQO6B+RnHP5Vx2kpPC2+SJlPIDkcZ7gV0kUjbFjChi4OSRzQBtWOpxzlvMkIYnC5GMn+tb1jCob94FwwBya4ZrcrMrq3XnavAJ9K0bHW5YpwsnLpwW6qAP6UAem6Tbb4XYOeDwSvNVb+Ym6DM43HhhyMf/AK6qeGPEltqMzJC5WRflPHBPTitu+09pEMkH3gcshHJx3oAy0VgAQBg9B/jVDUwxcAqu1e7cZ+lacKMVB2gOnXnr6CkvEBhYHPI5GKAOeba2ONr4IBXkfSqc29lwn3RjgDrg9a1PLK3IVY/3fcjjB9PSq8ikuVRdoVs5wOaAMZYW37nUDIyBj/OaKt3aAEMpZWJwdoz+BooAkjfgAleRxxkfnVG43SX6qoGFxuycVbjChTIXJH3sFeh9qr6aryM8gQDcw5Pc570AatlGFRHUHBPUnr+Fdj4cgkSBpVVd+cZJ6iuZtEy3TAJ/h6H2zXWaDHm1ABJY8lemKAJtekK6bKQ373bkZr538UpeXdw/lQM2TjcT2/pX0bqkCEbpmxk4HpXmviqyhkSSSPCovJ4xmgDwDWNMmYiOVlUAnKqckH3rLitbezc/KzjoeeB+HrW34q1uztppVBc4JI28e1cJqXiWRpCLWBUA4+bmgDadrV5GRYvmJzyM0WqLGhmICq3G4/yriX1O/lnP70g9gOKkFxcOrJLOeOAAaAOxkuoVGZLhRnJ4OMGsu61Oy3u5lkfHTFc+2ScZ7etMkTPGVA6ZoA1ZNUsyPMe2kOTjO7iozf2zAYhdc9cHI+tZjKQ2ByoHrQBwMZNAGxaXdsX+Z2UeprSsHiEysTnbyMmuWK8Z6DPAFaFi8m4gD5sdSaAOstZEimwNpjJznPNbc1r54VlwF2BiAa8+iuJt4Tfg5zx2r0fQ3gOjhLsk4bIcjnpQB0Oh/aLa0hEZRt0mWBxgj3qbxI8LSwzW8al1GHAPAPrXDafcSpfT+XLKIgcDB6H1AraDNdKRuyCOp6Z//VQAkSWbyb7hXQ5z8o6nP8q07G8tYNSVWbO7BDD+tUDprzRKplRdoyM1Zg0NXnjlM5Kg44GDQB3wnsy6PsVT2INalrJbzkMI9pBxkNWBFptu8Z2s/A6/1xW3bWv+jxhWJKcKORQBrTSkmGPcEjI57g1zetzRK7GJsuRjA6e9aNyx8hcsFYZ3AjOR2xXKakvJdHJRfvKf4qALsN1A1sgDbccYPUVlXd1FE0u2VQp9QAenpVOa4dRiMfMQAfb1rK1OUea527iBg85oAivNUR5nKLuYfKMjiqS3ZcgwkKCcE/3Riqck+QSoUKMZx3phRQCS/wAuTwaAL0N1Kjl9ygH7pU45qwNUuCrR7hgckd8etU02KmEZWGeM8jGKfBb+ZPxxkjr0HpQBvafqBcIXi3AEEDH+ea6OHUNPdzuJidvl+5nk+hrl7QLEg2ght23Of6etXGYIpRFPAzgdcUAdlFbRTKXUiVM8Nnn8u1advbW7xYMUi7eMr2964rTbtYGfD7SBhR9fb8K2G1+eC1w7rIq46HPagDdvNOaZEETBR6jkfjXC+JnktpWgdWGOGb1H+FdDa+JLe5dIwTFJwfUelTahYx3ALzO0qkZ4wccdqAOT0HU2tbsPbSFVHccDPavovwjqq6rpaSbh5sYwzZ4PvXzl/ZEkUvm2Dbk3H5SvIHrXrHwpvHSGeCYYCcH2oA7PVrMxOZIvljc4wvrWai53qMYHX5uTXSXEa3ViYZPlkA4weeO9cy0flEg/eXg4FAFFo2xJIQcEkKO5PvWfkucyFRs6hT0rQ1BXjIIztIGNo5/+vWRJH8pXhYyDg9Mk9aAK2oyqIxIiEjOAc9Ce9FVr1FdFVSdhIBI64+o6UUAWbuYpBGAB85w3HWptLjwp8wKMnOTgkVm3u6e4VVOFGB0wfyrW06PAJIy3AI6+2aAOgtLRpnREwQ3K/jXZWFqtrAsajkDk1ieFbMqv2hlzngE9v8aveIr5rDS55A2GAPzHoOKAMvxfrUNrAyR4lkXkgdBXgvjDXbm68zbcSCN+Nqnn6VfvPF0d3c3FtKzbnBwc4zmvOtduX81kVskcfLzzQBy+rEztJuUMM4GfT3rmLu3yx8tTj2rr7qxu7gkxRELnJzwCKi/4R6UIZbiTy+M8daAOIKsrEdDSGTaD/Ee9dTPoUQZTIztkenSkg0m0QkNG5JOACPzoA5qOX5yxJ4HHFSEl0IRXJrpZLWyjc+TbNnOMEZqdFlRyI7eNQpxhlH60AcslvM65EcjenHSrFtp1w02fLJ9O1dHJCxH724hQnqAw4FNSLa2VnVwP4lbrQBlrpUiuTMv5Hk1bg0y4nuFhtlCZPf8AxrYjXdAAoUt1LYzj2q7pqLbFZJmVVU4yeoPbigCdPCIhtTI2ZDjDEevsKl0lJZZZbc7sKO/bHTNXotYaWVYzJlW/iAzj3pv2ptP1JmhJJB53c5oAZZ6c8SvceUxfnA9auEPCqGSPYWG7b0x712mnIs2mRyiDMxOAMdKr61p6yWyGYANyCuM8+tAHK/aw7FS6qcYBznFaFqJPOCAqWBXueaq22ixrIfJlEm3kbh79atCZYLjNw2x/TOKAOps5sAZcgEdMdfWtqBlKAxF8Zwdxyc/WsHT4UZvMDt5eMKcZI/PtXS6fHEWDhwdw5zzntQBFf7suyr83bH5VjSW4mdyVwuABg8/SuuvArbRAh29PWsXUlitAMtvYsCQO3t/9egDno9NwGWdRnHDCsHVLBY1LooK5xkenrjvXbSTlbMlnQyHp2/OuT1u9IgLMFGDyAev0oAxI7SAfJ9n3v0HzVIbWI/ujAgCc/NipF1e1MXyQAOT27n1qxLdAhQIhz19Tx6+lAFCG3s1lzKgY/wCw2Rmr9vZxSzO7SKiHoM7QPbFVmvcouIRjOQMY+tSRajbmXH2diijLbeP880AWo9NmikDJtYjOOe2KsxafNyxiDADv1PtVeHU7WNyGLRgEHaOgrZ06+FxIXhljbPO0NyaAMSSCWP5XVslvvY/LmrdnHHlxMcBlyp75/wA+tdDtLKwMW9eNzdxQumLLL5oADYwxYc4oA49YJY7ngDMfIXaBkmpJ9ZubC1Yq5YINoBPHH1rcn0OYs6267u5Ldar3ujb7CRTGBKAeT1z6YoAveENRttaCEMI7rGCp6Hjt7V6r4as4Yo/LVQr9d4Xk+1fO2gma2vlDbg4bjA7D+te1eEfEbebHb3BUYI2lj19zQB6RYLIkWZAoyDwaymTM8gjXgHOMZzW/A0c0A2bSCO386yJ7dba4IywGNwOOCaAMu+tp/nZW2qq4CKMZ/HvXN3EMijK4HOdo/rXYXkbsVLOeFDYAyCK5+eJmdlUEAkBtw5JoA5u7C8eWHV+u7t07UVLewAOQ68FsA/wg0UAMjKiXLKDIx6j6dSa2rNFjC7iFDEEY681Qs0Ds0b4Yk9hnjHStuxSFrlN6fMMAA0AdtpcRgsIY+NwXOeorlPiZNKdLa2tULSSIwz2UnvXaQqEjRVyFAAANc341RrjTxHCR1JPPGR3NAHzpN4dWGUXN5N5k+7JReBUFwqTA+TColzjagGT75rX8Ua5o+lfurhhcXJIDovb3zXmWs+KLie6c6Z+5t84Hy4oA6q+iZY1wF+TjngE1jXzWVpCsl3eAbmJCrzxXMz6rcXCbDNIzEc5PHX0rDuSzS5fr6mgDoL3W7OAAQo7jPB9KyZvEVx0ihCEcgkdfr61nEZJLt9B600xswYADJ5zigBZ9VvHkLCTYG5IVcVTu7u5aPDSv+f8AOrbW7BQWAPrk1ScNvKlcdwfSgCBJHJU7i/Izk9KvwO5ypcgDrg9qhWExpu5P9atW0YON4znpx0oAuwPISFXcB94gt1qN7yQz4aRiBztzxSMzKAFHyDj3qIW0szqyRMSPagDUsNTl89MnGGyB0rpGvvt05J++cDg1yUdjJFuMiFa1NNdFmV5VZl/LFAHrfgTVLx4GtGI+QblZv6HvWrdT7kVRgksSzHvXN/D6RZbadixyPlVSMAD0zXU+UqgMyR+YRhQT27UAYF7A7P8AuEzIQM8kd+1VLvQbuSeF5ZQc8dffpXW+QiFRMRuHIXPH/wBaoNSbBgchQ5GMY6EdaAHjS5LcqqS72VQfv4X6Ctmzt2jAYE+UuN2PeopJFSNH3hl/2Rxj1qZLqPaNjFuMkjAoAt/aXEjJ8wTOA2a527nlDE7vnVsbfb1rZupFKFt4VgOeO1Yd2vyxMWVhOflC84APf0oAo39yzW7NvwM457f/AF65298t4nJ7DaoHJIrcvFZ5AmMoT+GR6mqlzYMH2YLHPynP+RQBzdrHJ9p5UAKcjjrW0oBCSIhDk7SFPBqT+zZWdGj5bPDEfL9Ku22kyyMhDBpW+UK3H5elAGUIGkU7nCnftPPeqcwEbLhffOc5PrW1c6ddQSkyxMETLE9wM96oXVu8jFtmCOgb+WKAOeuGJkyMsM5OM8VLZTSxTxvG5Vjzjrj8KvSwAncoKJ1xSm2VX3kEg9x1oA6DSdWngIjWQspUHBGa66DXIo2iLIAWOA4Xv6VwIjQGPyvlPXcxxxW/p7KFBlJCHI6cgD0oA6xLuK4uSIZgCQMjPerzxqVOMMW+U/3c49a89nwrm4HTcMrnkelbGnatdWkTYZnUYOGX7vtigCtd6TuvnMRHmA9B3/OpLHdDdZmjkhjQ/wAXAPvkfyqK71e0+3CUySwtIw+bHGanvbxLix8ssZoJeN68YPt7UAelfD/xH9p1A2kh3Ruv7sjknHevRZo/MTgDcOhNfPHhxLrSL6zuba4d7ZeU3HnGfQd+tfQ1vMs0cbKeWQPj2NAGJPG3mYjDKVzu9M1n3sAOD/Goy2AP0ra1dAs0ZLhUcHI9/X+lZcsZVPLMaknOMdKAOP1ZHeNtpJKncfm/WiptZjYZYrg55VR1HTpRQBJbxs0abdpJBIHeuj8N2X2pxLKMImCF6c1mafAdyFVAkY4UZ5zXcWNsLS1SIHOByfU0ATuQqksQAOSTXlHxQ8TYsmt7HhslSw44Peuz8Y6slrbNbrJtZh839BXgvivVTI0qB0J+9wM8igDybV7cwztvDODzknP61kXUm5Qo2qMfjXU3lld3jSbIWMZOWJ6A/WsOfw7NC5ee5UgnIA9KAOcclZMoTnP40M7Fipy2Dk8966JNIsomDu5lK8t6E1aisrdJVMUJHPQdvzoA5VYJpekZwDj05p8OmXk77EQknoe3512MlszFXEX7teelT2pS05eRYhjjJ6UAYcXhq5a0EbkK3Xkf54qovhxVuNjz4XPp2rbn1WzSdgZ3kxwFTpiqFzrNnASVjkb155H1oAP7M0+Jij7mI4HpToo4FbbFbKAf4mBIqsNcV2V47NSx/vHOaSXWZXVdltEgzjA4oA0rlIXClI4z64XGPemxSrHhYgOmCB3NRQaiVXMsKbgoAUgn9KjF4QuBCik/xYOTQBf8vzYQXJ3bsZI5IqrDaKWMaMxOeOOn4Vp2lxGiRnKrgDnrXQeHdPW4vRNJgxA7wMdffNAG/wCA9EaSBAA2R8xbafxBrstd0aSKxLWr5VF+97Unhe4td7gbt4yQVPUH+tXNQm8yFo1XdERkAnoaAORtVZUKzrKXwNv90j1NMLPNLwijbwF3ZIqW/wDMDnaPk6gt8o6dKoxC+Zi6xHcRt28Hd+P+HSgDTjEiLtPLOMMwBB47VbtbFySzEME+YZA59MY71XhtZIGU7SyFfmXdnH41dgmkClGOzJ7Dgf8A16ANJ7YfZl8w5VySV3ZrPkjS3MjIpyTwCOvbp6VcS4245Bx8uMcZ6Vn6tetNcsox5UY2ggYoAiuFUybkWNgFxyP5elZlyscqL5jsAe2RkLTJ7vErrHu6ADJxk98VlXl1KSI0VvL6YU+9AG7Z2r3FoERgHUcMzAAnr1ojhmlGWVQMfKm7rWfatvj+QDaOSgY8H1NIVl87DFgjdMcke9AG1DFc5IdXLKT827PFNnmRcGW3VlU7c4wB9DWNFJMJgFd9xzj5j/nNMOoTxsENxtV23YfkfWgDS8m0uZtpjGG5OByTUj6FAjhgZCOpyefaso6ncRTLt8phkEg9xXRL4jsWtioikFwy4IIyF96AM5fDuH34VouThmyAfrUsNjcW53SBJB35yMHpWtaXltPCrmdFjJALAcn6+1XSqGNDabNmOWyCGPc80AYM8QCDJ3LgsTtwM/1HvThZyyIpJCoRtyBkH1yfpW3aRl5pPOgG3IzvGRxVyz0+JnYqnlqpPy5+WgDybxKhaCWHy8HGQdx4+lYHh7xDPp5WK6/e26nbhuo9xXsPiXw19tt5GijVm/hY8EV8++JLKbStaaGTeozkZGAR7UAe8+F76C4lga0YTL1YN1BzyPp719A6c6yWcDxgY2DH5V8TeCdWubXVrc2pIj3jdgdR719deEdWhvbeAwvuJUKVxyCBQBs66M2eeOD3rj7q+aOYqgLZ/Suz1mNpLCTb1XnHrXDyIFcMykkcnuKAM+/nZ07h8/e9KKuTmMrwvXnHAFFAHReG4Fe9dwDsQZG7sa6isjw2uLWUlXDF+S3fitZuATQB434uW8utbnu7qZUtkcqsY5LDt9K57WdLgluUNrbqrOuFZj39a7LxBYvuuJZpEWAEs27oo9TXmPiP4iaTpbtbWSpPPEceaD8ufSgCLV9PldAjnaA2GwMA471z17a6VHuW7vF6YDZH8qxNY8U6jqmWaYxr0G3gCubumaVAp9yeep/xoA1rvVtKtCBbW7ylc8t0rB1LxVcTSMttFHCjHb05A+tV7uYCHyxgdz61i3C/vSAQV9TQBoyavds3ySuQP7pwKrC4kl2mRicc4z1qoO+M8UEhnznkDANAFpZHJUKo9SAM4pzKXk5xjGCKjtDhD5mAScZHf3q4yLtUpgBvXvQAsT7RuwAuMcVOAMBkGSegp3kqQoHKjnipEhkMrMqMdvG3HFADSXL73JLA59K0o7Rp180fOw7Y5p8Gn3E43iBjnp6fhXR6Lo1zIqxsAGY5GaAINH0mOdsOpwBlvau50+KO2jWNUUhiMDPT61LaaCbO381GLHjcf50XEDmRCigq3cfeoA29NQeaGiK7s7cdMVfuFkC7JpFXHzYB4zWTphm89Qi7gjYJI68Vf1QyRxGSSNc7uufuigCldtFujjkSUoD8xQcgf1qzdNGLaJoQoOccnmsqeYuyjjIY7s8Y5/WnW8r/ADBSvUHIx/KgDdgcCHlcNgZJ6H/69RlY1I38gH6j1zWdHenaAVyMZOR0qL7VLLN5aD5C3XGO1AFyVmmkkZl34G7ggAHt9aoamyO2+Mtnb84bHB9h2rQjtLl0d1VfKcHBBwQcYJwao3WnmNSs0g+YjoOc0AYlxJuk3BT5iDkdeDTXjZyHbcFPAPQf56VOtoRMfmBUsGJbr1rYe3h3qiRhh13dQPwoAyraIrCFRjuP3hg8/wCNS+UpJYZeQ9RnmtFLe3mkZSrKc4GTj8f/AK1S2WnQJO6IwwfmVD64oAxDC6ygMCq87VxtNZlzEPtDq6kvH+GB14rtDph2qSwk2kjOcGsm40uZboyIsSlTkHjOaAOdm3tJEyDPGOmAPoatEoVGxgwxyAMH8K0rnTJ2jx5ag/XPGOc1St7SdH+WEqqEYPPTHAxQBYaONoAyoyjODk9aSO+mgjVEdsqeABwP8aLrfjzNrEpw23jI9hUMUcssj7VIX7wYjrQB0Gn61O9uy3MitlhgNncRnpXWaZfW03G0rJ03EYz7VwlrZiJUHmK27qB8pU+3rxXTaLC69cEjpk0AdU0Tvl4D5idNoNcT8QvCFtrlluMQjmjx8yryK34WktpoxFK20tz3Oewrbt7hJD5V8iqzjIZOc+59KAPA9K8NT6YXeHD/AMOccjn0r0bwd4hk029jVvkI4IbqK2dY0j7HKbmBQUZui9xWFc2lrNPGxXyrhMlQByTQB7za38N3DDJCwdZByMdKyda0oITNCPkJyw9K8+8CeIriy8R/2dqKl7aYBY3A6N6+3pXsXysu3ggjpQB57LCu4Bx8gGcjqKK09Us3guHhY5hA3KxwOCelFAHVWMRhtI42ADKOQPWpJpEhieSVgqKMkn0p9cL8QdZNuRaCRFVvXnn/ABoA8G+MHjK61PU7ixtWe3sY2YYDYLk+vqK8ldYVAEiB5AcsR0z/AIV13xIeS71+TyVYq/ZRnJrBttDndkedginqucnFAEEUyzQEjAI7egqpdOyp8iEgn8q2pba3s0KpGXkP97gUiwPIFOFXPUDp70Acu0UrEjymLjnBFQf2fPcv8qgEnpu/pXZi0kZwQnAwTU8Fhb+eQZEjJ9RkE+goA4pdFkQfOV9QPWnw6ISxzk45NdjKthbK3nupKHkDnOP6VhzanCr7UBYYztFAFS30mNHKyOWPUYGa3bHTtOEqpOJWQ9Mf09qypdYRH3pCdxxknipItYkTDqiCTqDjmgDpo7G0QBYbQNMxwuR2q/Y71YxeQqZ4BA4H41zttrl1KV/eAEkHCqBV2LVb6WVYhMduPwFAHT6fp80kjAAlw2COgNdDplhPCyscjoecEVxdtPceWQrOPTmt3TXmYJulYuOiKf1oA72IB4j5agnAzk5Ofas+aM5ZVX52JAAPNQxal9ksyquXlxkkep4xVN79pHbzyobggg88UAdLpdq4RGKBWXs3X8as600c1mEKgkE7gB/M1iaZqEqGRGZ2Q/dA7D+VJNetcLIiPtA/ix/P3oAxr64aCQK6qVUbQw6YqBdZt4XJA4UAHoM1oC3hePbO5dc/xev4VVbSLQ3SFMkEdC3FAEEOqCSXJCsc52joa2LScMozn5h/D2+tFvY2MYkIjUYGM4qYxRRnbEGG04yB0980Aa9rNuhaBm2xgA4A9ar6vHDDy0zEqPlwM8euagDOuPLk/dgYBJxk9hVS+l2AuRufG0hf0zQBmSSR+epL8ZBwRgE1oSXEaMu35nQk49aw7mQyzyHAVwPunpTIZ2ickO3zc7SM4/DtQB0azohWT5juJBPU/WrMUieduJ4deXxjHNYsG1lBLFmPPA6VbLYk2rIyHOdpH64oA13lt8bDKVfOcDj8ajje0dtyyFsk9e9USWI+ZlwzEYx0xUJjHmHeqjA/hY4oA6RfspRlWYA4HOBgnHWkayE4LRYOTnK9D+HrWFZ5DMdx5Py5z0Aqy088Khl5XODtOAO9AF+Sw81nV0CY4AJ6+/tSxWCxkgxgjPRBgZrLm1KUrne+QQBxnI789c1dtdZYLvuU3Y4Dnt70AWxpkTx7mXh+B6fU1dtNO8i0ZInY92fufoak02/t227juBPQiuoji3xJnaflyOOSKAOVhQgjcxXb0BNBQhzIQylj06ZFb89qBw0anJ4I71SudPDMoLkEHJ5/SgDNu7to7URvkwjO5R3Fc/5JubqW6tZwykYIf7w46ZNbt6jLvDKMqfl9K4XXLS4S6W6tn2OBkgHrQB0ulyCOWJbpCiBvvE/Nn1BFe62ZDWsLDoyA/pXzd4V8UQ6reGx1kCG5GVjkPAJFfQugTM+k2vnEl9u0E98fyoAh8Q2weNJgq7lOCcc4orRvo/MtJVHXGfyooAZqd7Fp9lLczkBEHevH/EEN3qmredMwWyIJ3n/CvQfiPbtc6AsYkEcXmq0h9hk4rEnt0vbG3eIHYseQcY5H86APOtc0C2khxbQDOfv964m+sJrGQKSFdcgtgd/5fSvTPEuu2ukwukkg87G7bnBz/jXiHizWLi+nJtnaOLP97lu9AFXV7yyijI87ewySD1rlbvxBHkCIkHt/9eqWoo6THLZJz3rHkVvMGVAPQUAbf9u3b/IJNpBzgcVGmpTMCS3PtWYit1AHHNOQM3zY/DPWgDQE7SoSWIO7mpYyxC8jDDqKgs4y4bG0KODjrV1IWQkLuYY4470AFtaoLgM6glu+eK1ZLZUkA+VlxjoetS6TZSyzAlGAPHIrpTozxuii2ZyRnjjp70Ac7a2znaBgDdjriti2tGyHdUXsEzyPetO10G6LEQwndno/BH+NdRY+GZXdftAjjyBnsaAMa3tHm8sxJsQHOehyeP5Vs29qtvtVBncMHn7tbjaDDaIC1yojIPP9KpvaRlVRN5VW69M/WgCnCOWwxKrktvqhe3SxMS8YJJOGByMetat5bK8bx4xxnI/lWC9rLcLhAgVeCXPSgDTsL0/ZwuCuW25P+f1qW5uVjtiGJPGMA9RVO1hVpFEUi4XHzHp9auapZ4gLyJlSPvKKAMyHUF/fBm+UH6j/APXVywvWnhBLLleenFc7cBoF2o4z0APpU+hp5kjmc7UXgBT1P0oA7K3kDxjkknnJPepfPLs5G3jjAOcf/XrHs7yMTbYm46Ek5xW/bR7xu4bdzn6d6AF+aSDGAFI5zxWdexsUb51yOQPUV0j7GhCjaCOpYdqxb5I5CzY+YDmgDnZjiU5Py47Cn+SZE3QopDjBck07U443VnjyhI71NbusVoSp+Y4wMYyaAJLRfKZgQcYHDdcetWpvnlUnbtGMFeeP8aSxn+ZEK5XA5Patm3eKRI2MSfKSo28E0AZSxcuTkBvmOGztNXLcK0YAwXIIGSD9M9q0Egtnd03ldw5GM/rU8GnjyzsK5z3HLUAZFvGUfayiR8cAcAe9SyFXQneNhPGfX0NXtVtngQIqkuSM8e3SswK5lUFMoATuX19PpQBVuhKsUin90cjBJxnPcelCKoUPKzYHDY6/XHrUsyNG7v0V+Np7H6VFdREbWSMvjk4bFAF6xlCMSASFPrzj6V1NrfMFQq7FlHAPpXK2C4lGUXcwzknOz8q2wHGJ2HzEfKfb3oA6WLUkkAWUn5uARx749qvxIj434KjksT09640qzKBuOzO9gOufWrFlqkkU6xgkx4ztbkHHagDcuLKMqx4aM9Mj9a5jXtBSa2M1qwZwDhT0yfauttb9LtwMgSkE89PpVTUI57eT9xGHQ43Fl5zQB8+eIbF4JRcgukiHGCMt719J/CPV21TwpbxXOBcRcA45YdjXCeIvC662EZP3Nyo5GOoFV9FvZvD0iRqzI0bgBST0HU0Ae+ryOaKr6bdpf2EF1EcpKgYUUAQ63ZDUNOltzjnBGeleS+NvGFr4btXsoJhLeRqdqtnAHrXr2rzNb6XdSoNzrG20epxx+tfGHin7XNrU9xfEm48w7gBlcfX0oAr6hrFxqF48t44kkYlt/X8BWVcgXEhYZCAY+bualmfaf3aFt2eQvWqkly7sUhJKA5xjvQBnXdvGyMZ2/wB1R1rBuURW4GSe2a6VrJ7tw7njd0A5NS2+hZnJAJ7gHmgDlILWRgrFWAPY8VpafpyysVbr/s+tdfB4aMtx85IYrkAdTWtBolvZyB2/g+Z9xHFAGDpmhxuq7YuowSepI/rXU+F9Ms/MdZUZtp6Fen1qKTWtPtgq2+WKgnBX1qmfE8lvFL5cSlnGOR39aAO0i02McRR5TOd4HUU65aC1ikee5hXPDZbacfSvNpfEmpyqAsxQEjjP9KWO5a4YtcAzFeMt+tAHpdrqGnyMoS4dlHOe546Ctqz1Czjj+abMnXLDtXn2nTpBbtMVULn5Qe5qX7ejIvmZO75R3oA7K71W2uJkElwSmSUG3v61Ebu03MPPYbR8zCuVSdGHliPaODnuMU3zA6MPM/d8HGep9aAOhF5DKkqk/e75rFE2ZQq4LE/cHIFY8kreb8pYDBqazkG7g7Tg5I5xQB2Wmw2wjzLMm4nJX0Hp7VZ1CdVtTGkm+MgsqsffvXOWki+ZIUk+6BuY8Y/CtMIr28jmQMRnA20Ac3f2guJA+xmBOQRwKqWtlKJ2xkKOSc9K6QoyIAo6jjd3HoaqvFtjfqpP3iB0+lADbHT28tWJBIPOODj0rr9NikktUjfnGenpWFZwxoEMbsfVeuK6K0kKp+7AC49OpoAJ8qAo5bjIx2qhellDGPJO0E7jV+eVnVkUDIHfisx7hQJckE7c4YZ5oA5zW78xSiLqeCcmoYtT34G1dwwOTwPeqWtAvqBaXLZ9v0qpDIu8MV3Y4GB0oA6e1vJY2V9yeXk8Y68f56VuW2pEKpaGMHGCw6Y9Mdq5PTyzkmQ5C84BHFamnO3OMNg8ZGd1AHT/ANoKHA8lHYkkn1rpNKvIJRwBuXn2FcJbSbZMFX9yMg//AFq6DSzsbeF5PzDA6UAa8xiuJ2VzkMe/O4+9RtENpUKoJOMEY24/SmSRMMSRYGSNxPUfSo2E0coZy3Jye1ABJaROQrRguDknr+gpFtowzqsRK7eNxzg/Wp1uh5u1mKLn68//AF6vFt7AY+YjgDGaAMuGw+zEuBkt90kc+9Ds29fMU4xk7eM+1bjKtwFIVmZRnA7VXngZ9qfLnGcg4oAy1Z1YEb9hoVmMZk5PPTH8qle3cIzqJNg4wDnFVIvNVnVsBV5JJ/z9KAHLf+VPwcKo+Vs/NW9pmrPLKkdzKSR15xmuH1E7gJIyVCtkhDnNT2V+EYI7duCx7UAejPGYyJYuoOVZT2rH1u2W/tXniQfaU5DqPvDuTUOk+IYEURzYeJvu5xlT6/Sr8twmnyQyxfvIJDglRnP4UAb/AML9RW40uWyLkvbt0Pof/r0VB4Tt1t/EImtD+4uISrqTyCOeQfeigDa8T6gBbXVunVEySPWvmzxmLa+eaSJR5yjLIqkZA717HPfCeWRXz5krnk85FeXXuhsviO4N2WFmsmQerMP60Aeax2E9xGZIgPLzy3bHetG00qMWyqoCqzcseMmvVr7w1Dc2kktiAsaEERtwM49K5S4gtLNXiuXAIGcZ6EdcUAZ+j6JYp890SIwSAB14o1TUNKsCFAwVH3VP3vrXH61rc15c7LRDBAp44xXOyyLJOTKWdicUAdHqXiOW5uE+ww+QB3PfFZrXc00gaeVpM5GAeprOe4Ytt4zjGepFSW5C/eIOeMkcigCeNiRyDj+HFWGiJzuJJYZ64qKa5VFCxqCp4x71C90wA25XA+nNAEgaKM7Tjd3A5qykrOQnJU8kCqNvCcgrhmbk+341s6fZpEsk8mGCjgDuTQBpPKotizHbj+HtmoY7r5dsIzgDPPeqbxzXRLbCi54X0q5Fp9zBEBIuG7jOM0AWUlKoo3FpWb5sckCpJ71Vj8tVcAjBwaZFa/KWmlQE4IVDk1abTol2OzN83IAPGKAKUUxkk2IpIAzmrkSsGVm6Z4PStCGCOJ1XCjPQA9BUlykQmUDhM+g6+lAFWOOdQSikqOCccmtbSjISN5UgHgBug9qilut8SxIuQTngd62/D9tlo9sSlejHpj8KAKt2NszQOBleRjmmJHujYP07e9XNbgC3bFVyoPB6ZHass3wRAnlEFSeT/KgC55u1gqrtzypFTW16NoXOWPT2rnp9QujK3lR7VH3WAyfetnw9az6hMJJCEA5wRjIoA2l8x4A4xkjHPes6/h3KSnHy7ea2bxJII2XIHbJOTn2rJSOYuVlDMD6/1oA4vVLaWK6UPt2bfTim+SpP+j5y3B9q09ZZzelJUfOAOaSNfLUMSDwMg9aAMxf3br5gYuOBW/pT+ZhRtyGyck9Pc1VjQNMDKNynJGO1bWk2cTSr5cjbweemMUAXI0UMo5YsSx2nnb2FbumJISjsMkgkqR0FUodKlWRmePYoYkc8k1pLIzRCLhfr6UATynbgMDyclg3X2FSNITA64J3dBnIFU5ZPMQADJAxuzn8afbSfIwY5XsDwCaAIQQsjliGPTJGQP/r1YS5SOHepYKSFYHqf8KrPgodgG49QecD6UElgrK+B/e/+tQBpCR4JA23KN79fbNXYbmGWMkqdw45ORWJbykri4Vs56g9SenFBYCRunzclsYb8u1AG1cRjyg0Ss4I557+lVLu1aSJxgln4V88rjqaorfyAFVBAPXd2rTjljuIwAy7R1JOP1oA5e7gdHdCgaMqDu/vD1zWJqSyxbERQVJ6d67l4Q7PuQkEY2jr+Fct4is1t3EiyHZnlsH5TQBnIjvBkgjbncQc/pXT+Fdaee3GnXw+VuY2b16Vyem6hHA8u4BsdWrEv9WNrfRz275Ebg7c9aAPoH4eGWPWJILkYwhMRHQjp1oqf4aEara2mqxuceWQykAfMf17UUAYugwyX92S6l9pwXB7+lburaNBNw2wFeeDnHtU2mWI0/T4oIclgcuQOc+prL8Z67Fo+mlEYG+lU4UjqfUUAcX4k8Rw+HXlgkAZ2H3T/APW6GvGNd1R728MtxG4UsTkHp7V0mtrNfQtd3iyOdxfcy5ya5C8kNyCilQRwP/r+9AGTqlykrDyAwHSsW6cRruUgYrbv42Vyv3WXt2PvWDqcaMMuxJzzgdaAHQzOfmODuHr0qRZ1TIbO4n8qgsrWeZgIlY57elbVno/mMrEtnpz2oAqW/nyAOiZUHoe9a+n6PLfhpGODnoorVstIjiC+YepyV7fhWnaailkJ0UAdSBwKAG6RoUNi4mlAAI5Ljk+vFTyXgknKRpGsJzxgf5FYt7rkhyI/vN3zyKzRdTyhmDMcnGCeTQB2CTWm1TPMkbITgZ6n3NZd1q+n3F0EEjsec4Ga5y7mQQlXJJA7nPPeqlltCmRicHpQB076laJIGAkYqep/rV2DVkmO4n5QMgA9K4mW4EriOHueeDWrbx7UVFxuOMDFAHRx6mJnd84Ud+tJe6orcRnLbuCfSseSQ2mEQZJ6getEgACrgbic5IoA6rRNSjeUW7Lw5xuU8g129lqC2yKkag7VwQBhs56mvK9MAWQ4O5geOa6/TbkywYaQKVHQZ5NAGrfyNNMWlbJfPGc/mKrlYA6+dGSeMHdwDSJKhSMFBuGQ2Mkn3JqxIXncAIVwDyKAAQQIXKqpGRwx9ulSadfiCTCrsbuKrrbSffZWBIzjoMYqzpVmxmDzIcbuQeRQBvvI0oDYPzdPl6VTuZmS3IXHmgZOO49fat6IqkIQDJ4BbpWbeQ+YCFDFc5wOAaAPNNcuJjfvIxZWwOB37VWWdjtVhls89iK6bU9B+03plVWVAASV6Zp8GixQuCYxwc5b19qAM7TQ8weN1wCOG+nb/wCtXRaX5MZ3EEBfQfhg1EkyIcwkxrjBx605ZVgK5yYzlifegDooLvMYVXypJUgnkUwSIXIIVivyhS3GDz/KucS+YTYdvkGSMjrTjelJFeMZX+EA5OTQB04gBQnaNo6+gqMK6uVRSVznjn6VnwaoXAHUnHQdPUmrqXQbbtwMsRkdP/1e1ABMQSzL6c5HpQSApVmyw+UY4p4dSfMDBgRwmcj65ps8TGISK67vuFScYHrigCAytHkCTJ9vf/Co/OVsldqlBks3ftzVeRwpVVgZAucsT3zUIY3C+YqbtpzwcigDQmkVZFTc2zAJ44B9zVeS+W1JcEMhJ69D+FUJb2NZNhJVugVTkc+tZ8s6IZN8UfovzYAPrzQB2djrdvcRbDxLwpjHBIrF167VhJbqjbGJJB6n2FedXuq3FvdeeJOh+XaccVJH4wOpW81szj7SeAT1JoAxtevJtOuJQm7aT8vt9aq6JdyTTshJd3GSp6e3NF4kkzeTdMW3nJY9ua634f6AttqsUs6khjuTIzke/wDOgD3v4Gxy2Wjy2t3kTMBIAew9KKl8F3UNnqiqWyX+Xr2PSigDQm1O2htpL25fy4oVySOM+1eH+JNYGravLcGZyc4XLZ47VtfFrXYrd49Egkx5IDSn7uW9K820m5WeQuXwFbILjgketAHR3shi0ScXbOGUfKSePpXmqSCWfzAMLnqPWui8Sao09syKx2jotcl5mxwgIz6YzigDSvIhduCZMsOB9Koro8lzMBIwVf5VoaIrw3SGWQAnuegru9P0q01CBpnYJdLypJwpoA4200VY2V48AcER92x3raWHyYR8pDDjkYAJq9cW1xZyGUKHUKSCvIUVz1/cz3OFZWUFvm75oAg1G6aNyuQz56DpVO5ZjDgY34ycf1q6mngsGCuz4xk+tRnS5UG7Bx6gd6AMm3tpJHMjA7c8gmrLq6owj6L3zxWoljcLwVwewPSormymO1Y4yO54/SgDEKh5d4wR1ww4NVpskkLjBBwMV1UGi3E8JC27Mx4OFJxW9p/gq8lQKy7VA7rg0Aee6ZaO0yKqfOe9dFHZyQqRsLMT1J6V6lpHgiO308bgQ+dxHGat/wDCHxMC653KOWbH9KAPK4dHnlzIy7WU5Iz1qx/ZjIwk8pXAOMEbhXq0XhiBIyJDwedw4P60smg2QiOGLyE5we1AHmFnpcjsoijYbjk8ZxXR6VorpBvYZU5x2b8PauxttGto8FXIx29q0PsUKspb5goAOQKAOSawZECRklmAU84Iqxbac8Uihue4wetdPdWVuzq+Gz7jmmMmArIVL5PJ/rQBltYCZWHLjHc1Yt7N4wo3LtzkD0q3j5c4K+pPSpGVcru6HjJxxQBMtsoUKzM5Xklen50kscBAHKNnGM06JyowVx6ew96rylklyg3e9AFS4AYsrAuT8zDpWfd2W9sRc5PUMeP8avO4EjsrAcdSM8+lQlw6qwOC/ViOmPSgDJubDbArN94Hbk+vtVOa1ccvvMfYrXSE/vF3BQq5GSvUYqG5tgypswc/ewepoA5OaMF2dTg9AOc0wxzFRtzuGMHOAPrW9eWisCRERhvunPPvTobcRg5A25O3sefagDFDzq2RFjGH5+8and5JHPlBsD73p7VpRW6bvnyxLEEEc+1PW1DmR8ng/wAPSgDJWW6iKkNwTjOetb+m3Mk0SswAI4Yg8H61UaAO+VBz1JZcED+tatugQJFGu0/e9M0ANMO9HYxqByN3T9KyriJ4GZoyGRicYGSorqooFL7SxBQZwff6VbGkxzKGjjRSfXqaAPK7pHErTSgkAcHvXE+Mdc+zrsU/PnOVPPHrXt+t+FBIS0eGX0NeG/EnwpqFpem5aKR7fqSBwv1oA4y41Wa8Zskg9RzzmodPM0NwJSxypyMetRfIkvGM1oQMH2xqCvHPPWgDr7ELqmnmYKRLGMkr+tel+BbT+0dP8mdHEkHzKQ+Dx2GK8g0C8l09pUyTE/3k9a9v+HsW2FJo5MxSnK4HQUAb1pdPaapbPIpVhKoYcniipfEkKWyLexTMwB3PgZyaKAPIvH+nXI8UXnm/feQtuI6j1rnpbqOJFS3H7tRglhgk16/8Sra3nQiRSLo9Mfwj0rxG9ylx5CdCOmOpoAgu5/ODRDIdjwRS2sSW0ZDktITjP92tjStHnuQBGp3dSwPSt/SfCHn3A3eZLuzyq/zzQBzGmwvcTRJEjSyE4RQOv1r0+98OX9lp6GCEtJIvzHHyrx2rrfCPhJdMRJJUjBI3AYBI5rr3tkEpZ1L7gMZYGgDxCHwrrtzJ5fklEUfNvf8AwrpbDwe6PD9rtw+Bxg969KKwRAp5eeeo/qaGMeGIwCOAc0AcdbeHE3LstoRg5GQOvfmpptAV2kMsELEDB46V0fmESgJn5u3p9DUEsgYEJ0PGM96AOZk0i3idGeCNgCR8y8Uz+y4GZHNtFgc5C/yro3CumGwRnP41FLsXeWAyQAR6UAMW1gSEExRjA/hGKV7lIYsg7QQTtA44rOuZ0VyFBJHI7YFZ1zdl9wXqMigDce/TAC9cE5+tRyXRSBvLwC3JyeTXP+a4i+8Tz+lOM7PFliQOhBHegCxcahg/MSE7c9fpURn3uDjnpxWe8e5CDwpqQuFT93kupHI6D3oA17e42nOd205xV1blRtZSeGwBjiuegmU/MmTxyR7d6vWzqVRPmxnO31OeTQBoyTE5LcDPB9KRZGXJVgcnBPTn0qq7gOTwAG6g8/jUTOY23MM5J60AWzcEfKRk5xyOooZ1D/MG+U8EetVRLtONx3Due9JuIjaPk5yTheR9aAL5nON8ik9evr2qNrnIDF9u3kcnj8KqCVQQPMJRuQckc+1NZv3hUDcDxz/D70ARXMhaVd7nce68Aj3qEuZFbBGDzxzxSyneZM8b+dy1EsrM5Cex3Z5/CgC4HYQqqsWXH93I96eLj94rSEeYxHI6E+uKrocHO7cpPBzjH4VKgDEgsmOv1FAFpgHRVkVm+cgAnIx600WY3thR8ucZOPwpkCbTgHgk4z2/GrttsPcbRz83THX8aAMyVDH82Dz0CnrSQhmYkKpOQcN0b/69a/2ZWLMRjncSvb0pq2gjO4DLHPB5OKAIRGjLuABcDlSc59/arFrGHVfTPOOw/wD10Kis3BYHOTnpUhUrsA7DIx60AWreKNclCxJ75xk1qWMjgqrZV/Ss+MNwxGBjg8jFWLckSqyjIXqeuKANuWHaeQpOP4eTWfqejx3kBR0VlfgowyCPcVpWpLqMZB9cVaKhT97njt/nFAHgfi74P207vcaKuyU9YycgH2rynV/CepaLeBbqEgjrX2eVQS5DbR6DvWZ4j8OWniCApMi7tv3u5A70AfIERYO6ZxkZIPcAV7H8JrhmspNPuSPlHmwvu6Zx8tVPEvgNrK6+WMckhSBnj61jac40XUradgUZDyT0AB60AewXUq3Vm9q+35sALjrzRUMEa6nPYzW8SGKYq24dPfiigDmfE9v5sSMxaWVjhV/iYVh6D4GutTv2uZ7YJkjarDn9K7nwXaRXMEV1cbpJ9oIZjnFeu29rDFaqI41GUDE45zjNAHmOj+AYrZxJcFBIoyQydP8ADvXRWmm29m5jhVCvXI4LVp6ycIuMjOc8/Ss9z5cHHJbgk/59qAHyzqWA4O0YBHG4Cq0k5K5AjZi3Bz0quhPmbRwCcY/Cq8H7yJGfkktn8OlAFqVpOHLfNzwe/sKqSXHzdM89s/lULOwUnc3GAOfWoZHbbI+fmB60AWImJ3NnK4JHsaQvuYk9znPSoIXZkb5iM88cUyaIBH5b5fegBWnRMKGDcnNUWujNIPmAxnIz/OqkjM52bmGT1HWoEyY2kJO7gdfagCWZ1SNnDEnt3qghx8w2jd39KdeL5UKlSeo4qGIs29Cx2r8w+tADd5jByxyOcYz2qOW4AZhGCeME/wCelDyMyQAnjJpDM37xcLtyDjGKAEaWRtrcHt9T/wDWoj8wNlkOWGeD2psPzXaxn7pwadMTCgCE8uRn8qAJrWFVD+a2ScnAOfyqcIwVDgleqnpwPT3qnFIxUtxuJ5OParcDs5RSxx04oAQXBUsWJzzg55P4UpuS+dvJxxxx/wDrqnO5SdY0AUcnipIyS7r0HIwPSgC0lx0Y8BBjPXOPSjzRtBU+5Az+dZcNxI128Zb5QCBWjGvyeYCQ23oOlAEm5pACFCsWz83cfT1odm/iYk9wB6etNiyYFcEglucd6Wd280xKSq5P3eCfxoAbMqoMAYZscE4qEFl+dhub73Jxx0p6zM0YJVeGOOPSq/mkIpwuWY54oAux5OxFwrjpkcnPWpETBL5bBbbjsQPWorNi8ETMeSMmpIWLgdvvDj2oAtYYAnJGc9W4X6VOGXID/eY8H+6KpwOVZigC8Y4FWYjvZ2KrlRkcUAXYJz8i43gHGT2FXAVVPmIGeTgfoDWfJhQ4VRwoxU0WVi3AnOQBQBbZUYZ2EqoA9aicfLuYvjORxjIqeMZdAfemr80yofu5oAbGz742JOR1zkY96tWwwclsbuA2cioYHLOykDg44qYKEDMo5DYFAGjYXKoCScgHkg5A/GtSO63EIxGT19jWBAQygED7pq/bnJU9Ce9AG4tvkBlIYD7pxz+VMO5CNijPqO341Jp8rsjqx3bTkZq/5aypKzjnG78aAOW1u1ivo2DYBwfvfyrzDxJ4Vle8AVVPChTtxj/9Ves3MY84kknZyKypgHt3kYAspzz3+tAFz4e6WtnpEKSNkxHAIHXnt6UVteClD2Wxv4OQe5Oe9FAH/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A chest radiograph demonstrates marked hyperexpansion of right upper lobe with cardiomediastinal shift to left.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Paul Spark, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26305=[""].join("\n");
var outline_f25_44_26305=null;
var title_f25_44_26306="Iodoquinol: Pediatric drug information";
var content_f25_44_26306=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"11\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Iodoquinol: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?20/38/21091?source=see_link\">",
"    see \"Iodoquinol: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?39/61/40915?source=see_link\">",
"    see \"Iodoquinol: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F183810\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Yodoxin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F183811\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Diodoquin&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1048014\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Amebicide",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1048008\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/38/21091?source=see_link\">",
"      see \"Iodoquinol: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children: 30-40 mg/kg/day in 3 divided doses for 20 days; not to exceed 1.95 g/day",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Adults: 650 mg 3 times/day after meals for 20 days; not to exceed 2 g/day",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F183795\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Yodoxin&reg;: 210 mg, 650 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F183780\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1048017\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral: Administer medication after meals; tablets may be crushed and mixed with applesauce or chocolate syrup",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1048016\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of acute and chronic intestinal amebiasis due to",
"     <i>",
"      Entamoeba histolytica",
"     </i>",
"     ; asymptomatic cyst passers;",
"     <i>",
"      Blastocystis hominis",
"     </i>",
"     infections; iodoquinol alone is ineffective for amebic hepatitis or hepatic abscess",
"    </p>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F183830\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Chills, fever, headache, vertigo",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, rash, skin eruptions, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Thyroid gland enlargement",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Abdominal cramps, anal itching, diarrhea, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Peripheral neuropathy",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Optic atrophy, optic neuritis",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1048020\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to iodine, iodoquinol, or any component; hepatic or renal damage; pre-existing optic neuropathy",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1048007\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with thyroid disease or neurological disorders",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299529\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F183789\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There are no known significant interactions.",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10253274\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     There is very limited data on the use of iodoquinol during pregnancy and safety has not been established.  Adverse effects have occurred in children exposed to topical iodoquinol.",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1048013\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Ophthalmologic exam",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1048006\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Contact amebicide that works in the lumen of the intestine by an unknown mechanism",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1048019\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: Oral: Poor and irregular",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: In the liver",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: In feces; metabolites appear in urine",
"    </p>",
"   </div>",
"   <div class=\"block pai drugH1Div\" id=\"F1048012\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Patient Information",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/61/40915?source=see_link\">",
"      see \"Iodoquinol: Patient drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Notify physician if rash occurs",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 13386 Version 31.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.234.146.186-0E46A87C69-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26306=[""].join("\n");
var outline_f25_44_26306=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183810\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183811\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048014\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048008\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183795\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183780\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048017\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048016\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183830\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048020\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048007\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299529\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F183789\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10253274\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048013\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048006\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048019\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1048012\">",
"      Patient Information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13386\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/13386|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?20/38/21091?source=related_link\">",
"      Iodoquinol: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?39/61/40915?source=related_link\">",
"      Iodoquinol: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_44_26307="Lymphoma with extensive bony metastases PET scan";
var content_f25_44_26307=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F88299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F88299&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Lymphoma with extensive bony metastases PET scan",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 442px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    55-year-old female patient with widely metastatic, PET scan positive diffuse large B cell lymphoma shown in the whole body view (A), and in&nbsp;an axial view through the pelvis (B). The corresponding CT scan (C) is almost normal.",
"    <br>",
"     <div class=\"footnotes\">",
"     </div>",
"     <div class=\"reference\">",
"     </div>",
"    </br>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26307=[""].join("\n");
var outline_f25_44_26307=null;
var title_f25_44_26308="Polysaccharide-iron complex, vitamin B12, and folic acid: Drug information";
var content_f25_44_26308=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Polysaccharide-iron complex, vitamin B12, and folic acid: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?41/52/42820?source=see_link\">",
"    see \"Polysaccharide-iron complex, vitamin B12, and folic acid: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F10009730\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or",
"     <a href=\"file://www.fda.gov\" target=\"_blank\">",
"      www.fda.gov",
"     </a>",
"     .",
"    </p>",
"   </div>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F10009734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Ferrex&trade; 150 Forte;",
"     </li>",
"     <li>",
"      Ferrex&trade; 150 Forte Plus;",
"     </li>",
"     <li>",
"      Maxaron&reg; Forte;",
"     </li>",
"     <li>",
"      Poly-Iron 150 Forte;",
"     </li>",
"     <li>",
"      Polysaccharide Iron 150 Forte",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F10009737\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Iron Salt",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F10009755\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Iron deficiency (prevention/treatment):",
"     </b>",
"     Oral: 1-2 capsules daily",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F10009756\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F10009766\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Capsule, oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferrex&trade; 150 Forte: Elemental iron 150 mg, cyanocobalamin 25 mcg, and folic acid 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Ferrex&trade; 150 Forte Plus: Elemental iron 150 mg (50 mg as ferrous asparto glycinate), cyanocobalamin 25 mcg, and folic acid 1 mg [contains ascorbic acid 60 mg and succinic acid 50 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Maxaron&reg; Forte: Elemental iron 150 mg (80 mg as ferrous bisglycinate), cyanocobalamin 25 mcg, and folic acid 1 mg [contains ascorbic acid 60 mg]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Poly-Iron 150 Forte: Elemental iron 150 mg, cyanocobalamin 25 mcg, and folic acid 1 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Polysaccharide Iron 150 Forte: Elemental iron 150 mg, cyanocobalamin 25 mcg, and folic acid 1 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F10009735\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F10009740\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Prevention and treatment of iron-deficiency anemias and/or nutritional megaloblastic anemias",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F10009748\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Gastrointestinal: Abdominal pain, constipation, dark stools, diarrhea, epigastric pain, GI irritation, nausea, stomach cramping, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Genitourinary: Discolored urine",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Miscellaneous: Hypersensitivity reaction",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F10009744\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Anemia: Not appropriate for with pernicious, aplastic, or normocytic anemias when anemia is present with vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     deficiency.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pernicious anemia: Folate doses &gt;0.1 mg/day may obscure pernicious anemia in that hematologic remission can occur with continuing irreversible nerve damage progression.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     &bull; Pediatrics:",
"     <b>",
"      [U.S. Boxed Warning]: Accidental overdose of iron-containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep this product out of the reach of children. In case of accidental overdose call the poison control center immediately.",
"     </b>",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299908\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F10073257\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Antacids: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Bisphosphonate Derivatives: Iron Salts may decrease the serum concentration of Bisphosphonate Derivatives.  Management: Avoid administration of oral iron supplements within: 2 hours before or after tiludronate/clodronate/etidronate; 60 minutes after oral ibandronate; or 30 minutes after alendronate/risedronate.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Pamidronate; Zoledronic Acid.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cefdinir: Iron Salts may decrease the serum concentration of Cefdinir. Red-appearing, non-bloody stools may also develop due to the formation of an insoluble iron-cefdinir complex.  Management: Avoid concurrent cefdinir and oral iron when possible.  Separating doses by several hours may minimize interaction.  Iron-containing infant formulas do not appear to interact with cefdinir.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Deferiprone: Iron Salts may decrease the serum concentration of Deferiprone.  Management: Separate administration of deferiprone and oral medications or supplements that contain polyvalent cations by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Dimercaprol: May enhance the nephrotoxic effect of Iron Salts.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Eltrombopag: Iron Salts may decrease the serum concentration of Eltrombopag.  Management: Separate administration of eltrombopag and any orally administered polyvalent cation (e.g., iron-containing products) by at least 4 hours.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Fosphenytoin: Folic Acid may decrease the serum concentration of Fosphenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Green Tea: May decrease the serum concentration of Folic Acid.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     H2-Antagonists: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levodopa: Iron Salts may decrease the serum concentration of Levodopa. Only applies to oral iron preparations.  Management: Consider separating doses of the agents by 2 or more hours to minimize the effects of this interaction. Monitor for decreased therapeutic effects of levodopa during concomitant therapy, particularly if doses cannot be separated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Levothyroxine: Iron Salts may decrease the serum concentration of Levothyroxine.  Management: Separate oral administration of iron salts and levothyroxine by at least 4 hours.  Separation of doses is not required with parenterally administered iron salts or levothyroxine.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methyldopa: Iron Salts may decrease the serum concentration of Methyldopa.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pancrelipase: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PenicillAMINE: Iron Salts may decrease the absorption of PenicillAMINE. Only oral iron salts are a concern.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     PHENobarbital: Folic Acid may decrease the serum concentration of PHENobarbital.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phenytoin: Folic Acid may decrease the serum concentration of Phenytoin.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Phosphate Supplements: Iron Salts may decrease the absorption of Phosphate Supplements.  Management: Administer oral phosphate supplements at least 1 hour before, or 2 hours after, oral iron salt administration.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Potassium Phosphate.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Primidone: Folic Acid may decrease the serum concentration of Primidone. Additionally, folic acid may decrease concentrations of active metabolites of primidone (e.g., phenobarbital).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Proton Pump Inhibitors: May decrease the absorption of Iron Salts.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Quinolone Antibiotics: Iron Salts may decrease the absorption of Quinolone Antibiotics. Of concern only with oral administration of both agents.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Raltitrexed: Folic Acid may diminish the therapeutic effect of Raltitrexed.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tetracycline Derivatives: Iron Salts may decrease the absorption of Tetracycline Derivatives. Only a concern with orally administered products.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Trientine: Iron Salts may decrease the serum concentration of Trientine. Trientine may decrease the serum concentration of Iron Salts.  Management: Trientine manufacturer recommends avoiding concurrent administration with oral iron salts due to the risk for impaired GI absorption of both trientine and the iron salt. Short courses of iron may be used however separate administration by at least 2 hours",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F10009741\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     It is recommended that pregnant women meet the dietary requirements of iron with diet and/or supplements in order to prevent adverse events associated with iron-deficiency anemia in pregnancy. Treatment of iron-deficiency anemia in pregnant women is the same as in nonpregnant women, and in most cases, oral iron preparations may be used. Except in severe cases of maternal anemia, the fetus achieves normal iron stores regardless of maternal concentrations.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F10009742\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Enters breast milk",
"    </p>",
"   </div>",
"   <div class=\"block brc drugH1Div\" id=\"F10009743\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Breast-Feeding Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Iron is normally found in breast milk. Breast milk or iron-fortified formulas generally provide enough iron to meet the recommended dietary requirements of infants. The amount of iron in breast milk is generally not influenced by maternal iron status.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Vegetarian diets which contain no animal products do not supply any vitamin B",
"     <sub>",
"      12",
"     </sub>",
"     . Deficiency recognized in infants of vegetarian mothers who were breast-fed; consider supplementation during breast-feeding.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Folic acid requirements are increased during pregnancy; a deficiency may result in fetal harm.",
"    </p>",
"   </div>",
"   <div class=\"block dic drugH1Div\" id=\"F10009757\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dietary Considerations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Dietary sources of iron include beans, cereal (enriched), clams, beef, lentils, liver, oysters, shrimp, and turkey. Foods that enhance dietary absorption of iron include broccoli, grapefruit, orange juice, peppers and strawberries. Foods that decrease dietary absorption of iron include coffee, dairy products, soy products, spinach, and tea.",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16322836\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Capsules",
"     </b>",
"     (Ferrex 150 Forte Plus Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     50-100 mg (90): $114.35",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American College of Obstetricians and Gynecologists, &ldquo;ACOG Practice Bulletin No. 95: Anemia in Pregnancy,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2008, 112(1):201-7.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/44/26308/abstract-text/18591330/pubmed\" id=\"18591330\" target=\"_blank\">",
"        18591330",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Baker WF Jr, &ldquo;Iron Deficiency in Pregnancy, Obstetrics, and Gynecology,&rdquo;",
"      <i>",
"       Hematol Oncol Clin North Am",
"      </i>",
"      , 2000, 14(5):1061-77.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/44/26308/abstract-text/11005034/pubmed\" id=\"11005034\" target=\"_blank\">",
"        11005034",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      IOM (Institute of  Medicine),",
"      <i>",
"       Dietary Reference Intakes for Vitamin A, Vitamin K, Arsenic, Boron, Chromium, Copper, Iodine, Iron, Manganese, Molybdenum, Nickel, Silicon, Vanadium, and Zinc",
"      </i>",
"      , Washington, DC: National Academy Press, 2001.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Nutrition During Lactation.&rdquo; Subcommittee on Nutrition During Lactation, Committee on Nutritional Status During Pregnancy and Lactation, Food and Nutrition Board Institute of Medicine, National Academy of Sciences Washington, DC: National Academy Press, 1991. Available at",
"      <a href=\"file://www.nap.edu\" target=\"_blank\">",
"       file://www.nap.edu",
"      </a>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Recommendations to Prevent and Control Iron Deficiency in the United States. Centers for Disease Control and Prevention,&rdquo;",
"      <i>",
"       MMWR Recomm Rep",
"      </i>",
"      , 1998, 47(RR-3):1-29.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/44/26308/abstract-text/9563847/pubmed\" id=\"9563847\" target=\"_blank\">",
"        9563847",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Routine Iron Supplementation During Pregnancy. Review Article. US Preventive Services Task Force,&rdquo;",
"      <i>",
"       JAMA",
"      </i>",
"      , 1993, 270(23):2848-54.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?25/44/26308/abstract-text/8133626/pubmed\" id=\"8133626\" target=\"_blank\">",
"        8133626",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9908 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-202.43.93.2-04D01F2D42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26308=[""].join("\n");
var outline_f25_44_26308=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009730\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009734\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009737\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009755\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009756\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009766\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009735\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009740\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009748\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009744\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299908\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10073257\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009741\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009742\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009743\">",
"      Breast-Feeding Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10009757\">",
"      Dietary Considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16322836\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9908\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9908|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?41/52/42820?source=related_link\">",
"      Polysaccharide-iron complex, vitamin B12, and folic acid: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_44_26309="Duplication cyst EUS";
var content_f25_44_26309=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65472&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Duplication cyst in the esophagus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 405px; height: 390px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endosonographic view of an esophageal duplication cyst. Duplication cysts are usually anechoic homogeneous lesions with regular margins arising from the submucosal (third layer) or extrinsic to the gastrointestinal wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Mary Lee Krinsky, DO and Kenneth Binmoeller, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26309=[""].join("\n");
var outline_f25_44_26309=null;
var title_f25_44_26310="Radiofrequency ablation and cryoablation for renal cell carcinoma";
var content_f25_44_26310=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Radiofrequency ablation and cryoablation for renal cell carcinoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26310/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26310/contributors\">",
"     Andrew Hines-Peralta, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26310/contributors\">",
"     S Nahum Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26310/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26310/contributors\">",
"     Michael B Atkins, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26310/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26310/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/44/26310/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are over 50,000 new cases of renal cell carcinoma (RCC) diagnosed each year in the United States, and the incidence has been increasing over time. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=see_link\">",
"     \"Epidemiology, pathology, and pathogenesis of renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The average size of these RCCs at presentation is decreasing, and more patients are presenting with small, localized lesions. In addition, there is an increasing awareness of the importance of preserving renal function, if this can be accomplished without compromising the oncologic outcome. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=see_link\">",
"     \"Diagnostic approach, differential diagnosis, and treatment of a small renal mass\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link&amp;anchor=H6#H6\">",
"     \"Surgical management of localized renal cell carcinoma\", section on 'Renal function'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Sharply delineated areas of very high or low temperature can be created in a minimally invasive fashion with either radiofrequency ablation (RFA) or cryoablation. These temperature extremes are used to produce tumor cell death. Emerging technologies, such as microwave ablation and high-intensity focused ultrasound (HIFU), can also induce local hyperthermia and are being studied experimentally. These minimally or noninvasive technologies are rapidly gaining acceptance as alternatives to surgery for many tumors, including RCC.",
"   </p>",
"   <p>",
"    The increasing acceptance of RFA and cryoablation for kidney tumors is based upon favorable outcomes in initial studies, a low incidence of serious complications, less immediate morbidity and mortality than with surgery, lower cost, and the ability to treat patients in the outpatient setting. Optimal application of these ablative techniques requires interventional radiologists and urologists who are experienced and skilled in the application of the technology.",
"   </p>",
"   <p>",
"    The potential benefits of these ablative techniques must be balanced against the lack of long-term, comparative efficacy data. In addition, multiple treatment sessions may be required because of difficulties in monitoring the extent of ablation. Furthermore, these ablative techniques may not be appropriate for large lesions or tumors near the renal hilum.",
"   </p>",
"   <p>",
"    The various ablative techniques, indications, and outcomes for patients with RCC are reviewed here. The surgical management of RCC is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link\">",
"     \"Surgical management of localized renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The indications for RFA or cryoablation to treat RCC have not been definitively established.",
"   </p>",
"   <p>",
"    Factors that can lead to consideration of an ablative approach rather than surgery include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A small, incidentally detected RCC (ideally &lt;4 cm in diameter and limited to the kidney). The benefit of a total or partial nephrectomy is unclear for these small, RCCs whose natural course may not affect patient longevity.",
"     </li>",
"     <li>",
"      A patient who is considered a poor surgical candidate, based upon older age or significant comorbidity.",
"     </li>",
"     <li>",
"      The need for nephron-sparing treatment, as a way to postpone or avoid the need for chronic dialysis. This includes patients with a single kidney, bilateral RCCs, or a genetic predisposition to multiple tumors (eg, von Hippel-Lindau syndrome).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For patients with one or more of these factors, RFA or cryoablation may be an attractive option since ablation may avoid the morbidity of surgery while offering an effective and potentially curative treatment option [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/1\">",
"     1",
"    </a>",
"    ]. Tumor ablation may be preferred over surgery for small RCC treatment at a societal level because of the lower costs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the application of these techniques for small RCCs, RFA and cryoablation may be useful in some patients with local tumor recurrence after nephrectomy, intractable tumor-related hematuria, tumor debulking in patients with metastatic disease, or in the management of symptomatic distant metastases from a primary kidney tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Patient selection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are usually evaluated by both an urologist and a radiologist prior to treatment. Imaging is used to define the extent of disease and the presence or absence of metastases. In addition, treatment planning requires pretreatment imaging that can be performed with ultrasound, magnetic resonance, or CT guidance [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. A pretreatment biopsy prior is not mandatory but is strongly encouraged as imaging does not always accurately differentiate benign from malignant disease. In addition, systemic treatments for patients with advanced RCC are increasingly being based on tumor histology and other pathologic features.",
"   </p>",
"   <p>",
"    Tumor size and location are the most important factors that govern whether RCCs can be successfully treated [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/5,6\">",
"     5,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In determining the volume to be treated, a 0.5 to 1.0 cm \"ablation margin\" surrounding the tumor is needed to ensure that the entire tumor is treated [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/3\">",
"       3",
"      </a>",
"      ]. Since temperature gradients exponentially decrease with distance from the radiofrequency or cryoablation probe, large tumors pose a significant challenge. In general, tumors &lt;4 cm in diameter are ideal. Most tumors &lt;3 cm can be treated in a single session. Tumors between 3.0 and 4.0 cm in diameter can also be successfully treated, although multiple ablations may be required [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/5-13\">",
"       5-13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Exophytic tumors are most amenable to ablation, since these are surrounded by heat-insulating perirenal fat with relatively little vascular tissue, which can draw heat away from tumor (\"heat-sink\" effect). As a result, large exophytic tumors as large as 4 cm are almost always successfully treated, with 70 percent or more requiring only a single session. Parenchymal tumors may be more difficult to treat. Centrally located tumors are the hardest to successfully ablate due to the heat-sink effect and have an increased risk of treatment failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Relative contraindications to RFA or cryoablation include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A life expectancy less than one year",
"     </li>",
"     <li>",
"      The presence of distant metastases",
"     </li>",
"     <li>",
"      Tumors &gt;5 cm or tumors in the hilum or central collecting system are generally not candidates for ablation. For tumors in which treatment may cause thermal injury to the proximal ureter (resulting in urine extravasation and urinoma), an intraureteral stent is usually inserted prior to treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Absolute contraindications include irreversible coagulopathies or severe medical instability.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PROCEDURE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Successful percutaneous tumor ablation requires killing all viable malignant cells including a 5 to 10 mm \"ablative\" margin of surrounding tissue, while minimizing damage to adjacent normal kidney. The most extensively used techniques are radiofrequency ablation (RFA) and cryoablation. Other techniques using alternative energy sources (microwave, high-intensity focused ultrasound) show some promise but are available only in experimental settings.",
"   </p>",
"   <p>",
"    Both RFA and cryoablation typically are performed with a percutaneous approach. When done percutaneously, either technique is usually an outpatient procedure unless comorbid conditions require hospitalization or closer observation. Only conscious sedation is typically necessary for anesthesia, although some clinicians and patients prefer general anesthesia.",
"   </p>",
"   <p>",
"    The patient is placed prone. After local anesthesia is applied, the applicator is percutaneously advanced into the center of the tumor under CT, ultrasound, or MRI guidance. Heat or cold is then applied for approximately 10 to 20 minutes as dictated by the device maker's recommendations. Depending upon the size and location of the tumor, the applicator may need to be readjusted, and additional treatments administered.",
"   </p>",
"   <p>",
"    After the procedure, the patient is monitored for several hours, and discharged home with oral analgesics for post-procedural pain. Patients usually are able to resume full activity within a couple of days.",
"   </p>",
"   <p>",
"    A laparoscopic approach is similar to other surgical laparoscopic procedures requiring general anesthesia, and image-guidance is limited to small transducer ultrasonography. Most patients treated laparoscopically are hospitalized overnight, and there may be more post-procedural pain [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Radiofrequency ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;RFA utilizes a high-frequency (460 to 500 kHz) alternating current that is delivered into the tumor through a thin needle (usually 21 to 14 gauge) that is electrically insulated except for its terminal 1 to 3 cm. The current produces resistive friction in the tissue that is converted into heat, analogous to heat production from an electrical resister in a circuit. Heat, in turn, causes cellular destruction and protein denaturation. Most RFA systems used for the kidney are monopolar, and the current is completed with grounding pads placed on the patient's back and thighs.",
"   </p>",
"   <p>",
"    Efforts to increase tumor ablation have led to the development of various RF applicators, such as multi-tined applicators, cluster applicators, and pulsed energy delivery. There are multiple RFA devices available for soft tumor ablation. There is no demonstrated advantage of any one device.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Cryoablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For cryoablation, liquid nitrogen or argon is introduced into a probe in a controlled fashion, resulting in freezing of the surrounding tissues, with the formation of an \"iceball\" that can be visualized. Intracellular ice crystals disrupt the cell membrane and other intracellular activities, leading to cell death. Cells that are not directly killed may undergo apoptosis.",
"   </p>",
"   <p>",
"    A typical cryoablation session involves freezing, thawing, and refreezing, which is particularly effective at mediating cellular disruption. The applicators initially developed for cryoablation were relatively large, and laparoscopy was required. Smaller applicators are now available, enabling percutaneous image-guided cryoablation.",
"   </p>",
"   <p>",
"    During cryoablation, the iceball can be visualized in real time with either CT or MRI, which allows the extent of cell death to be more reliably predicted. Complete cell death is thought to occur 3 mm inside the edge of the ice ball; thus, most operators extend the ice ball at least 5 mm beyond the tumor margin to ensure complete tumor coverage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Emerging technologies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Microwave and high intensity focused ultrasound (HIFU) have been used as alternative approaches to heat target lesions.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Microwave energy is a potential source of heat for use in thermal ablation, although the technology has only been applied experimentally to small series of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/15\">",
"       15",
"      </a>",
"      ]. In contrast to RFA, a microwave incorporates an antenna to receive externally applied energy at 1000 to 2450 mHz. This microwave energy results in rotation of polar molecules that is opposed by frictional forces, which is converted to heat.",
"      <br/>",
"      <br/>",
"      A potential advantage of microwave ablation over RFA is greater energy deposition and thus the development of higher temperatures. This may allow microwave ablation to avoid the effects of tissue charring which can occur around the RFA applicator. The higher energy may also be more resilient to the heat-sink effect, which can be an important obstacle for RFA. Microwave ablation is only available in experimental settings, as its efficacy and safety are not established.",
"     </li>",
"     <li>",
"      HIFU uses extracorporeally generated sonic waves to generate a sharply delineated area of thermal energy that destroys the target tissue. The most extensive experience with HIFU is in the treatment of prostate cancer, but there is only preliminary experience in patients with renal tumors [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/16,17\">",
"       16,17",
"      </a>",
"      ]. One theoretical benefit of this approach is that HIFU does not involve any physical penetration of the skin.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Surveillance after ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT is typically used to assess the success of tumor ablation, starting about one month after treatment. On CT, viable tumor is usually nodular and maintains its enhancement (&gt;10 Hounsfield units after contrast injection) whereas successfully ablated tumor no longer enhances with contrast.",
"   </p>",
"   <p>",
"    Imaging immediately following the ablation is difficult to interpret because inflammation at the periphery of the lesion may mimic viable tumor [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/18\">",
"     18",
"    </a>",
"    ]. Thus, post-treatment CT imaging is usually performed at three to six months, 12 months, 18 months, and 24 months after ablation, and yearly thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OUTCOMES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rapid advances in technique and experience make interpretation of the reported results difficult. There are no randomized trials comparing these techniques with surgery, and such trials are not likely to be carried out in the near future.",
"   </p>",
"   <p>",
"    Multiple series have reported excellent short-term disease control with both RFA and cryoablation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/19\">",
"     19",
"    </a>",
"    ]. Although these results appear similar to those with partial nephrectomy or radical nephrectomy, longer follow-up is required before these techniques can be considered as an alternative to surgery in patients who are candidates for a definitive surgical resection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link\">",
"     \"Surgical management of localized renal cell carcinoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Both RFA and cryoablation appear to be well tolerated, with a low incidence of serious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/12,20\">",
"     12,20",
"    </a>",
"    ]. A self-limited syndrome manifested by fever and flu-like symptoms has been reported in up to one-third of patients following RFA and cryoablation [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Available data from retrospective series do provide some insight into the relative safety and efficacy of the percutaneous versus laparoscopic routes of treatment, as well as the relative benefits of RFA versus cryoablation",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Percutaneous versus laparoscopic ablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that compared the efficacy of a percutaneous versus a laparoscopic approach to RCC ablation.",
"   </p>",
"   <p>",
"    These approaches were compared in a meta-analysis that included data from 46 observational series (28 with percutaneous treatment and 18 with laparoscopic therapy), which included 1055 patients who were treated for 1180 tumors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/21\">",
"     21",
"    </a>",
"    ]. Of the 28 series using a percutaneous approach, 21 used RFA and seven used cryoablation; of the 18 series performed with laparoscopy, three used RFA and 15 used cryoablation.",
"   </p>",
"   <p>",
"    Key observations from this review included:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Tumor size was similar in the percutaneous and laparoscopic treatment groups (2.8 and 2.5 cm, respectively).",
"     </li>",
"     <li>",
"      Major complications were less frequent with percutaneous treatment (3.1 versus 7.4 percent using laparoscopy), and the mean hospital stay was shorter (1.4 versus 3.0 days).",
"     </li>",
"     <li>",
"      A percutaneous approach was less effective than a laparoscopic approach when only the initial treatment was considered (87 versus 94), and retreatment was required more frequently. The difference in local control between the percutaneous and laparoscopic approaches was not statistically significant when retreatment was considered (92 versus 95 percent).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the mean length of follow-up was short for both groups (13 and 16 months for percutaneous and laparoscopic ablation, respectively). Long-term follow-up data are very limited, but limited results suggest that the recurrence-free survival rate is approximately 90 percent at five years.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     RFA versus cryoablation",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no randomized trials that compare RFA with cryoablation in the management of RCC. Numerous retrospective series have been published, which do give some insight into the outcomes with these approaches.",
"   </p>",
"   <p>",
"    The results with these two approaches were compared in a meta-analysis that included 47 series [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26310/abstract/19\">",
"     19",
"    </a>",
"    ]. The meta-analysis was limited to patients with sporadic, localized RCCs.",
"   </p>",
"   <p>",
"    Key observations included the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The meta-analysis included 1375 patients (600 treated with RFA and 775 treated with cryoablation). The mean age of all patients treated was 67 years, the mean tumor size was 2.6 cm, and the mean duration of follow-up was 19 months. These parameters were not significantly different for patients treated with either modality.",
"     </li>",
"     <li>",
"      Cryoablation was performed laparoscopically, percutaneously, or by open surgery in 65, 23, and 12 percent of cases, respectively. In contrast, RFA was performed percutaneously or at laparoscopy in 94 and 6 percent of cases, respectively.",
"     </li>",
"     <li>",
"      Local tumor progression after a single treatment session was more frequent after RFA (12.9 versus 5.2 percent with cryoablation), and repeat ablation therapy was required more often following initial treatment with RFA (8.5 versus 1.3 percent). These differences were statistically significant.",
"     </li>",
"     <li>",
"      Overall, progression to metastatic disease was seen in 25 cases (1.8 percent). The difference in incidence of metastasis between cryoablation and RFA was not statistically significant on multivariate analysis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Beyond the Basics topic (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=see_link\">",
"       \"Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiofrequency ablation (RFA) and cryoablation are gaining acceptance in the treatment of carefully selected patients with small renal cell carcinomas (RCCs). Although these approaches offer some significant advantages, long-term efficacy data are lacking.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with stage I, II, or III renal cell carcinoma (RCC) (",
"      <a class=\"graphic graphic_table graphicRef54563 \" href=\"UTD.htm?14/54/15213\">",
"       table 1",
"      </a>",
"      ), we recommend surgery as the primary treatment approach (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=see_link\">",
"       \"Surgical management of localized renal cell carcinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For carefully selected patients, RFA or cryoablation represent a less invasive alternative associated with less morbidity and fewer complications. However, the long-term efficacy of these approaches remains to be established. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Outcomes'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Patient factors that potentially make ablation advantageous include older age, significant comorbidity, a small, incidentally discovered lesion, or the need to preserve as much renal parenchyma as possible (eg, patients with a solitary kidney, those with multiple lesions). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The most favorable lesions for use with an ablative approach are smaller RCCs (&le;4 cm) and those in the periphery of the kidney. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Patient selection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      There are no randomized trials comparing RFA with cryoablation. For patients who are treated with ablation, the choice of RFA or cryoablation should be based upon the availability of local expertise. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'RFA versus cryoablation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H11\">",
"       'Percutaneous versus laparoscopic ablation'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/1\">",
"      Onishi T, Nishikawa K, Hasegawa Y, et al. Assessment of health-related quality of life after radiofrequency ablation or laparoscopic surgery for small renal cell carcinoma: a prospective study with medical outcomes Study 36-Item Health Survey (SF-36). Jpn J Clin Oncol 2007; 37:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/2\">",
"      Pandharipande PV, Gervais DA, Mueller PR, et al. Radiofrequency ablation versus nephron-sparing surgery for small unilateral renal cell carcinoma: cost-effectiveness analysis. Radiology 2008; 248:169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/3\">",
"      Nahum Goldberg S, Dupuy DE. Image-guided radiofrequency tumor ablation: challenges and opportunities--part I. J Vasc Interv Radiol 2001; 12:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/4\">",
"      Ahmed M, Brace CL, Lee FT Jr, Goldberg SN. Principles of and advances in percutaneous ablation. Radiology 2011; 258:351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/5\">",
"      Gervais DA, McGovern FJ, Arellano RS, et al. Radiofrequency ablation of renal cell carcinoma: part 1, Indications, results, and role in patient management over a 6-year period and ablation of 100 tumors. AJR Am J Roentgenol 2005; 185:64.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/6\">",
"      Gervais DA, Arellano RS, McGovern FJ, et al. Radiofrequency ablation of renal cell carcinoma: part 2, Lessons learned with ablation of 100 tumors. AJR Am J Roentgenol 2005; 185:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/7\">",
"      Tracy CR, Raman JD, Donnally C, et al. Durable oncologic outcomes after radiofrequency ablation: experience from treating 243 small renal masses over 7.5 years. Cancer 2010; 116:3135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/8\">",
"      Zagoria RJ, Traver MA, Werle DM, et al. Oncologic efficacy of CT-guided percutaneous radiofrequency ablation of renal cell carcinomas. AJR Am J Roentgenol 2007; 189:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/9\">",
"      Breen DJ, Rutherford EE, Stedman B, et al. Management of renal tumors by image-guided radiofrequency ablation: experience in 105 tumors. Cardiovasc Intervent Radiol 2007; 30:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/10\">",
"      Levinson AW, Su LM, Agarwal D, et al. Long-term oncological and overall outcomes of percutaneous radio frequency ablation in high risk surgical patients with a solitary small renal mass. J Urol 2008; 180:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/11\">",
"      Stein RJ, Kaouk JH. Renal cryotherapy: a detailed review including a 5-year follow-up. BJU Int 2007; 99:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/12\">",
"      Atwell TD, Callstrom MR, Farrell MA, et al. Percutaneous renal cryoablation: local control at mean 26 months of followup. J Urol 2010; 184:1291.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/13\">",
"      Atwell TD, Farrell MA, Callstrom MR, et al. Percutaneous cryoablation of large renal masses: technical feasibility and short-term outcome. AJR Am J Roentgenol 2007; 188:1195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/14\">",
"      Finley DS, Beck S, Box G, et al. Percutaneous and laparoscopic cryoablation of small renal masses. J Urol 2008; 180:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/15\">",
"      Liang P, Wang Y, Zhang D, et al. Ultrasound guided percutaneous microwave ablation for small renal cancer: initial experience. J Urol 2008; 180:844.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/16\">",
"      Klingler HC, Susani M, Seip R, et al. A novel approach to energy ablative therapy of small renal tumours: laparoscopic high-intensity focused ultrasound. Eur Urol 2008; 53:810.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/17\">",
"      Ritchie RW, Leslie T, Phillips R, et al. Extracorporeal high intensity focused ultrasound for renal tumours: a 3-year follow-up. BJU Int 2010; 106:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/18\">",
"      Allen BC, Remer EM. Percutaneous cryoablation of renal tumors: patient selection, technique, and postprocedural imaging. Radiographics 2010; 30:887.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/19\">",
"      Kunkle DA, Uzzo RG. Cryoablation or radiofrequency ablation of the small renal mass : a meta-analysis. Cancer 2008; 113:2671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/20\">",
"      Wah TM, Arellano RS, Gervais DA, et al. Image-guided percutaneous radiofrequency ablation and incidence of post-radiofrequency ablation syndrome: prospective survey. Radiology 2005; 237:1097.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26310/abstract/21\">",
"      Hui GC, Tuncali K, Tatli S, et al. Comparison of percutaneous and surgical approaches to renal tumor ablation: metaanalysis of effectiveness and complication rates. J Vasc Interv Radiol 2008; 19:1311.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3001 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-200.131.240.2-817E36F31F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26310=[""].join("\n");
var outline_f25_44_26310=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Patient selection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PROCEDURE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Radiofrequency ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Cryoablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Emerging technologies",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Surveillance after ablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OUTCOMES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Percutaneous versus laparoscopic ablation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      RFA versus cryoablation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/3001\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/3001|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?14/54/15213\" title=\"table 1\">",
"      TNM staging RCC",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/9/2200?source=related_link\">",
"      Diagnostic approach, differential diagnosis, and treatment of a small renal mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?17/52/18250?source=related_link\">",
"      Epidemiology, pathology, and pathogenesis of renal cell carcinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/53/30546?source=related_link\">",
"      Patient information: Renal cell carcinoma (kidney cancer) (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/26/5546?source=related_link\">",
"      Surgical management of localized renal cell carcinoma",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_44_26311="Corticotropin-releasing hormone stimulation test";
var content_f25_44_26311=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Corticotropin-releasing hormone stimulation test",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26311/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26311/contributors\">",
"     Lynnette K Nieman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26311/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26311/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26311/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26311/contributors\">",
"     Kathryn A Martin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/44/26311/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Apr 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Corticotropin-releasing hormone (CRH) is a 41-amino acid peptide that is the major physiologic ACTH secretagogue [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/1\">",
"     1",
"    </a>",
"    ]. There is considerable sequence homology of CRH among species, particularly in the amino-terminal region, which is required for biologic activity. As a result, both ovine and human sequences are used in endocrine testing to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluate the cause of ACTH-dependent Cushing's syndrome (with or without vasopressin analogs).",
"     </li>",
"     <li>",
"      Discriminate between pseudo-Cushing's and Cushing's syndrome.",
"     </li>",
"     <li>",
"      Discriminate between pituitary or hypothalamic localization of central adrenal insufficiency.",
"     </li>",
"     <li>",
"      To assess ACTH suppression in patients suspected of primary adrenal mild Cushing's syndrome when basal ACTH levels are incompletely suppressed between 5 and 15",
"      <span class=\"nowrap\">",
"       pg/mL",
"      </span>",
"      [1.1 to 3.3",
"      <span class=\"nowrap\">",
"       pmol/L].",
"      </span>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=see_link\">",
"       \"Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CRH test is expensive; the cost for the CRH dose alone is over $300 (United States). Most investigators use an increase in either plasma ACTH or plasma cortisol concentration as the criterion for response. Multiple blood samples must be obtained (at least one basal sample and at least two and as many as eight post-CRH samples). As a result, the test should probably be performed only by specialists in carefully selected patients. In the United States, ovine CRH is available and carries FDA labeling for the differential diagnosis of Cushing's syndrome. In Europe, the human analog is available.",
"   </p>",
"   <p>",
"    This topic will review the technique and interpretation of the CRH stimulation test, and combination tests including CRH plus arginine vasopressin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    , and low-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    . The vasopressin and desmopressin stimulation tests are discussed in more detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36312?source=see_link\">",
"     \"Vasopressin and desmopressin stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CORTICOTROPIN-RELEASING HORMONE STIMULATION TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is useful to review the procedure for performing the CRH test and the normal response before discussing its use in Cushing's syndrome and adrenal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The patient usually fasts for four hours or more, after which an intravenous access line is established and synthetic ovine CRH (1 mcg [200 nmoles] per kg body weight or 100 mcg total dose) is injected as an intravenous bolus. Blood samples for ACTH and cortisol are drawn 15 (or 5) and 0 minutes before and as often as 5, 10, 15, 30, 45, 60, 90 and 120 minutes after CRH injection. However, in Cushing's syndrome, if one measures only the plasma ACTH response, the samples at -5, -0, 15 and 30 minutes are sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/2\">",
"     2",
"    </a>",
"    ], and if one measures only the serum cortisol response, the samples at -15, 0, 45, and 60 minutes are sufficient [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/3\">",
"     3",
"    </a>",
"    ]. Normally both hormones should be measured since the criteria for a positive response may include increases in either plasma ACTH or serum cortisol concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Synthetic ovine CRH is equipotent to human CRH and has a more prolonged duration of action than human CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/4-6\">",
"     4-6",
"    </a>",
"    ], which makes it useful for clinical testing [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/7\">",
"     7",
"    </a>",
"    ]. Some patients have mild, brief facial flushing immediately after injection, but there are no other side effects at this dose level [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/8\">",
"     8",
"    </a>",
"    ]. Allergic reactions have not been reported.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Normal values",
"    </span>",
"    &nbsp;&mdash;&nbsp;Responses to CRH are quite variable among subjects and from one time to another in the same subject. The cause of this variability is unknown, but cannot be accounted for simply by inhibition by variable basal plasma cortisol concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/9\">",
"     9",
"    </a>",
"    ]. Basal plasma ACTH concentrations increase 35 to 900 percent (mean 400 percent) in normal subjects and reach a peak of 10 to 120",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (2.2 to 24",
"    <span class=\"nowrap\">",
"     pmol/L)",
"    </span>",
"    10 to 30 minutes after CRH injection; serum cortisol concentrations increase 20 to 600 percent (mean 250 percent) to 13 to 36",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (mean 25",
"    <span class=\"nowrap\">",
"     mcg/dL)",
"    </span>",
"    (360 to 1000",
"    <span class=\"nowrap\">",
"     nmol/L",
"    </span>",
"    [mean 690",
"    <span class=\"nowrap\">",
"     nmol/L]),",
"    </span>",
"    reaching a peak 30 to 60 minutes after CRH injection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/3,6,10,11\">",
"     3,6,10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increment in plasma ACTH is the same in the morning and evening; however, the peak value is greater in the morning in normal subjects when the basal plasma ACTH concentration is higher. In contrast, the peak serum cortisol value is similar at both times of day, but the increment is smaller in the morning when the basal value is higher. In patients with Cushing's syndrome, in whom the normal circadian rhythm in ACTH secretion is absent, the CRH test can be performed at any time of day with similar results. Hyperglycemia does not appear to influence the results, as judged by response during a hyperglycemic clamp study [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/12,13\">",
"     12,13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CRH PLUS ARGININE VASOPRESSIN OR DESMOPRESSIN",
"    </span>",
"    &nbsp;&mdash;&nbsp;Arginine vasopressin (AVP) potentiates the response to CRH in most normal subjects, producing a greater than additive increase in plasma ACTH and serum cortisol [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. In contrast,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    does not appear to potentiate CRH-stimulated ACTH release in most normal subjects [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36312?source=see_link\">",
"     \"Vasopressin and desmopressin stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     DIAGNOSIS OF THE CAUSE OF CUSHING'S SYNDROME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The concept underlying use of the CRH and CRH plus vasopressin stimulation tests in Cushing's syndrome is that pituitary tumors causing Cushing's disease usually respond to CRH and vasopressin, whereas ectopic ACTH-secreting tumors usually do not [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/20\">",
"     20",
"    </a>",
"    ]. Adrenal tumors, which secrete sufficient cortisol to increase urinary free cortisol levels, are also unable to respond because ACTH secretion is suppressed. However, this disorder can be easily differentiated by the demonstration of low plasma ACTH concentrations versus normal or the high concentrations in pituitary or ectopic Cushing's syndrome. Thus, a response to CRH or CRH plus vasopressin should differentiate Cushing's disease from all other causes of ACTH-dependent Cushing's syndrome.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     CRH stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with Cushing's disease respond with ACTH and cortisol increases within 45 minutes after CRH [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/2,20-24\">",
"     2,20-24",
"    </a>",
"    ]. However, the criteria for interpretation have varied at different centers.",
"   </p>",
"   <p>",
"    One group developed criteria for the diagnosis of Cushing's disease that excluded all patients with ectopic ACTH secretion (100 percent specificity). The ACTH and cortisol responses to ovine CRH in Cushing's disease were defined as a 35 percent increase in the basal plasma ACTH concentration or a 20 percent increase in the basal serum cortisol concentration [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/2\">",
"     2",
"    </a>",
"    ]. This report included 101 patients with untreated Cushing's disease and 17 patients with ectopic ACTH syndrome. At 100 percent specificity, the sensitivity for ACTH was 93 percent, while it was 88 percent for cortisol.",
"   </p>",
"   <p>",
"    Ovine CRH was evaluated in another study of 49 patients with Cushing's disease and 10 with ectopic ACTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/21\">",
"     21",
"    </a>",
"    ]. ROC curve analysis determined that an ACTH increment of at least 50 percent gave the best diagnostic accuracy (sensitivity for Cushing's disease, 86 percent and specificity 90 percent). Cortisol did not work as well and was not analyzed further.",
"   </p>",
"   <p>",
"    Another study analyzed the responses to human CRH, 100 mcg, in 101 patients with Cushing's disease and 14 with ectopic ACTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/23\">",
"     23",
"    </a>",
"    ]. The mean serum cortisol value at 15 and 30 minutes after CRH increased by at least 14 percent in 85 percent of patients with Cushing's disease, but in none with ectopic ACTH secretion. The best plasma ACTH criterion, a maximal increase of 105 percent at any time point, had only 70 percent sensitivity for Cushing's disease. Thus, the criteria for interpretation of the test are different for the ovine and human CRH analogs; if the latter is used, cortisol is probably the best outcome measure, based on the superior sensitivity and specificity in this study. Another study evaluated the utility of either human or ovine CRH stimulation in 148 patients with Cushing's disease and 12 with ectopic ACTH secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/24\">",
"     24",
"    </a>",
"    ], using an increase in ACTH or cortisol levels of at least 50 percent to indicate Cushing's disease. Ovine CRH had better sensitivity than human CRH, probably because of the criteria used for interpretation; the sensitivity of the ACTH increment was similar (&asymp;86 percent) for each. No patient with ectopic ACTH secretion had a positive response.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     CRH plus arginine vasopressin stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with Cushing's disease respond with a 35 percent or greater increase in plasma ACTH concentrations 10 to 15 minutes after CRH plus AVP injection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/9,14-17,20,25\">",
"     9,14-17,20,25",
"    </a>",
"    ]. The absolute ACTH response tends to be exaggerated, although the percent increase above the high baseline is not much different in our experience from that in normal subjects.",
"   </p>",
"   <p>",
"    Although the CRH plus AVP test appeared to eliminate the false negative responses associated with the lone administration of CRH or AVP as no patients with ectopic ACTH syndrome were tested, the discriminatory value of the combined test remains unproven. Because of the potential for adverse side-effects, and the limited data on the performance of the test, the combined CRH plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    stimulation is preferred. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36312?source=see_link\">",
"     \"Vasopressin and desmopressin stimulation test\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     CRH plus desmopressin stimulation test",
"    </span>",
"    &nbsp;&mdash;&nbsp;Using appropriate ACTH criteria, the combined CRH-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    test may be useful for differentiating patients with Cushing's disease from those with ectopic ACTH syndrome caused by indolent tumors.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One study evaluated the response to ovine CRH alone (100 mcg),",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      alone (10 mcg given intravenously over 15 seconds), and the combination of CRH and desmopressin in patients with Cushing's disease, ectopic ACTH syndrome, and ACTH-independent (ie, primary adrenal) Cushing's syndrome [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/26\">",
"       26",
"      </a>",
"      ]. In this study, the combined test strategy had the highest diagnostic accuracy. It correctly identified 16 of 17 patients (94 percent) with Cushing's disease using and ACTH response criterion of 350 percent or more at 15 to 30 minutes after desmopressin. All five patients with ectopic ACTH secretion had lower responses.",
"     </li>",
"     <li>",
"      Another study using human CRH also demonstrated that",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      enhanced the response to CRH in patients with Cushing's disease [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/22\">",
"       22",
"      </a>",
"      ]. ROC analysis indicated that an ACTH rise of 218 percent after combined administration gave the best diagnostic outcome, with a sensitivity of 88 percent and specificity of 80 percent. There was complete overlap in the cortisol responses between the 26 patients with Cushing's disease and the five with ectopic ACTH secretion.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Thus, using appropriate ACTH criteria, the combined CRH-",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    test appears to be useful for differentiating patients with Cushing's disease from those with ectopic ACTH syndrome caused by indolent tumors. However, while the combined CRH-desmopressin test is promising, until additional patients are studied, it is probably wise to use conservative cut-off points for its interpretation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Caveats to the use of CRH, AVP or desmopressin in Cushing's syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most patients with an adrenal tumor causing Cushing's syndrome or ectopic ACTH secretion do not respond to CRH alone or in combination with AVP or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/9,10,14-17,25-30\">",
"     9,10,14-17,25-30",
"    </a>",
"    ]. There are, however, exceptions to these generalizations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Approximately 8 percent of patients with Cushing's disease do not respond to CRH with an appreciable increase in peripheral plasma ACTH or serum cortisol concentrations. However, they apparently secrete enough additional ACTH to produce a threefold inferior petrosal sinus-to-peripheral vein gradient in the plasma ACTH concentration [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/31\">",
"       31",
"      </a>",
"      ]. As many as 29 percent fail to respond to AVP or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"       desmopressin",
"      </a>",
"      alone [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/25,26\">",
"       25,26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Occasional patients with ectopic ACTH syndrome or primary adrenal disease respond. Some patients presumably respond because their hypothalamic-pituitary axis is not completely suppressed. In one report, a bronchial carcinoid tumor responded to the secretagogue [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/32\">",
"       32",
"      </a>",
"      ]. Patients receiving multiple medications and those with lower than predicted serum",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      levels may have a falsely abnormal test [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/12,33\">",
"       12,33",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Chronic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/41/41624?source=see_link\">",
"       imipramine",
"      </a>",
"      therapy may decrease the plasma ACTH and serum cortisol responses to CRH in depressed patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/34\">",
"       34",
"      </a>",
"      ]. Depression is one of the more common causes of pseudo-Cushing's syndrome.",
"     </li>",
"     <li>",
"      To assess ACTH-suppression in patients with adrenal tumors or hyperplasia and sub-clinical Cushing's syndrome.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Overall, inferior petrosal sinus sampling (IPSS) is the best test for distinguishing between Cushing's disease and ectopic ACTH secretion. However, it is expensive and not widely available. If IPSS is not used, the 8 mg",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    test and the CRH test with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    may provide useful diagnostic information.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CRH AFTER LOW-DOSE DEXAMETHASONE TEST",
"    </span>",
"    &nbsp;&mdash;&nbsp;This combined test exploits the absolute or relative resistance of ACTH secretion to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    suppression in patients with Cushing's syndrome of any cause and the greater response to CRH in patients with Cushing's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/35\">",
"     35",
"    </a>",
"    ]; it has been proposed as a way of distinguishing true Cushing's syndrome from a pseudo-Cushing's state.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CRH test is performed two hours after the last 0.5 mg dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    in the standard two-day low-dose dexamethasone suppression test [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combined test has been proposed to differentiate patients with pseudo-Cushing's syndrome from those with Cushing's syndrome. The initial report of this approach reported 100 percent diagnostic accuracy using a serum cortisol criterion of &gt;1.4",
"    <span class=\"nowrap\">",
"     mcg/dL",
"    </span>",
"    (38",
"    <span class=\"nowrap\">",
"     nmol/L)",
"    </span>",
"    at 15 minutes after CRH for the diagnosis of Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/35\">",
"     35",
"    </a>",
"    ]. However, later reports showed lower diagnostic performance, particularly in patients without Cushing's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/36-40\">",
"     36-40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The test may occasionally be a useful adjunctive test in patients with equivocal 24-hour urinary cortisol excretion who are suspected of having pseudo-Cushing's syndrome. However, a single midnight serum or salivary cortisol measurement may provide as sensitive and specific a result [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/41-43\">",
"     41-43",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=see_link\">",
"     \"Establishing the diagnosis of Cushing's syndrome\"",
"    </a>",
"    .) As a result, this test should be reserved for those rare patients in whom the results of other tests are equivocal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     ADRENAL INSUFFICIENCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The CRH test has been proposed for the diagnosis of secondary adrenal insufficiency and for the distinction between secondary or tertiary adrenal insufficiency. The rationale for the latter use is that a maximally stimulating dose of exogenous CRH will stimulate ACTH secretion by anterior pituitary corticotrophs if they are intact and the problem lies in the hypothalamus, but will not stimulate ACTH secretion if the pituitary is damaged. The test is primarily used in patients without the expected elevation in basal plasma ACTH levels in the presence of adrenal insufficiency, indicating that they have a hypothalamic or pituitary cause rather than primary adrenal disease. The CRH plus vasopressin tests have not been evaluated in patients with adrenal insufficiency.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Interpretation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The response to CRH depends upon the cause of the hypoadrenalism:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with primary pituitary ACTH deficiency (secondary adrenal insufficiency) have decreased plasma ACTH and serum cortisol responses to CRH. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=see_link\">",
"       \"Causes of secondary and tertiary adrenal insufficiency in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients with hypothalamic disease (ie, CRH deficiency) usually have exaggerated and prolonged plasma ACTH responses; the plasma cortisol responses are subnormal.",
"     </li>",
"     <li>",
"      Patients with primary adrenal deficiency have high basal plasma ACTH concentrations and greatly exaggerated responses to CRH; their serum cortisol concentrations are low before and after CRH injection. However, the CRH test is not recommended for differentiating primary from secondary adrenal deficiency, since this can be accomplished by demonstrating the high plasma ACTH concentrations in primary adrenal insufficiency.",
"     </li>",
"     <li>",
"      The CRH stimulation test is more reliable than the ACTH stimulation test in detecting pituitary-adrenal suppression in preterm infants whose mothers received a short course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"       dexamethasone",
"      </a>",
"      before delivery to hasten fetal lung development [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/44\">",
"       44",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In patients with hypothalamic-pituitary disease, the CRH stimulation test correlated well with response to insulin in one study [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/45\">",
"       45",
"      </a>",
"      ] but had a poor sensitivity (76 percent) in another [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The CRH stimulation test can be performed as part of a combined anterior pituitary function test in which CRH, growth hormone releasing hormone, gonadotropin-hormone releasing hormone, and thyrotropin-releasing hormone are administered simultaneously and plasma concentrations of all of the anterior pituitary hormones are measured [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26311/abstract/3\">",
"     3",
"    </a>",
"    ]. The multi-hormone test is useful in evaluating the site (ie, hypothalamic versus pituitary) and extent (ie, partial versus panhypopituitarism) of deficiency in patients with suspected pituitary dysfunction and in evaluating residual pituitary function after pituitary surgery and radiation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    The hypothalamic hormone CRH is a major physiologic stimulator of pituitary ACTH secretion in humans. Both human and ovine synthetic CRH are used in diagnostic tests of the hypothalamic-pituitary-adrenal axis to:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluate the cause of ACTH-dependent Cushing's syndrome (with or without vasopressin analogs).",
"     </li>",
"     <li>",
"      Discriminate between pseudo-Cushing's and Cushing's syndrome.",
"     </li>",
"     <li>",
"      Discriminate between primary and central adrenal insufficiency.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Data support the use of the CRH stimulation test for the differential diagnosis between patients with an ectopic or a pituitary ACTH-secreting tumor. In general about 90 percent of each group is correctly diagnosed by the test.",
"   </p>",
"   <p>",
"    The use of CRH during inferior petrosal sinus sampling conveys a nearly 100 percent diagnostic accuracy amongst patients with ACTH-dependent Cushing's syndrome.",
"   </p>",
"   <p>",
"    The limited data on the utility of a combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/60/10184?source=see_link\">",
"     desmopressin",
"    </a>",
"    -CRH stimulation test for this distinction suggest that the combination strategy increases diagnostic accuracy in patients with Cushing's disease, but decreases it in those with ectopic ACTH secretion.",
"   </p>",
"   <p>",
"    The combined",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    -CRH stimulation test may have utility in identifying patients with Cushing's syndrome, but the optimal criterion has not been defined.",
"   </p>",
"   <p>",
"    Similarly, the CRH stimulation test may be useful in distinguishing between primary and secondary adrenal insufficiency, but the criteria for its interpretation in this setting have not been defined.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/1\">",
"      Vale W, Rivier C, Brown MR, et al. Chemical and biological characterization of corticotropin releasing factor. Recent Prog Horm Res 1983; 39:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/2\">",
"      Nieman LK, Oldfield EH, Wesley R, et al. A simplified morning ovine corticotropin-releasing hormone stimulation test for the differential diagnosis of adrenocorticotropin-dependent Cushing's syndrome. J Clin Endocrinol Metab 1993; 77:1308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/3\">",
"      Sheldon WR Jr, DeBold CR, Evans WS, et al. Rapid sequential intravenous administration of four hypothalamic releasing hormones as a combined anterior pituitary function test in normal subjects. J Clin Endocrinol Metab 1985; 60:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/4\">",
"      Nicholson WE, DeCherney GS, Jackson RV, et al. Plasma distribution, disappearance half-time, metabolic clearance rate, and degradation of synthetic ovine corticotropin-releasing factor in man. J Clin Endocrinol Metab 1983; 57:1263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/5\">",
"      Sch&uuml;rmeyer TH, Avgerinos PC, Gold PW, et al. Human corticotropin-releasing factor in man: pharmacokinetic properties and dose-response of plasma adrenocorticotropin and cortisol secretion. J Clin Endocrinol Metab 1984; 59:1103.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/6\">",
"      DeBold CR, DeCherney GS, Jackson RV, et al. Effect of synthetic ovine corticotropin-releasing factor: prolonged duration of action and biphasic response of plasma adrenocorticotropin and cortisol. J Clin Endocrinol Metab 1983; 57:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/7\">",
"      Orth DN, Jackson RV, DeCherney GS, et al. Effect of synthetic ovine corticotropin-releasing factor. Dose response of plasma adrenocorticotropin and cortisol. J Clin Invest 1983; 71:587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/8\">",
"      Nieman LK, Cutler GB Jr, Oldfield EH, et al. The ovine corticotropin-releasing hormone (CRH) stimulation test is superior to the human CRH stimulation test for the diagnosis of Cushing's disease. J Clin Endocrinol Metab 1989; 69:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/9\">",
"      Chrousos GP, Schulte HM, Oldfield EH, et al. The corticotropin-releasing factor stimulation test. An aid in the evaluation of patients with Cushing's syndrome. N Engl J Med 1984; 310:622.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/10\">",
"      Kaye TB, Crapo L. The Cushing syndrome: an update on diagnostic tests. Ann Intern Med 1990; 112:434.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/11\">",
"      DeCherney GS, DeBold CR, Jackson RV, et al. Diurnal variation in the response of plasma adrenocorticotropin and cortisol to intravenous ovine corticotropin-releasing hormone. J Clin Endocrinol Metab 1985; 61:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/12\">",
"      Valassi E, Swearingen B, Lee H, et al. Concomitant medication use can confound interpretation of the combined dexamethasone-corticotropin releasing hormone test in Cushing's syndrome. J Clin Endocrinol Metab 2009; 94:4851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/13\">",
"      Jakobsd&oacute;ttir S, Twisk JW, Drent ML. The impact of blood glucose levels on stimulated adrenocorticotropin hormone and growth hormone release in healthy subjects. Clin Endocrinol (Oxf) 2009; 71:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/14\">",
"      Liu JH, Muse K, Contreras P, et al. Augmentation of ACTH-releasing activity of synthetic corticotropin releasing factor (CRF) by vasopressin in women. J Clin Endocrinol Metab 1983; 57:1087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/15\">",
"      DeBold CR, Sheldon WR, DeCherney GS, et al. Arginine vasopressin potentiates adrenocorticotropin release induced by ovine corticotropin-releasing factor. J Clin Invest 1984; 73:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/16\">",
"      Gaillard RC, Riondel AM, Ling N, Muller AF. Corticotropin releasing factor activity of CRF 41 in normal man is potentiated by angiotensin II and vasopressin but not by desmopressin. Life Sci 1988; 43:1935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/17\">",
"      Malerbi DA, Mendon&ccedil;a BB, Liberman B, et al. The desmopressin stimulation test in the differential diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1993; 38:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/18\">",
"      Malerbi DA, Fragoso MC, Vieira Filho AH, et al. Cortisol and adrenocorticotropin response to desmopressin in women with Cushing's disease compared with depressive illness. J Clin Endocrinol Metab 1996; 81:2233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/19\">",
"      Scott LV, Medbak S, Dinan TG. Desmopressin augments pituitary-adrenal responsivity to corticotropin-releasing hormone in subjects with chronic fatigue syndrome and in healthy volunteers. Biol Psychiatry 1999; 45:1447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/20\">",
"      Orth DN, DeBold CR, DeCherney GS, et al. Pituitary microadenomas causing Cushing's disease respond to corticotropin-releasing factor. J Clin Endocrinol Metab 1982; 55:1017.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/21\">",
"      Reimondo G, Paccotti P, Minetto M, et al. The corticotrophin-releasing hormone test is the most reliable noninvasive method to differentiate pituitary from ectopic ACTH secretion in Cushing's syndrome. Clin Endocrinol (Oxf) 2003; 58:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/22\">",
"      Tsagarakis S, Tsigos C, Vasiliou V, et al. The desmopressin and combined CRH-desmopressin tests in the differential diagnosis of ACTH-dependent Cushing's syndrome: constraints imposed by the expression of V2 vasopressin receptors in tumors with ectopic ACTH secretion. J Clin Endocrinol Metab 2002; 87:1646.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/23\">",
"      Newell-Price J, Morris DG, Drake WM, et al. Optimal response criteria for the human CRH test in the differential diagnosis of ACTH-dependent Cushing's syndrome. J Clin Endocrinol Metab 2002; 87:1640.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/24\">",
"      Pecori Giraldi F, Invitti C, Cavagnini F, Study Group of the Italian Society of Endocrinology on the Pathophysiology of the Hypothalamic-pituitary-adrenal axis. The corticotropin-releasing hormone test in the diagnosis of ACTH-dependent Cushing's syndrome: a reappraisal. Clin Endocrinol (Oxf) 2001; 54:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/25\">",
"      Dickstein G, DeBold CR, Gaitan D, et al. Plasma corticotropin and cortisol responses to ovine corticotropin-releasing hormone (CRH), arginine vasopressin (AVP), CRH plus AVP, and CRH plus metyrapone in patients with Cushing's disease. J Clin Endocrinol Metab 1996; 81:2934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/26\">",
"      Newell-Price J, Perry L, Medbak S, et al. A combined test using desmopressin and corticotropin-releasing hormone in the differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1997; 82:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/27\">",
"      Nakahara M, Shibasaki T, Shizume K, et al. Corticotropin-releasing factor test in normal subjects and patients with hypothalamic-pituitary-adrenal disorders. J Clin Endocrinol Metab 1983; 57:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/28\">",
"      Lytras N, Grossman A, Perry L, et al. Corticotrophin releasing factor: responses in normal subjects and patients with disorders of the hypothalamus and pituitary. Clin Endocrinol (Oxf) 1984; 20:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/29\">",
"      M&uuml;ller OA, Stalla GK, von Werder K. Corticotropin releasing factor: a new tool for the differential diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 1983; 57:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/30\">",
"      Pieters GF, Hermus AR, Smals AG, et al. Responsiveness of the hypophyseal-adrenocortical axis to corticotropin-releasing factor in pituitary-dependent Cushing's disease. J Clin Endocrinol Metab 1983; 57:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/31\">",
"      Oldfield EH, Doppman JL, Nieman LK, et al. Petrosal sinus sampling with and without corticotropin-releasing hormone for the differential diagnosis of Cushing's syndrome. N Engl J Med 1991; 325:897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/32\">",
"      Arlt W, Dahia PL, Callies F, et al. Ectopic ACTH production by a bronchial carcinoid tumour responsive to desmopressin in vivo and in vitro. Clin Endocrinol (Oxf) 1997; 47:623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/33\">",
"      Baid SK, Rubino D, Sinaii N, et al. Specificity of screening tests for Cushing's syndrome in an overweight and obese population. J Clin Endocrinol Metab 2009; 94:3857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/34\">",
"      Michelson D, Galliven E, Hill L, et al. Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. J Clin Endocrinol Metab 1997; 82:2601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/35\">",
"      Yanovski JA, Cutler GB Jr, Chrousos GP, Nieman LK. Corticotropin-releasing hormone stimulation following low-dose dexamethasone administration. A new test to distinguish Cushing's syndrome from pseudo-Cushing's states. JAMA 1993; 269:2232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/36\">",
"      Nieman L. Editorial: The dexamethasone-suppressed corticotropin-releasing hormone test for the diagnosis of Cushing's syndrome: what have we learned in 14 years? J Clin Endocrinol Metab 2007; 92:2876.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/37\">",
"      Erickson D, Natt N, Nippoldt T, et al. Dexamethasone-suppressed corticotropin-releasing hormone stimulation test for diagnosis of mild hypercortisolism. J Clin Endocrinol Metab 2007; 92:2972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/38\">",
"      Martin NM, Dhillo WS, Banerjee A, et al. Comparison of the dexamethasone-suppressed corticotropin-releasing hormone test and low-dose dexamethasone suppression test in the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2006; 91:2582.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/39\">",
"      Pecori Giraldi F, Pivonello R, Ambrogio AG, et al. The dexamethasone-suppressed corticotropin-releasing hormone stimulation test and the desmopressin test to distinguish Cushing's syndrome from pseudo-Cushing's states. Clin Endocrinol (Oxf) 2007; 66:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/40\">",
"      Gatta B, Chabre O, Cortet C, et al. Reevaluation of the combined dexamethasone suppression-corticotropin-releasing hormone test for differentiation of mild cushing's disease from pseudo-Cushing's syndrome. J Clin Endocrinol Metab 2007; 92:4290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/41\">",
"      Newell-Price J, Trainer P, Perry L, et al. A single sleeping midnight cortisol has 100% sensitivity for the diagnosis of Cushing's syndrome. Clin Endocrinol (Oxf) 1995; 43:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/42\">",
"      Raff H, Raff JL, Findling JW. Late-night salivary cortisol as a screening test for Cushing's syndrome. J Clin Endocrinol Metab 1998; 83:2681.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/43\">",
"      Papanicolaou DA, Mullen N, Kyrou I, Nieman LK. Nighttime salivary cortisol: a useful test for the diagnosis of Cushing's syndrome. J Clin Endocrinol Metab 2002; 87:4515.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/44\">",
"      Karlsson R, Kallio J, Irjala K, et al. Adrenocorticotropin and corticotropin-releasing hormone tests in preterm infants. J Clin Endocrinol Metab 2000; 85:4592.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/45\">",
"      Schlaghecke R, Kornely E, Santen RT, Ridderskamp P. The effect of long-term glucocorticoid therapy on pituitary-adrenal responses to exogenous corticotropin-releasing hormone. N Engl J Med 1992; 326:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26311/abstract/46\">",
"      Schmidt IL, Lahner H, Mann K, Petersenn S. Diagnosis of adrenal insufficiency: Evaluation of the corticotropin-releasing hormone test and Basal serum cortisol in comparison to the insulin tolerance test in patients with hypothalamic-pituitary-adrenal disease. J Clin Endocrinol Metab 2003; 88:4193.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 163 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-A277839E2F-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26311=[""].join("\n");
var outline_f25_44_26311=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CORTICOTROPIN-RELEASING HORMONE STIMULATION TEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Normal values",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CRH PLUS ARGININE VASOPRESSIN OR DESMOPRESSIN",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      DIAGNOSIS OF THE CAUSE OF CUSHING'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CRH stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      CRH plus arginine vasopressin stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CRH plus desmopressin stimulation test",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Caveats to the use of CRH, AVP or desmopressin in Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CRH AFTER LOW-DOSE DEXAMETHASONE TEST",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      ADRENAL INSUFFICIENCY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Interpretation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3880?source=related_link\">",
"      Causes of secondary and tertiary adrenal insufficiency in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/45/730?source=related_link\">",
"      Cushing's syndrome due to ACTH-independent macronodular adrenal hyperplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21913?source=related_link\">",
"      Establishing the diagnosis of Cushing's syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36312?source=related_link\">",
"      Vasopressin and desmopressin stimulation test",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_44_26312="Neurosyphilis";
var content_f25_44_26312=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Neurosyphilis",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26312/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26312/contributors\">",
"     Christina M Marra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26312/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26312/contributors\">",
"     Francisco Gonzalez-Scarano, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26312/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26312/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26312/contributors\">",
"     John F Dashe, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/44/26312/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The term \"neurosyphilis\" refers to infection of the central nervous system (CNS) by Treponema pallidum (T. pallidum), subspecies pallidum. Neurosyphilis can occur at any time after initial infection.",
"   </p>",
"   <p>",
"    Early in the course of syphilis, the most common forms of neurosyphilis involve the cerebrospinal fluid (CSF), meninges, and vasculature (asymptomatic meningitis, symptomatic meningitis, and meningovascular disease). Late in disease, the most common forms involve the brain and spinal cord parenchyma (general paralysis of the insane and tabes dorsalis). Each form has characteristic clinical findings, but in some cases there is overlap between these findings.",
"   </p>",
"   <p>",
"    This topic will review the pathogenesis, epidemiology, clinical findings, diagnosis, and treatment of neurosyphilis. Other aspects of syphilis are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12150?source=see_link\">",
"     \"Pathophysiology, transmission, and natural history of syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of early syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurosyphilis begins with invasion of the cerebrospinal fluid (CSF), a process that probably occurs shortly after acquisition of Treponema pallidum (T. pallidum) infection. The organism can be identified in the CSF from approximately one-quarter of untreated patients with early syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Although investigators in the first half of the 20",
"    <sup>",
"     th",
"    </sup>",
"    century did not believe that there were \"neurotropic strains\" of T. pallidum, a study conducted in the antibiotic era suggested that strain variability may affect the characteristics of the infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Unlike other bacteria that can infect the CSF, invasion of CSF with T. pallidum does not always result in persistent infection, as spontaneous resolution may occur in some cases without an inflammatory response. In other cases, spontaneous resolution may occur after a transient meningitis.",
"   </p>",
"   <p>",
"    Persistent meningitis is the result of failure to clear organisms from the CSF. Patients with persistent meningitis have \"asymptomatic neurosyphilis\", and individuals with this form of neurosyphilis are at risk for subsequent forms of symptomatic neurosyphilis (",
"    <a class=\"graphic graphic_figure graphicRef64295 \" href=\"UTD.htm?42/1/43038\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/4\">",
"     4",
"    </a>",
"    ]. Studies performed in the early 20",
"    <sup>",
"     th",
"    </sup>",
"    century showed that the more abnormal the CSF in asymptomatic meningitis, the more likely that symptomatic neurosyphilis will develop [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mechanism of T. pallidum clearance from CSF is probably similar to the immune response that occurs in peripheral infection, where opsonized organisms are cleared by activated macrophages. Supporting evidence comes from a study of nonhuman primates infected with T. pallidum; the number of CSF CD4+ T cells and the amount of gamma-interferon produced by CSF lymphocytes increased throughout the period of bacterial clearance, consistent with a \"Th-1-type\" cellular immune response [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurosyphilis was common in the preantibiotic era, occurring in 25 to 35 percent of patients with syphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. Of these, approximately one-third had asymptomatic neurosyphilis, one-third had tabes dorsalis, and at least 10 percent had paresis. Meningovascular syphilis was seen in about 10 percent, with the remaining patients having other forms of neurosyphilis, including symptomatic meningitis and cranial nerve abnormalities.",
"   </p>",
"   <p>",
"    In the current era, early neurosyphilis is more common than late neurosyphilis, and is most frequently seen in patients with human immunodeficiency virus (HIV) infection. This association may simply reflect the fact that syphilis is most common in men who have sex with men, many of whom are HIV-infected, or it may reflect a true difference in susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/8\">",
"     8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"     \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV-infected persons with lower peripheral CD4+ T cell counts are more likely to have symptomatic neurosyphilis than those with higher CD4+ T cell counts [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The frequency of the late forms of neurosyphilis (general paresis and tabes dorsalis) has declined in the antibiotic era, with the result that these forms, particularly tabes dorsalis, are now uncommon [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/10\">",
"     10",
"    </a>",
"    ]. Many experts believe that this decline is due, at least in part, to the widespread use of antibiotics for unrelated illnesses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neurosyphilis can be classified into early forms and late forms (",
"    <a class=\"graphic graphic_figure graphicRef64295 \" href=\"UTD.htm?42/1/43038\">",
"     figure 1",
"    </a>",
"    ). The early forms typically affect the cerebrospinal fluid (CSF), meninges, and vasculature, while the late forms affect the brain and spinal cord parenchyma. Most of what we know about the clinical manifestations of neurosyphilis comes from observations made before the advent of penicillin [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/4,7\">",
"     4,7",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Early neurosyphilis",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Asymptomatic neurosyphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;By definition, patients with asymptomatic neurosyphilis have no symptoms or signs of central nervous system (CNS) disease, although they may have evidence of concomitant primary or secondary syphilis. Asymptomatic neurosyphilis can occur within weeks to months after infection, but less commonly occurs more than two years after infection.",
"   </p>",
"   <p>",
"    The diagnosis is based on the identification of CSF abnormalities, including a lymphocytic pleocytosis that is typically &lt;100",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    an elevated protein concentration that is usually &lt;100",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    a reactive CSF-Venereal Disease Research Laboratory (VDRL), or a combination of these abnormalities.",
"   </p>",
"   <p>",
"    In patients with suspected asymptomatic neurosyphilis who do not have HIV infection, a CSF lymphocyte count &gt;5",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    or a protein concentration &gt;45",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    is consistent with the diagnosis of neurosyphilis. Establishing the diagnosis of asymptomatic neurosyphilis in patients who have HIV infection with CSF pleocytosis but nonreactive CSF-VDRL is difficult because mild CSF pleocytosis and elevated protein can be due to HIV itself. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Diagnosis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Patients with asymptomatic neurosyphilis, regardless of CSF-VDRL reactivity, should be treated for neurosyphilis to prevent progression to symptomatic disease. (See",
"    <a class=\"local\" href=\"#H19\">",
"     'Treatment'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Symptomatic meningitis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most often, symptomatic meningitis occurs within the first year after infection, but it can occur years later. As with asymptomatic neurosyphilis, peripheral findings of early syphilis may coexist, particularly the rash of secondary disease.",
"   </p>",
"   <p>",
"    Patients with symptomatic syphilitic meningitis complain of headache, confusion, nausea and vomiting, and stiff neck. Visual acuity may be impaired if there is concomitant uveitis, vitritis, retinitis, or optic neuritis. Signs include cranial neuropathies, particularly of the optic, facial, or auditory nerves. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Ocular syphilis'",
"    </a>",
"    below and",
"    <a class=\"local\" href=\"#H9\">",
"     'Otosyphilis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Meningitis may cause hydrocephalus as well as arteritis of small-, medium-, or large-sized vessels, leading to ischemia or infarction of brain or spinal cord. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Meningovascular syphilis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Focal meningeal inflammation may lead to diffuse leptomeningitis or to syphilitic gummas, which are focal areas of inflammation that present as mass lesions contiguous with the leptomeninges (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64262 \" href=\"UTD.htm?26/14/26848\">",
"     image 1",
"    </a>",
"    ). Meningitis, brain ischemia, or gummas may cause seizures.",
"   </p>",
"   <p>",
"    Syphilitic meningitis may uncommonly affect the spinal cord and cause meningomyelitis or hyperplastic pachymeningitis with polyradiculopathy. Symptoms and signs include back pain, sensory loss, incontinence, leg weakness, or muscle atrophy.",
"   </p>",
"   <p>",
"    The CSF abnormalities that accompany symptomatic meningitis are more severe than those seen in asymptomatic meningitis. CSF lymphocyte counts are generally between 200 to 400",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    CSF protein concentration is typically between 100 to 200",
"    <span class=\"nowrap\">",
"     mg/dL,",
"    </span>",
"    and CSF-VDRL is almost always reactive. Neuroimaging may show enhancement of meninges, spinal fluid, cranial nerves, or spinal roots. Cerebral gummas show focal areas of enhancement adjacent to the meninges, often with a \"dural tail\", and surrounding edema (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef64262 \" href=\"UTD.htm?26/14/26848\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Ocular syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ocular syphilis can involve almost any eye structure, but posterior uveitis is most common and presents with diminished visual acuity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Additional manifestations may include optic neuropathy, interstitial keratitis, anterior and intermediate uveitis, chorioretinitis, and retinal vasculitis. Ocular syphilis is often, but not always, accompanied by syphilitic meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Otosyphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hearing loss, with or without tinnitus, should be considered as part of the neurologic symptoms or signs of neurosyphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/13\">",
"     13",
"    </a>",
"    ]. Like ocular syphilis, hearing loss may or may not be accompanied by meningitis.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Meningovascular syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;As with other bacterial meningitides, syphilitic meningitis can cause an infectious arteritis that may affect any vessel in the subarachnoid space surrounding the brain or spinal cord and result in thrombosis, ischemia, and infarction. This form of neurosyphilis may present as an ischemic stroke in a young person. Stroke may develop at any time from the first months to the first few years after infection, with an average interval of seven years in a series conducted in the preantibiotic era [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Many patients with meningovascular syphilis have prodromal symptoms, such as headache, dizziness, or personality changes, for days or weeks before the onset of ischemia or stroke. These symptoms are probably due to concomitant meningitis.",
"   </p>",
"   <p>",
"    The manifestations of cerebral ischemia may be acute or chronic. The clinical findings with stroke reflect the territory of the vessel involved. The middle cerebral artery and its branches are most commonly affected. Less commonly, meningovascular disease affects the anterior spinal artery and thereby causes spinal cord infarction.",
"   </p>",
"   <p>",
"    The CSF abnormalities associated with meningovascular neurosyphilis are generally less severe than in those of acute meningitis, with lymphocytic pleocytosis between 10 to 100",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and protein concentration of 100 to 200",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    As with all of the early symptomatic forms of neurosyphilis, CSF-VDRL is usually but not always reactive.",
"   </p>",
"   <p>",
"    Angiography (performed with computed tomographic, magnetic resonance, or conventional catheter techniques) may demonstrate either focal segmental arterial narrowing, focal narrowing and dilatation, or total occlusion, similar to the findings seen in other infectious or noninfectious vasculitides. Neuroimaging shows one or more areas of infarction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Late neurosyphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;General paresis and tabes dorsalis are considered \"tertiary\" forms of neurosyphilis, while the early forms of neurosyphilis are not.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     General paresis",
"    </span>",
"    &nbsp;&mdash;&nbsp;General paresis (also known as general paralysis of the insane, paretic neurosyphilis, or dementia paralytica) is a progressive dementing illness. In the pre-penicillin era, general paresis resulted in death within an average of 2.5 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/4\">",
"     4",
"    </a>",
"    ]. General paresis usually develops 10 to 25 years after infection, but it can occur as early as two years after infection. In the first half of the 20",
"    <sup>",
"     th",
"    </sup>",
"    century, this form of neurosyphilis accounted for about 10 percent of all admissions to psychiatric hospitals.",
"   </p>",
"   <p>",
"    In the early stage of disease, general paresis is associated with symptoms of forgetfulness and personality change. Most affected individuals experience progression of deficits in memory and judgment leading to severe dementia. Less often, patients may develop psychiatric symptoms such as depression, mania, or psychosis.",
"   </p>",
"   <p>",
"    While the neurologic examination may be normal in some patients with general paresis, common abnormal findings include dysarthria, facial and limb hypotonia, intention tremors of the face, tongue, and hands, and reflex abnormalities. Pupillary abnormalities, including Argyll-Robertson pupils, may also be seen. However, pupillary findings are more typical of tabes dorsalis. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Tabes dorsalis'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    CSF abnormalities are the rule in paretic neurosyphilis, with elevated lymphocytes of 25 to 75",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and a protein concentration in the range of 50 to 100",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    The CSF-VDRL is reactive in virtually all patients, although rare cases with a nonreactive CSF serology have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/14\">",
"     14",
"    </a>",
"    ]. Neuroimaging most commonly shows atrophy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Tabes dorsalis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Tabes dorsalis (also called locomotor ataxia) is a disease of the posterior columns of the spinal cord and of the dorsal roots. It has the longest latent period between primary infection and onset of symptoms of all forms of neurosyphilis, with the interval averaging about 20 years, but sometimes as few as three years.",
"   </p>",
"   <p>",
"    While tabes dorsalis was the most common form of neurosyphilis in the preantibiotic era, it is uncommon in the antibiotic era. (See",
"    <a class=\"local\" href=\"#H3\">",
"     'Epidemiology'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The most frequent symptoms of tabes dorsalis are sensory ataxia and lancinating pains. The latter are characterized by sudden, brief, severe stabs of pain that may affect the limbs, back, or face and that may last for minutes or days. Less common symptoms are paresthesias and gastric crises, characterized by recurrent attacks of severe epigastric pain, nausea, and vomiting.",
"   </p>",
"   <p>",
"    Pupillary irregularities are among the most common signs with tabes dorsalis, and the Argyll-Robertson pupil accounts for approximately one-half of these. An Argyll-Robertson pupil is small, does not respond to light, contracts normally to accommodation and convergence, dilates imperfectly to mydriatics, and does not dilate in response to painful stimuli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44117?source=see_link&amp;anchor=H6#H6\">",
"     \"Tonic pupil\", section on 'Differential diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other findings seen with tabes dorsalis include absent lower extremity reflexes, impaired vibratory and position sensation, and, less commonly, impaired touch and pain, sensory ataxia, and optic atrophy.",
"   </p>",
"   <p>",
"    The CSF may be completely normal in tabes dorsalis, or may show a mild lymphocytic pleocytosis with 10 to 50",
"    <span class=\"nowrap\">",
"     cells/microL",
"    </span>",
"    and protein concentrations of 45 to 75",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    In this form of neurosyphilis, as many as one-quarter of the CSF-VDRL tests are nonreactive.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Atypical neurosyphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Some studies from the antibiotic era have reported \"atypical\" forms of neurosyphilis, a term that is used to describe neurosyphilis that does not fulfill the clinical criteria for one of the \"classic\" forms (eg, symptomatic meningitis, meningovascular syphilis, general paresis, and tabes dorsalis). As an example, a study from the early 1970s of 289 patients with reactive serum CSF-FTA-ABS tests reported that neurosyphilis was diagnosed in 241 (84 percent) based on the identification of reflex, sensory, or pupillary changes, or seizures [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/15\">",
"     15",
"    </a>",
"    ]. However, similar cases of neurosyphilis were described in the 1940s [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/4\">",
"     4",
"    </a>",
"    ]. Thus, it is likely that such \"atypical\" forms of neurosyphilis have always existed.",
"   </p>",
"   <p>",
"    That said, several modern case reports have described patients with neurosyphilis that mimicked herpes encephalitis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/16\">",
"     16",
"    </a>",
"    ]. These patients generally had acute onset of cognitive changes, although some patients had more slowly progressive presentations. Virtually all had seizures. Brain MRI showed unilateral or bilateral medial temporal lobe lesions characterized by high signal on T2 and fluid-attenuated inversion recovery (FLAIR) sequences, and these temporal lobe changes resolved after treatment for neurosyphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is difficult to categorize these cases into one of the classic clinical descriptions of neurosyphilis described above (eg, symptomatic meningitis, meningovascular syphilis, general paresis, tabes dorsalis). While patients with a more slowly progressive course could be considered to have general paresis, those with acute onset and temporal lobe imaging abnormalities present a greater challenge for classification. The features of these cases are most similar to meningovascular syphilis, except that the temporal lobe abnormalities do not respect vascular territories. Thus, it is probably best to describe them as an overlap between meningeal and parenchymal disease, rather than attribute them to one of the classic clinical forms of neurosyphilis. The fact that seizures themselves may cause reversible temporal lobe abnormalities further complicates categorization of these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;In his 1944 text, Stokes wrote, \"The frequency of neurosyphilis in general medical practice depends to a large extent on the thoroughness of the search for signs of neuraxis involvement and the frequency with which the spinal fluid examination is employed\" [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/7\">",
"     7",
"    </a>",
"    ]. This axiom remains true today.",
"   </p>",
"   <p>",
"    Clinical suspicion and spinal fluid examination are keys to the diagnosis of neurosyphilis (",
"    <a class=\"graphic graphic_algorithm graphicRef57300 \" href=\"UTD.htm?39/51/40766\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef71518 \" href=\"UTD.htm?7/27/7615\">",
"     algorithm 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Lumbar puncture should be considered in the evaluation of a patient who presents with neurologic or ocular disease that could be caused by syphilis, but with unknown syphilis history.",
"     </li>",
"     <li>",
"      Lumbar puncture should be performed in the evaluation of a patient with known history of syphilis who presents with neurologic or ocular disease that could be caused by syphilis.",
"     </li>",
"     <li>",
"      Lumbar puncture should be considered in all patients with HIV infection and syphilis of any stage, even in the absence of neurologic or ocular disease (",
"      <a class=\"graphic graphic_algorithm graphicRef71518 \" href=\"UTD.htm?7/27/7615\">",
"       algorithm 2",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Unknown syphilis history",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the setting of an unknown syphilis history, the first step in establishing the diagnosis of neurosyphilis is confirming that the patient has been infected with Treponema pallidum (T. pallidum), as a patient cannot have neurosyphilis without first having syphilis.",
"   </p>",
"   <p>",
"    Tests for syphilis include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum nontreponemal tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Venereal disease research laboratory (VDRL)",
"     </li>",
"     <li>",
"      Rapid plasma reagin (RPR)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Serum treponemal tests",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Fluorescent treponemal antibody absorption (FTA-ABS)",
"     </li>",
"     <li>",
"      Treponema pallidum particle agglutination assay (TPPA)",
"     </li>",
"     <li>",
"      Syphilis enzyme immunoassay (EIA)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Confirmation is straightforward when serum nontreponemal tests and treponemal tests are reactive, as they virtually always are in early neurosyphilis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Unfortunately, the nontreponemal tests (VDRL and RPR) may be nonreactive in late neurosyphilis, particularly in tabes dorsalis. When there is suspicion for late forms of neurosyphilis, serum treponemal tests (FTA-ABS, TPPA, or syphilis EIA) should always be performed. These tests remain reactive for life in virtually all individuals regardless of previous treatment. Reactivity of these serum tests confirms that the patient has had syphilis at some time, and that he or she is at risk for neurosyphilis.",
"   </p>",
"   <p>",
"    Patients with nonreactive serum treponemal tests do not merit further evaluation for late neurosyphilis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=see_link\">",
"     \"Diagnostic testing for syphilis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Known syphilis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In patients with known syphilis, a lumbar puncture with cerebrospinal fluid (CSF) examination should be performed in certain clinical situations to evaluate the possibility of symptomatic or asymptomatic neurosyphilis (",
"    <a class=\"graphic graphic_algorithm graphicRef57300 \" href=\"UTD.htm?39/51/40766\">",
"     algorithm 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_algorithm graphicRef71518 \" href=\"UTD.htm?7/27/7615\">",
"     algorithm 2",
"    </a>",
"    ). The United States Centers for Disease Control and Prevention (CDC) recommendations are that CSF examination should be performed in any of the following situations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurologic or ophthalmic signs or symptoms in any stage of syphilis.",
"     </li>",
"     <li>",
"      Evidence of active tertiary syphilis affecting other parts of the body. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=see_link&amp;anchor=H4#H4\">",
"       \"Pathogenesis, clinical manifestations, and treatment of early syphilis\", section on 'Latent syphilis'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment failure (including failure of serum nontreponemal tests to fall appropriately) in any stage of syphilis.",
"     </li>",
"     <li>",
"      Human immunodeficiency virus (HIV) infection with late latent syphilis or syphilis of unknown duration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A few caveats should be noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients who have ocular syphilis or otosyphilis, with or without CSF abnormalities, should receive standard neurosyphilis treatment. The value of lumbar puncture is that if CSF abnormalities are identified, they can be followed to assess efficacy of treatment. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      below.)",
"     </li>",
"     <li>",
"      Some experts recommend LP in all patients with concomitant HIV infection and syphilis, regardless of stage, because of reports of neurosyphilis (asymptomatic and symptomatic) occurring after standard treatment for early syphilis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=see_link\">",
"       \"Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Patients who have a serum RPR titer &ge;1:32, with or without HIV infection, have an increased likelihood of a reactive CSF-VDRL. Available data suggest that the risk is increased approximately 11-fold in those without HIV infection and sixfold in those with HIV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/19\">",
"       19",
"      </a>",
"      ], regardless of syphilis stage or prior syphilis treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/20\">",
"       20",
"      </a>",
"      ]. In addition, in patients with HIV infection, a peripheral blood CD4 count of &le;350",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      conveys an approximately three-fold increased risk of asymptomatic neurosyphilis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/19,21\">",
"       19,21",
"      </a>",
"      ]. Compared with the stage-based criteria for lumbar puncture recommended by the CDC for patients with concurrent HIV infection and syphilis, a retrospective analysis reported that performing lumbar puncture in patients with a serum RPR titer &ge;1:32 or CD4 count &lt;350",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      resulted in fewer missed cases of asymptomatic neurosyphilis [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Given these data, we suggest lumbar puncture for the diagnosis of neurosyphilis in asymptomatic or symptomatic patients with a serum RPR titer &ge;1:32",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the presence of HIV infection with a CD4 count &le;350",
"    <span class=\"nowrap\">",
"     cells/mm3.",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Spinal fluid examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;While a reactive CSF-VDRL establishes the diagnosis of neurosyphilis, a nonreactive rest does not exclude the diagnosis. The CSF-VDRL test may be falsely negative in as many as 70 percent of patients with neurosyphilis. Furthermore, the CSF-VDRL test may be falsely positive when the CSF is visibly blood-tinged and the serum nontreponemal test titer is high.",
"   </p>",
"   <p>",
"    In contrast to the CSF-VDRL, the CSF FTA-ABS test is sensitive but not specific, particularly in asymptomatic neurosyphilis. In the setting of lymphocytic CSF pleocytosis and a nonreactive CSF-VDRL, a nonreactive CSF-FTA-ABS test excludes the diagnosis of neurosyphilis in most instances [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Elevation of the CSF protein concentration is consistent with neurosyphilis. However, it may be less specific than CSF pleocytosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with suspected neurosyphilis who do not have HIV infection and who have nonreactive CSF-VDRL, a CSF lymphocyte count &gt;5",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      or a protein concentration &gt;45",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      is consistent with the diagnosis of neurosyphilis (",
"      <a class=\"graphic graphic_algorithm graphicRef57300 \" href=\"UTD.htm?39/51/40766\">",
"       algorithm 1",
"      </a>",
"      ). Results of the CSF-FTA-ABS test may be helpful in establishing or refuting the diagnosis of neurosyphilis when protein elevation is the sole CSF abnormality.",
"     </li>",
"     <li>",
"      In patients who have HIV infection and syphilis, establishing a diagnosis of neurosyphilis is particularly difficult when the CSF-VDRL is nonreactive in the setting of a mild CSF pleocytosis. The difficulty arises because HIV itself causes mild CSF pleocytosis and mild elevation of the CSF protein concentration. As noted earlier, in patients with neurosyphilis who are seronegative for HIV infection, the CSF leukocyte count is usually elevated to &gt;5",
"      <span class=\"nowrap\">",
"       cells/microL.",
"      </span>",
"      This contrasts with patients who have HIV coinfection, where a CSF leukocyte count of &gt;20",
"      <span class=\"nowrap\">",
"       cells/microL",
"      </span>",
"      is considered to be consistent with neurosyphilis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    One study found that an HIV-induced CSF pleocytosis was independently and significantly associated with three factors [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/26\">",
"     26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Lack of current antiretroviral use (OR 5.9, 95% CI 1.8-18.6)",
"     </li>",
"     <li>",
"      CD4 count",
"      <span class=\"nowrap\">",
"       &gt;200/microL",
"      </span>",
"      (OR 23.4, 95% CI 3.1-177.3)",
"     </li>",
"     <li>",
"      Detectable plasma HIV RNA (OR 3.3, 95% CI 1.1-9.4)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In HIV-infected patients who are taking antiretroviral agents, have CD4 counts &le;200",
"    <span class=\"nowrap\">",
"     cells/microL,",
"    </span>",
"    or have an undetectable plasma HIV RNA viral load, the likelihood of an HIV-induced CSF pleocytosis appears to be reduced by 70 to 96 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/26\">",
"     26",
"    </a>",
"    ]. Thus, a CSF pleocytosis in such patients who have syphilis is more likely to be due to neurosyphilis than to HIV.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of neurosyphilis is discussed separately and reviewed here briefly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=see_link&amp;anchor=H15#H15\">",
"     \"Pathogenesis, clinical manifestations, and treatment of late syphilis\", section on 'Neurosyphilis'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The standard regimens recommended by current Centers for Disease Control and Prevention (CDC) guidelines for the treatment of neurosyphilis, including ocular syphilis, are as follows (",
"    <a class=\"graphic graphic_table graphicRef50435 \" href=\"UTD.htm?26/1/26652\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/18\">",
"     18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aqueous crystalline",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (18 to 24 million units per day, administered as 3 to 4 million units IV every four hours, or 24 million units daily as a continuous infusion) for 10 to 14 days, or",
"     </li>",
"     <li>",
"      Procaine&nbsp;",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"       penicillin G",
"      </a>",
"      (2.4 million units IM once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?36/18/37157?source=see_link\">",
"       probenecid",
"      </a>",
"      (500 mg orally four times a day) for 10 to 14 days",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These regimens can also be used following desensitization to beta-lactams for patients who have a serious penicillin allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/18\">",
"     18",
"    </a>",
"    ]. Desensitization should be managed in consultation with a specialist.",
"   </p>",
"   <p>",
"    An alternative treatment for patients who have a mild penicillin allergy is",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    (2 gm IV daily) for 10 to 14 days, with careful observation for cross-reactivity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    No controlled trials have evaluated the efficacy of the currently used forms of penicillin for neurosyphilis treatment. Thus, recommendations for treatment are based on clinical experience and on predicted penetration of penicillin into the cerebrospinal fluid (CSF) and central nervous system (CNS). Over the years, successively higher doses of intravenous (IV) aqueous",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/42/22183?source=see_link\">",
"     penicillin G",
"    </a>",
"    have been recommended as first-line therapy for neurosyphilis (",
"    <a class=\"graphic graphic_table graphicRef50435 \" href=\"UTD.htm?26/1/26652\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"     ceftriaxone",
"    </a>",
"    or high-dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"     doxycycline",
"    </a>",
"    could be used as alternatives to IV penicillin in patients with neurosyphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/27,28\">",
"     27,28",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Ocular syphilis and otosyphilis are treated with the same regimen as is used for neurosyphilis, regardless of the presence or absence of CSF abnormalities. Treatment with topical glucocorticoids for ocular syphilis and oral glucocorticoids for otosyphilis is often used in conjunction with antibiotics.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Monitoring",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because Treponema pallidum (T. pallidum) cannot be grown in the laboratory, there is no microbiological test of cure. Thus, the success of neurosyphilis therapy is judged by resolution or stabilization of clinical abnormalities and by normalization of CSF abnormalities.",
"   </p>",
"   <p>",
"    Neurologic examination and lumbar puncture should be performed at three to six months after treatment and every six months thereafter until the CSF white blood cell count is normal and the CSF-Venereal Disease Research Laboratory (VDRL) is nonreactive. The CSF white blood cell count should decline at six months after successful treatment, and all CSF abnormalities should resolve by two years after treatment. Failure to meet these criteria should prompt retreatment. Retreatment is also indicated if any follow-up CSF sample shows an increase in CSF white blood cell count, or a fourfold increase in CSF-VDRL titer. CSF abnormalities may normalize more slowly in patients who have human immunodeficiency virus (HIV) infection compared with those who are not infected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Normalization of serum rapid plasma reagin (RPR) titer may predict successful neurosyphilis treatment. Supporting evidence comes from a longitudinal study of 110 patients with neurosyphilis, most with HIV coinfection, who were treated for neurosyphilis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/25\">",
"     25",
"    </a>",
"    ]. At four, seven, and 13 months after treatment, normalization of the serum RPR test, defined as a fourfold or greater decline in RPR titer or reversion to nonreactive, predicted normalization of CSF white blood cell count and CSF-VDRL reactivity in &gt;90 percent of patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26312/abstract/25\">",
"     25",
"    </a>",
"    ]. However, the predictive value of serum RPR normalization was lower for HIV-infected patients who were not taking antiretroviral agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Epidemiology and clinical manifestations",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neurosyphilis refers to infection of the central nervous system (CNS) by Treponema pallidum. This disorder begins with invasion of the cerebrospinal fluid (CSF), a process that probably occurs shortly after acquisition of T. pallidum infection. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Pathogenesis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early in the course of syphilis, the most common forms of neurosyphilis involve the CSF, meninges, and vasculature (asymptomatic meningitis, symptomatic meningitis, and meningovascular disease). Late in disease, the most common forms involve the brain and spinal cord parenchyma (general paresis and tabes dorsalis) (",
"      <a class=\"graphic graphic_figure graphicRef64295 \" href=\"UTD.htm?42/1/43038\">",
"       figure 1",
"      </a>",
"      ). In the current era, early neurosyphilis is more common than late neurosyphilis, and is most frequently seen in patients with human immunodeficiency virus (HIV) infection. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H4\">",
"       'Clinical manifestations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic neurosyphilis lacks symptoms or signs of CNS disease, although there may be concomitant evidence of primary or secondary syphilis. Treatment of asymptomatic neurosyphilis prevents progression to the symptomatic forms. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Asymptomatic neurosyphilis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Symptomatic syphilitic meningitis is typically manifested by headache, confusion, nausea and vomiting, and stiff neck. Visual acuity may be impaired if there is concomitant uveitis, vitritis, retinitis, or optic neuritis. Signs include cranial neuropathies. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Symptomatic meningitis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Syphilitic meningitis can cause an infectious arteritis that may affect any vessel in the subarachnoid space and result in thrombosis, ischemia, and stroke involving the brain or spinal cord. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Meningovascular syphilis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The late forms of neurosyphilis (general paresis and tabes dorsalis) are the \"tertiary\" forms, while the early forms of neurosyphilis are not.",
"     </li>",
"     <li>",
"      General paresis is a progressive dementing illness that usually develops 10 to 25 years after infection. Symptoms of forgetfulness and personality change predominate early on, but progression leads to severe dementia. Common signs include dysarthria, facial and limb hypotonia, intention tremors of the face, tongue, and hands, and reflex abnormalities. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'General paresis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Tabes dorsalis, uncommon in the modern era, is a disease of the posterior columns of the spinal cord and of the dorsal roots. The latent period between primary infection and onset of symptoms averages about 20 years. The most frequent manifestations include ataxia, lancinating pains, and pupillary irregularities. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Tabes dorsalis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Diagnosis summary",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Clinical suspicion and spinal fluid examination are keys to the diagnosis of neurosyphilis. In the setting of unknown syphilis history, the first step is confirming current or previous infection with T. pallidum (",
"      <a class=\"graphic graphic_algorithm graphicRef57300 \" href=\"UTD.htm?39/51/40766\">",
"       algorithm 1",
"      </a>",
"      and",
"      <a class=\"graphic graphic_algorithm graphicRef71518 \" href=\"UTD.htm?7/27/7615\">",
"       algorithm 2",
"      </a>",
"      ). Serum nontreponemal tests (Venereal Disease Research Laboratory [VDRL] and RPR) and serum treponemal tests (fluorescent treponemal antibody absorption [FTA-ABS], treponema pallidum particle agglutination assay [TPPA], or syphilis enzyme immunoassay [EIA]) are virtually always reactive in early neurosyphilis. However, the nontreponemal tests may be nonreactive in late neurosyphilis, while the treponemal tests remain reactive. Therefore, serum treponemal tests (FTA-ABS, TPPA, or syphilis EIA) should always be performed when there is suspicion for late forms of neurosyphilis. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In a patient with known syphilis, we recommend lumbar puncture with CSF examination for those who have neurologic or ocular signs or symptoms, active tertiary syphilis affecting other parts of the body, or treatment failure in any stage of syphilis. In addition, we suggest lumbar puncture for all asymptomatic or symptomatic patients with a serum RPR titer &ge;1:32 or the presence of HIV infection with a CD4 count &le;350",
"      <span class=\"nowrap\">",
"       cells/mm",
"       <sup>",
"        3",
"       </sup>",
"       .",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Known syphilis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The CSF-VDRL is specific but not sensitive for the diagnosis of neurosyphilis. In contrast, the CSF FTA-ABS test is sensitive but not specific, particularly in asymptomatic neurosyphilis. Establishing a diagnosis of neurosyphilis is difficult when the CSF-VDRL is nonreactive in patients with concurrent HIV infection and syphilis who have a mild CSF pleocytosis, because HIV itself can cause a mild CSF pleocytosis and elevation of the CSF protein concentration. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Spinal fluid examination'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Treatment summary",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with neurosyphilis who are not penicillin-allergic, we recommend treatment with penicillin (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). The standard regimens recommended by the Centers for Disease Control and Prevention (CDC) are listed above and shown in the table (",
"      <a class=\"graphic graphic_table graphicRef50435 \" href=\"UTD.htm?26/1/26652\">",
"       table 1",
"      </a>",
"      ). Patients who have a serious penicillin allergy must first undergo desensitization to beta-lactams prior to penicillin therapy. For patients who have a mild penicillin allergy, we suggest",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/17/10521?source=see_link\">",
"       ceftriaxone",
"      </a>",
"      (2 gm IV daily) for 10 to 14 days with careful observation for cross-reactivity (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). For patients with serious penicillin allergies who refuse desensitization or those who cannot be treated with penicillin and ceftriaxone, an alternative is oral",
"      <a class=\"drug drug_general\" href=\"UTD.htm?2/41/2714?source=see_link\">",
"       doxycycline",
"      </a>",
"      (200 mg twice daily) for 21 to 28 days. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Lumbar puncture should be performed three to six months after treatment and every six months thereafter until the CSF white blood cell count is normal and the CSF-VDRL is nonreactive. We suggest retreatment if these criteria are not met by two years after treatment. In addition, we suggest retreatment if there is an increase in the CSF white blood cell count, or a fourfold increase in CSF-VDRL titer, in any follow-up CSF sample. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In immunocompetent patients or HIV-infected patients who are taking antiretroviral agents and in whom a follow-up lumbar puncture cannot be performed, normalization of the serum RPR titer can be used as a surrogate for success of neurosyphilis treatment. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/1\">",
"      Lukehart SA, Hook EW 3rd, Baker-Zander SA, et al. Invasion of the central nervous system by Treponema pallidum: implications for diagnosis and treatment. Ann Intern Med 1988; 109:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/2\">",
"      Rolfs RT, Joesoef MR, Hendershot EF, et al. A randomized trial of enhanced therapy for early syphilis in patients with and without human immunodeficiency virus infection. The Syphilis and HIV Study Group. N Engl J Med 1997; 337:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/3\">",
"      Tantalo LC, Lukehart SA, Marra CM. Treponema pallidum strain-specific differences in neuroinvasion and clinical phenotype in a rabbit model. J Infect Dis 2005; 191:75.",
"     </a>",
"    </li>",
"    <li>",
"     Merritt HH, Adams RD, Solomon HC. Neurosyphilis, Oxford, New York 1946.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/5\">",
"      Moore JE, Hopkins H. Asymptomatic neurosyphilis. The prognosis of early and late asymptomatic neurosyphilis. JAMA 1930; 95:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/6\">",
"      Marra CM, Castro CD, Kuller L, et al. Mechanisms of clearance of Treponema pallidum from the CSF in a nonhuman primate model. Neurology 1998; 51:957.",
"     </a>",
"    </li>",
"    <li>",
"     Stokes JH, Beerman H, Ingraham NR. Modern Clinical Syphilology: Diagnosis, Treatment, Case Study, 3rd ed, WB Saunders, Philadelphia 1944.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/8\">",
"      Taylor MM, Aynalem G, Olea LM, et al. A consequence of the syphilis epidemic among men who have sex with men (MSM): neurosyphilis in Los Angeles, 2001-2004. Sex Transm Dis 2008; 35:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/9\">",
"      Poliseli R, Vidal JE, Penalva De Oliveira AC, Hernandez AV. Neurosyphilis in HIV-infected patients: clinical manifestations, serum venereal disease research laboratory titers, and associated factors to symptomatic neurosyphilis. Sex Transm Dis 2008; 35:425.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/10\">",
"      Wolters EC. Neurosyphilis: a changing diagnostic problem? Eur Neurol 1987; 26:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/11\">",
"      Kiss S, Damico FM, Young LH. Ocular manifestations and treatment of syphilis. Semin Ophthalmol 2005; 20:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/12\">",
"      Gaudio PA. Update on ocular syphilis. Curr Opin Ophthalmol 2006; 17:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/13\">",
"      Yimtae K, Srirompotong S, Lertsukprasert K. Otosyphilis: a review of 85 cases. Otolaryngol Head Neck Surg 2007; 136:67.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/14\">",
"      Chiesi A, Vella S, Dally LG, et al. Epidemiology of AIDS dementia complex in Europe. AIDS in Europe Study Group. J Acquir Immune Defic Syndr Hum Retrovirol 1996; 11:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/15\">",
"      Hooshmand H, Escobar MR, Kopf SW. Neurosyphilis. A study of 241 patients. JAMA 1972; 219:726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/16\">",
"      Bash S, Hathout GM, Cohen S. Mesiotemporal T2-weighted hyperintensity: neurosyphilis mimicking herpes encephalitis. AJNR Am J Neuroradiol 2001; 22:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/17\">",
"      Hicdonmez T, Utku U, Turgut N, et al. Reversible postictal MRI change mimicking structural lesion. Clin Neurol Neurosurg 2003; 105:288.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/18\">",
"      Centers for Disease Control and Prevention, Workowski KA, Berman SM. Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006; 55:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/19\">",
"      Marra CM, Maxwell CL, Smith SL, et al. Cerebrospinal fluid abnormalities in patients with syphilis: association with clinical and laboratory features. J Infect Dis 2004; 189:369.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/20\">",
"      Libois A, De Wit S, Poll B, et al. HIV and syphilis: when to perform a lumbar puncture. Sex Transm Dis 2007; 34:141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/21\">",
"      Ghanem KG, Moore RD, Rompalo AM, et al. Neurosyphilis in a clinical cohort of HIV-1-infected patients. AIDS 2008; 22:1145.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/22\">",
"      Ghanem KG, Moore RD, Rompalo AM, et al. Lumbar puncture in HIV-infected patients with syphilis and no neurologic symptoms. Clin Infect Dis 2009; 48:816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/23\">",
"      Jaffe HW, Larsen SA, Peters M, et al. Tests for treponemal antibody in CSF. Arch Intern Med 1978; 138:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/24\">",
"      Marra CM, Maxwell CL, Tantalo L, et al. Normalization of cerebrospinal fluid abnormalities after neurosyphilis therapy: does HIV status matter? Clin Infect Dis 2004; 38:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/25\">",
"      Marra CM, Maxwell CL, Tantalo LC, et al. Normalization of serum rapid plasma reagin titer predicts normalization of cerebrospinal fluid and clinical abnormalities after treatment of neurosyphilis. Clin Infect Dis 2008; 47:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/26\">",
"      Marra CM, Maxwell CL, Collier AC, et al. Interpreting cerebrospinal fluid pleocytosis in HIV in the era of potent antiretroviral therapy. BMC Infect Dis 2007; 7:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/27\">",
"      Yim CW, Flynn NM, Fitzgerald FT. Penetration of oral doxycycline into the cerebrospinal fluid of patients with latent or neurosyphilis. Antimicrob Agents Chemother 1985; 28:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26312/abstract/28\">",
"      Parkes R, Renton A, Meheus A, Laukamm-Josten U. Review of current evidence and comparison of guidelines for effective syphilis treatment in Europe. Int J STD AIDS 2004; 15:73.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7599 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-183.166.191.243-4563C940AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26312=[""].join("\n");
var outline_f25_44_26312=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H21\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Early neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Asymptomatic neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Symptomatic meningitis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Ocular syphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Otosyphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Meningovascular syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Late neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - General paresis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Tabes dorsalis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Atypical neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Unknown syphilis history",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Known syphilis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Spinal fluid examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Epidemiology and clinical manifestations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Diagnosis summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Treatment summary",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEURO/7599\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/7599|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?39/51/40766\" title=\"algorithm 1\">",
"      Diagnosis neurosyphilis no HIV",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?7/27/7615\" title=\"algorithm 2\">",
"      Diagnosis neurosyphilis HIV infected",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/7599|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/14/26848\" title=\"diagnostic image 1\">",
"      Cerebral gumma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/7599|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?42/1/43038\" title=\"figure 1\">",
"      Natural history neurosyphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEURO/7599|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/1/26652\" title=\"table 1\">",
"      Rx syphilis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/44/39624?source=related_link\">",
"      Diagnostic testing for syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/49/3865?source=related_link\">",
"      Epidemiology, clinical presentation, and diagnosis of syphilis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/9/37017?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of early syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/48/776?source=related_link\">",
"      Pathogenesis, clinical manifestations, and treatment of late syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/55/12150?source=related_link\">",
"      Pathophysiology, transmission, and natural history of syphilis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/5/44117?source=related_link\">",
"      Tonic pupil",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_44_26313="HIV and the older patient";
var content_f25_44_26313=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   HIV and the older patient",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26313/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26313/contributors\">",
"     Charulata Jain Sabharwal, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26313/contributors\">",
"     Nathalie Casau-Schulhof, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26313/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26313/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?25/44/26313/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?25/44/26313/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?25/44/26313/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 1, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;With the introduction of more potent therapies, a greater prevalence of HIV-infected individuals over the age of 50 is projected over the next decade [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/1\">",
"     1",
"    </a>",
"    ]. This epidemiologic trend is expected due to longer survival of HIV-infected patients on antiretroviral therapy, and to increased case findings due to wider HIV testing. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=see_link\">",
"     \"Diagnostic assays for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HIV infection in the older patient (greater than 50 years of age) is associated with:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Delays in diagnosis due to unsuspected HIV infection",
"     </li>",
"     <li>",
"      Age-related differences in immune responses to HIV antigens",
"     </li>",
"     <li>",
"      Varying pharmacokinetics",
"     </li>",
"     <li>",
"      Less robust clinical outcomes",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Issues specific to an aging population, such as neurological and cardiovascular disorders, need to be addressed in the older HIV-infected patient, as well as gender-specific concerns (eg, osteoporosis and hypogonadism).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the 1980s, a growing proportion of HIV-infected patients are over the age of 50. The cumulative number of AIDS cases reported to the Centers for Disease Control and Prevention in adults aged 50 years or older increased sevenfold, from 16,288 in 1990 to 118,370 by the end of 2005 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/2,3\">",
"     2,3",
"    </a>",
"    ]. Certain US states have a higher prevalence of HIV infection in older individuals, such as Florida (13 percent) and Hawaii (20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/4-7\">",
"     4-7",
"    </a>",
"    ]. Estimates reveal that patients &ge;50 years of age account for 10 to 15 percent of all newly diagnosed",
"    <span class=\"nowrap\">",
"     HIV/AIDS",
"    </span>",
"    cases in these geographic areas.",
"   </p>",
"   <p>",
"    As of June 2001, 134,845 women aged 13 years or older were diagnosed with AIDS in the United States; almost 10 percent were aged 50 years or older at the time of their diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/8\">",
"     8",
"    </a>",
"    ]. Women diagnosed with AIDS in their 50s and 60s have a similar demographic make-up of younger women, with black women accounting for more than half of these cases; risk factors are mainly due to heterosexual transmission [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Risk groups",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk factors for HIV acquisition in older patients have changed over the last two decades.",
"   </p>",
"   <p>",
"    Early in the HIV epidemic, an increased risk of HIV acquisition was noted among older patients with a history of blood transfusion prior to 1985, before routine HIV testing. The risk of HIV infection was only 1 percent among patients aged 13 to 49 years of age, but increased to 6, 28, and 64 percent among persons aged 50 to 59 years, 60 to 69 years, and 70 years or older, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/10\">",
"     10",
"    </a>",
"    ]. This trend may be related to the increased exposure to multiple blood transfusions among older patients. However, this trend changed dramatically after the introduction of HIV antibody screening of all blood products.",
"   </p>",
"   <p>",
"    Apart from blood transfusions, cumulative AIDS cases by age group demonstrate trends in older patients by major exposure groups [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Injection drug use has a low prevalence in those aged 65 years or older (9 percent).",
"     </li>",
"     <li>",
"      Men who have sex with men (MSM) compose the largest group of Americans affected by the epidemic in the United States, including those older than 50 years of age. This pattern differs from the rest of the world where heterosexual transmission is common.",
"     </li>",
"     <li>",
"      For women aged 50 years or older, the primary exposure is through heterosexual contact. The proportion of AIDS cases represented by older black women (60 years of age or older) has grown from 36 percent in 1990 to 60 percent in 1999.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is important to review risk-taking behaviors within each of these high-risk groups. Trends among aging drug users were assessed in a study of more than 3000 active drug users, approximately one-half of whom were older than 50 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/11\">",
"     11",
"    </a>",
"    ]. Although older study participants engaged in less frequent sexual activity, those who did had qualitatively similar high-risk behaviors as younger individuals, especially if they used crack cocaine. In contrast, the older group had significantly less risky needle-sharing practices than the younger cohort. Gender differences were also noted amongst those aged &ge;50 years, with men tending to engage in overall more risky behaviors than their female counterparts.",
"   </p>",
"   <p>",
"    Self-reported risk behaviors among MSM aged 50 years and older were assessed for the previous 12 months through a telephone survey in four US cities [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/12\">",
"     12",
"    </a>",
"    ]. Although the median number of partners decreased with increasing age, the average number of sexual partners was still quite high (nine or more partners reported in 25 percent of men aged 60 to 69).",
"   </p>",
"   <p>",
"    The National Council on Aging evaluated gender differences as related to sexual activity and found that 71 percent of men and 51 percent of women aged 60 and older continue to engage in sexual activity [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/9\">",
"     9",
"    </a>",
"    ]. However, little is known about condom use for the prevention of sexually transmitted diseases in this patient population. Furthermore, age-related issues may cause women to be at higher risk for HIV acquisition, including atrophic vaginitis and other body changes associated with aging [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. Aging women would not be likely to use barrier contraception methods to block fertility, which may put them at risk for HIV acquisition if they entered a new sexual partnership [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/1\">",
"     1",
"    </a>",
"    ]. This highlights the need to discuss methods of barrier protection, in addition to obtaining a thorough sexual history.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     UNDERDIAGNOSIS OF HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Older persons are not perceived by their physicians as being at risk for HIV acquisition and consequently are less likely to be tested for HIV, as compared to younger adults [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of undiagnosed HIV infections was investigated by testing serum samples for HIV antibodies from patients 60 years or older who had died in a New York City hospital. Thirteen of 257 (5 percent) serum samples from patients between the ages of 60 and 79 years were HIV-antibody positive, although none of their deaths were directly attributable to underlying HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When testing for HIV is undertaken in the older patient, the diagnosis is often made later in the natural history of the individual's disease, which increases the risk of opportunistic infections and transmission to others [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. A retrospective Italian study analyzed determinants of \"late diagnosis\" (eg, HIV testing within three months of a diagnosis of AIDS) in patients attending a tertiary care center from 1986 to 1998 [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/20\">",
"     20",
"    </a>",
"    ]. Of 1977 patients included in the analysis, approximately one-quarter had a late diagnosis of AIDS; late diagnosis was significantly associated with age &ge;45 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One cost-effectiveness model suggested that HIV screening in sexually active persons older than 55 to 64 years of age with voluntary HIV screening that has streamlined counseling compares favorably with other screening interventions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/21\">",
"     21",
"    </a>",
"    ]. In 2009, the American College of Physicians (ACP) Guidance Statement suggested that the age range for routine HIV screening be expanded to 75 years, due to the growing number of HIV infections in older patients [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/22\">",
"     22",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=see_link\">",
"     \"Serologic screening for HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMMUNOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Research initiatives regarding age, immunity, and their interactions with HIV infection suggest a parallel between age-related immunologic senescence and HIV-related immune dysfunction.",
"   </p>",
"   <p>",
"    Aging has been associated with a decreased production of IL-2 and IL-2 receptors and with thymus involution [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/23-27\">",
"     23-27",
"    </a>",
"    ]. Lower responsiveness to IL-2 has been implicated as a mechanism for T cell dysfunction and a shift from a naive to a memory T cell phenotype [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/28\">",
"     28",
"    </a>",
"    ]. As a result, when an older individual becomes chronically infected with HIV, the depletion of na&iuml;ve CD4 T cells is more pronounced, as compared to a younger HIV-infected individual. Investigators have surmised that this might lead to delayed immune reconstitution [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/29\">",
"     29",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other researchers have attributed poor CD4 T cell responses to thymus involution that occurs with age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. These factors may contribute to less robust CD4 T cell increments in response to antiretroviral therapy, compared to younger HIV-infected individuals, since the thymus is integral in maintaining peripheral populations of naive T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/32\">",
"     32",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Immunologic recovery and viral suppression'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Mucosal host defenses are profoundly affected by HIV infection; reduced numbers of CD4 T cells in the gut-associated lymphoid tissue (GALT) do not reconstitute despite initiation of ART. Although studies of GALT in older HIV-infected patients have not been performed, there is data relative to other infections to suggest that gastrointestinal immunity declines with age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/27,33\">",
"     27,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=see_link\">",
"     \"Immunology of HIV-1 infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Recent studies have also emphasized the role of untreated HIV infection on aging and have concluded that immune activation results in \"immunosenescence\" (eg, accelerated aging of T cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. The implication of this observation is that a person with HIV infection is physiologically older than indicated by birth date; however, it is not clear that these changes are reversed by ART [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     MORBIDITY AND MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the pre-HAART era, several studies demonstrated that following HIV seroconversion, patients over the age of 50 had a more rapid progression towards AIDS and poor overall survival [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/37-49\">",
"     37-49",
"    </a>",
"    ]. In the HAART era, subsequent studies have also suggested that older HIV-infected patients have delayed immune recovery [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/50-52\">",
"     50-52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The mortality data are most compelling as illustrated below:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a multinational study of 16,534 HIV-infected patients with known duration of HIV infection, older age at seroconversion was associated with a higher risk of excess mortality for age &gt;45 years compared with ages 15 to 24 years (HR 2.54; 95% CI, 2.1-3.1); this effect persisted in the post-HAART era [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The 2007",
"      <span class=\"nowrap\">",
"       HIV/AIDS",
"      </span>",
"      Surveillance Report demonstrated that the proportion of persons surviving by months after an AIDS diagnosis during 1998 to 2005 declined significantly based on age range [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/54\">",
"       54",
"      </a>",
"      ]&nbsp;(",
"      <a class=\"graphic graphic_figure graphicRef70686 \" href=\"UTD.htm?34/32/35333\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In a retrospective cohort study, mortality rates in HIV-infected individuals older than 50 years (n = 253) were compared to younger HIV-positive patients (n = 535) [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/55\">",
"       55",
"      </a>",
"      ]. Although information on compliance and comorbidities was not provided, older untreated HIV-infected individuals had twice the risk of dying compared to the younger cohort (",
"      <a class=\"graphic graphic_table graphicRef62081 \" href=\"UTD.htm?33/5/33884\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, after the initiation of HAART, older patients had more than a twofold reduction in the hazard ratio for death or a 72 percent reduction in mortality after adjusting for confounders. After three months, there were no statistically or clinically significant differences in the survival rate between the treated younger and older HIV-positive groups. Taken together, these findings suggest that deferring treatment or failing to diagnose HIV infection in older individuals may adversely impact their survival as compared to younger HIV-infected individuals (",
"    <a class=\"graphic graphic_figure graphicRef56215 \" href=\"UTD.htm?31/40/32398\">",
"     figure 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef53606 \" href=\"UTD.htm?32/40/33422\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/55\">",
"     55",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 2012, the Department of Human Health and Services (DHHS) guidelines on the treatment of HIV and AIDS recommended antiretroviral therapy for all HIV-infected patients, regardless of CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/56\">",
"     56",
"    </a>",
"    ]. A new section on the treatment of the older HIV-infected patient emphasized this recommendation for universal antiretroviral therapy in HIV-infected patients older than 50 years of age because of a higher risk of non-AIDS-related complications in this age group and the reduced immunologic response to ART with advanced age. The 2010 International Antiviral Society-USA guidelines also recommend treatment for all HIV-infected patients older than 60 years of age, regardless of CD4 cell count [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/57\">",
"     57",
"    </a>",
"    ]. The strength of the evidence supporting these treatment guidelines and selection of antiretroviral regimens are reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link\">",
"     \"When to initiate antiretroviral therapy in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the clinical efficacy, pharmacokinetics, and long-term safety of ART have not been studied extensively in older patients, close clinical monitoring of HIV treatment and its complications is warranted in this population. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=see_link&amp;anchor=H4#H4\">",
"     \"Patient monitoring during HIV antiretroviral therapy\", section on 'General laboratory monitoring'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Immunologic recovery and viral suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies have demonstrated that immune recovery is less robust with increasing age, as illustrated by the following observational and prospective studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among 12,196 treatment-naive HIV-infected patients in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) who initiated ART, the mean baseline CD4 cell count was similar by age [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/58\">",
"       58",
"      </a>",
"      ]. However, the immunologic response after 24 months of treatment decreased with increasing age starting at age 40, while older age did not have an effect on viral suppression in this observational cohort.",
"     </li>",
"     <li>",
"      A French prospective study that evaluated treatment outcomes in 3015 treatment-na&iuml;ve patients (401 of whom were over age 50), found that rates of viral suppression were better in older patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/59\">",
"       59",
"      </a>",
"      ]. Despite better virologic control, the risk of clinical progression to an AIDS-defining illness was significantly higher in the older age group (HR 1.52; 95% CI 1.2-2.0).",
"     </li>",
"     <li>",
"      In the EuroSida cohort, which consisted of 1956 patients, an inverse relationship between age and maximum CD4 cell response to ART was demonstrated; younger patients attained a CD4 count &gt;200 cells in a significantly shorter time period than older patients [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/60\">",
"       60",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Another study of 6439 treatment-naive patients (665 who were older than 50 years of age) suggested that although older patients gained fewer absolute CD4 cells than younger participants, there was no difference among age groups in CD4 percentages [",
"      <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/61\">",
"       61",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data highlight the importance of diagnosis and treatment of HIV at an earlier age when possible.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Adherence",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have suggested that older patients with HIV tend to be more adherent with medications with some studies reporting more than 95 percent adherence [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/62-65\">",
"     62-65",
"    </a>",
"    ]. In a retrospective case control study, 101 HIV-infected patients with a mean age of 57 years were matched to 202 younger HIV-infected patients with a mean age of 33 years [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/62\">",
"     62",
"    </a>",
"    ]. Older HIV-infected patients were less likely to interrupt ART than younger patients (11 versus 26 percent). It is unclear whether this represented better medication adherence or tolerance. Increased medication exposure translated into better rates of viral suppression (47 versus 34 percent) with comparable immunologic outcomes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Safety and tolerability",
"    </span>",
"    &nbsp;&mdash;&nbsp;Few studies have examined the tolerability and safety of antiretrovirals in older HIV-infected patients, who may have decreased renal and hepatic function and increased comorbidities. This is of particular importance as a retrospective analysis of HIV-infected outpatients in Italy matched to 11 million HIV-negative patients across Italy found that four factors emerged as independent predictors of polypathology (simultaneous occurrence of two or more defined diseases): older age, male gender, CD4 nadir below 200, and every additional year of antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/66\">",
"     66",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Age-related decrease in renal function should be considered when choosing an ART regimen in the older patient. A study investigating the elimination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    in elderly patients found that clearance of zidovudine was substantially reduced, resulting in toxic serum drug levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/67\">",
"     67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Older age is also associated with decreases in hepatic function, which leads to higher serum levels of HIV drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/68,69\">",
"     68,69",
"    </a>",
"    ]. One study compared the response to a protease inhibitor-containing ART regimen in HIV-infected patients less than 40 years of age and older than 60 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/69\">",
"     69",
"    </a>",
"    ]. While there was no difference in virologic and immunologic outcomes at 24 months, the vast majority of older patients had switched to a non-nucleoside reverse transcriptase inhibitor-containing regimen due to a significantly higher incidence of adverse events (64 versus 35 percent). Another study of 508 treatment-na&iuml;ve patients who started ART from 2000 to 2005 found that the rate of treatment changes due to toxicity were associated with increasing age (for every 10-year increase in age the incidence rate ratio was 1.28, CI 1.04-1.57); however, in this multivariable analysis, current age was not found to be a significant predictor of this outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Drug-related toxicity in the older age group is hypothesized to be due to age-related decreases in albumin levels and changes in the cytochrome p450 enzyme system [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/69\">",
"     69",
"    </a>",
"    ]. Since both NNRTIs and PIs are metabolized by cytochrome p450, older HIV-infected patients may have significantly higher drug exposure when treated with antiretroviral agents as compared with younger HIV-infected patients. This principle was well illustrated in the ACTG 5015 protocol, where HIV-infected patients received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    -boosted PI-based therapy with lopinavir [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/71\">",
"     71",
"    </a>",
"    ]. Concentrations of lopinavir and ritonavir were measured at 24, 36, and 96 weeks. Increasing age was negatively associated with lopinavir clearance, consistent with an age-related loss of cyp3A4 activity. Changes in drug elimination in aging may lead to increased vulnerability to short and long-term drug toxicities in this patient population.",
"   </p>",
"   <p>",
"    Clearance of drugs is reduced in association with increasing age, heart failure, cirrhosis, or conditions that diminish cardiac output and hepatic blood flow. Higher drug exposure may result in greater drug intolerance",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    organ toxicity, which may also contribute to additional changes in the metabolic pathways of these organs. In addition, the risk for toxicity in older patients may be exacerbated by the multitude of comorbidities that result in polypharmacy and potential drug interactions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/72\">",
"     72",
"    </a>",
"    ]. However, one small study of 165 HIV-infected patients with and without comorbid conditions did not demonstrate a greater incidence of toxicity or treatment-limiting side effects in those with other medical conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are no guidelines for dose adjustments of antiretroviral agents based on age alone. However, renal and hepatic function should be carefully assessed in the older HIV-infected patient on an ongoing basis and regimen modifications made accordingly. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=see_link\">",
"     \"Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction\"",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     GENDER-SPECIFIC ISSUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Osteoporosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain lifestyle and hormonal factors, which increase the risk of disordered bone metabolism, are prevalent in HIV-infected patients. These include physical inactivity, decreased intake of calcium and vitamin D, cigarette smoking, alcohol use, depression, opiate use, and low testosterone levels [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/74\">",
"     74",
"    </a>",
"    ]. These factors place HIV-infected patients at risk for developing osteoporosis. The evaluation, diagnosis, and management of these patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=see_link\">",
"     \"Bone and calcium disorders in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Menopause",
"    </span>",
"    &nbsp;&mdash;&nbsp;Limited data are available about menopause and the use of hormonal replacement therapy in older HIV-infected women. This topic is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=see_link&amp;anchor=H21#H21\">",
"     \"HIV and women\", section on 'Menstrual abnormalities and menopause'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Hypogonadism",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hypogonadism is common in men with AIDS and has been associated with advanced disease, and in the ART era with presence of HIV RNA [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/75\">",
"     75",
"    </a>",
"    ]. This topic is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22312?source=see_link\">",
"     \"Pituitary and adrenal gland dysfunction in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     NEUROLOGIC COMPLICATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3509420\">",
"    <span class=\"h2\">",
"     Neurocognitive issues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Epidemiologic findings suggest that increasing age is a significant risk factor for HIV-associated dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/76\">",
"     76",
"    </a>",
"    ]. However, most of the studies performed to date are small in size. One longitudinal study compared 106 HIV-infected patients &gt;50 years of age to 96 patients ranging from 20 to 39 years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/77\">",
"     77",
"    </a>",
"    ]. After adjusting for education, race, substance abuse, antiretroviral medication use, viral load, CD4 T cell count, and Beck Depression Inventory score, the odds of having HIV-associated dementia among individuals in the older age group was threefold higher than that of the younger group. No apparent association was noted between the duration of HIV infection, nadir CD4 counts, and the risk of developing HIV-associated dementia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Longitudinal studies involving large numbers of older individuals are needed to determine whether there are age-related differences in the prevalence, nature, and severity of HIV-associated cognitive dysfunction. However, the CHARTER study of 1104 patients, which divided patients into young, middle-aged, and old, showed that family history of dementia regardless of age was worse in those individuals [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12249?source=see_link\">",
"     \"Dementia and delirium in HIV-infected patients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3509427\">",
"    <span class=\"h2\">",
"     Peripheral neuropathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aging is a risk factor for peripheral neuropathy. In an observational study of 2141 antiretroviral-na&iuml;ve HIV-infected patients who were seen annually between 2000 and 2007, aging was a significant risk factor for the development of peripheral neuropathy despite virologic and immunologic control of HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/79\">",
"     79",
"    </a>",
"    ]. Aging was also associated with lower odds of recovery after neurotoxic antiretroviral drugs were discontinued. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=see_link\">",
"     \"Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29577?source=see_link\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29577?source=see_link&amp;anchor=H2#H2\">",
"     \"Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy\", section on 'Epidemiology'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     CARDIOVASCULAR DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;HAART has drastically lengthened survival in HIV-infected individuals and has led to changing patterns of morbidities and mortality [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]. However, increased survival has led to an increased prevalence of HIV-related disorders of insulin metabolism, diabetes mellitus, lipodystrophy, and dyslipidemia [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/82-87\">",
"     82-87",
"    </a>",
"    ]. Premature cardiovascular and cerebrovascular disease have also been described, but there is still considerable debate as to whether this increased risk stems from metabolic toxicities secondary to HIV antiretroviral therapies, particularly protease inhibitors, or from endothelial disruption from the virus itself, or both [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/88-94\">",
"     88-94",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to HIV-specific related mechanisms, there is a high prevalence of cardiovascular risk factors in this patient population compared with HIV-negative patients in the same age group [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/95\">",
"     95",
"    </a>",
"    ]. Age greater than 50 itself nearly triples the risk (IRR 2.74, 95% CI 2.24-3.34) of admission for cardiovascular disease, which makes it all the more essential to address modifiable factors at clinic visits [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/96\">",
"     96",
"    </a>",
"    ]. For the individual, the absolute risk of cardiovascular disease is a composite of several factors including age, sex, diabetes status, and family history of cardiovascular disease. Modifiable risk factors include smoking, obesity, and physical inactivity. With the aging of the HIV-infected patient population, it is likely that rates of cardiovascular disease may increase unless interventions, such as smoking cessation and weight reduction, are undertaken. It will also be important to determine if standard prediction tools, such as the Framingham score, will be applicable to HIV-infected patient populations [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/97\">",
"     97",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proposed mechanisms of cardiovascular disease and its evaluation and management in HIV-infected patients are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=see_link\">",
"     \"Epidemiology of cardiovascular disease and risk factors in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=see_link\">",
"     \"Management of dyslipidemia and cardiovascular risk in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5271826\">",
"    <span class=\"h1\">",
"     MALIGNANCY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Observational studies have suggested that those cancers seen commonly among AIDS patients (lung, liver, anal) are occurring at generally younger ages of diagnosis among HIV-infected patients compared with the general population, which may be related to accelerating aging in this patient population [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/98\">",
"     98",
"    </a>",
"    ]. Using 15 HIV and cancer registry databases in the United States, including 212,055 persons with AIDS (restricted to non-white Hispanics and blacks), investigators evaluated the ages at diagnosis of several types of non-AIDS defining cancers in HIV-infected patients and the general population including those commonly seen among the general population (prostate, colon, breast cancer). After adjustment for differences in the age composition of the populations at risk, the age at cancer diagnosis did not differ significantly between HIV-infected patients and HIV-uninfected individuals, with the exception of lung and anal cancer, which is occurring in younger than expected AIDS patients (median age 50 versus 54; p &lt;0.001) and Hodgkin&rsquo;s lymphoma occurring in older than expected AIDS patients (age 42 versus 40; p &lt;0.001). Acceleration of carcinogenesis, or earlier exposure to cancer risk factors, may contribute to the younger age of onset of lung and anal cancer among HIV-infected patients. Overall, as HIV-infected patients are not at increased risk for prostate, colon, and breast cancer, risk screening should occur on the basis of recommendations of the general population.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25408154\">",
"    <span class=\"h1\">",
"     PULMONARY DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Data from the Veterans Aging Cohort Study, consisting of 33,420 HIV-infected veterans and 66,840 HIV-uninfected Veterans matched by age, sex, race and ethnicity found that the incidence of chronic obstructive pulmonary disease, lung cancer, pulmonary hypertension, pulmonary fibrosis as well as pulmonary infections was significantly more common among HIV-infected veterans [",
"    <a class=\"abstract\" href=\"UTD.htm?25/44/26313/abstract/99\">",
"     99",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     PREVENTIVE MEDICINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;As HIV-infected patients live longer, it is important for clinicians to keep in mind the routine screening examinations (eg, colonoscopy) and immunizations (eg, flu, tetanus vaccine) that should be offered to the older patient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=see_link\">",
"     \"Overview of preventive medicine in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=see_link\">",
"     \"Tetanus-diphtheria toxoid vaccination in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=see_link\">",
"       \"Patient information: Starting treatment for HIV (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=see_link\">",
"       \"Patient information: Initial treatment of HIV (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      HIV infection in the older patient is associated with delays in diagnosis due to unsuspected HIV infection, age-related differences in immune responses to HIV antigens, and varying pharmacokinetics. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cumulative number of reported AIDS cases in adults aged 50 years or older has increased sevenfold from 1990 to 2005. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Epidemiology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When testing for HIV is undertaken in the older patient, the diagnosis is often made later in the natural history of their disease, which increases the risk of opportunistic infections and transmission to others. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Underdiagnosis of HIV'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Less robust CD4 T cell increments in response to antiretroviral therapy have been reported in older HIV-infected patients, which may be related to immunosenescence. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Immunology'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although morbidity and mortality rates in older HIV-infected patients appear higher than younger HIV-infected patients, the initiation of antiretroviral therapy leads to a significant reduction in risk of death. In HIV-infected patients older than 50 years of age, antiretroviral therapy should be initiated regardless of CD4 count. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Morbidity and mortality'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=see_link&amp;anchor=H26#H26\">",
"       \"When to initiate antiretroviral therapy in HIV-infected patients\", section on 'Treatment recommendations'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"       \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"      </a>",
"      .) &nbsp;",
"     </li>",
"     <li>",
"      Several studies have suggested that older HIV-infected patients tend to be more adherent with medications than younger patients, with some studies reporting more than 95 percent adherence. However, the older patient may be at higher risk for drug-related toxicity. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemiologic findings suggest that increasing age is a risk factor for HIV-associated dementia, although most of the studies performed to date are small in size. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Neurologic complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is unclear if older HIV-infected patients have an increased risk for cardiovascular disease, although treatment with antiretroviral therapy may increase the risk of metabolic abnormalities, such as hypertriglyceridemia. (See",
"      <a class=\"local\" href=\"#H16\">",
"       'Cardiovascular disease'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/1\">",
"      Levy JA, Ory MG, Crystal S. HIV/AIDS interventions for midlife and older adults: current status and challenges. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S59.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/2\">",
"      Mack KA, Ory MG. AIDS and older Americans at the end of the Twentieth Century. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S68.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2005. Vol. 17. Rev ed. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2007. file://www.cdc.gov/hiv/topics/surveillance/resources/reports/ (Accessed on January 01, 2008).",
"    </li>",
"    <li>",
"     Bureau of HIV/AIDS. HIV prevalence estimates. Report, Florida Department of Health, FL 2002.",
"    </li>",
"    <li>",
"     The Florida Division of Disease Control. Surveillance report (hepatitis, HIV/AIDS, STD and TB), Vol. 28. Florida Department of Health, FL 2001.",
"    </li>",
"    <li>",
"     Hawaii Department of Health. HIV/AIDS surveillance quarterly report, cases to 31 December 2001. Hawaii Department of Health, HI 2001.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/7\">",
"      Schable B, Chu SY, Diaz T. Characteristics of women 50 years of age or older with heterosexually acquired AIDS. Am J Public Health 1996; 86:1616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/8\">",
"      Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, Midyear 2000. 2001; 12:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/9\">",
"      Zablotsky D, Kennedy M. Risk factors and HIV transmission to midlife and older women: knowledge, options, and the initiation of safer sexual practices. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/10\">",
"      Centers for Disease Control and Prevention (CDC). AIDS among persons aged &gt; or = 50 years--United States, 1991-1996. MMWR Morb Mortal Wkly Rep 1998; 47:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/11\">",
"      Kwiatkowski CF, Booth RE. HIV risk behaviors among older American drug users. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/12\">",
"      Dolcini MM, Catania JA, Stall RD, Pollack L. The HIV epidemic among older men who have sex with men. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/13\">",
"      Levy BR, Ding L, Lakra D, et al. Older persons' exclusion from sexually transmitted disease risk-reduction clinical trials. Sex Transm Dis 2007; 34:541.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/14\">",
"      Stone VE, Bounds BC, Muse VV, Ferry JA. Case records of the Massachusetts General Hospital. Case 29-2009. An 81-year-old man with weight loss, odynophagia, and failure to thrive. N Engl J Med 2009; 361:1189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/15\">",
"      el-Sadr W, Gettler J. Unrecognized human immunodeficiency virus infection in the elderly. Arch Intern Med 1995; 155:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/16\">",
"      Stall R, Catania J. AIDS risk behaviors among late middle-aged and elderly Americans. The National AIDS Behavioral Surveys. Arch Intern Med 1994; 154:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/17\">",
"      Feldman MD. Sex, AIDS, and the elderly. Arch Intern Med 1994; 154:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/18\">",
"      Gerbert B, Maguire BT, Coates TJ. Are patients talking to their physicians about AIDS? Am J Public Health 1990; 80:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/19\">",
"      Cuzin L, Delpierre C, Gerard S, et al. Immunologic and clinical responses to highly active antiretroviral therapy in patients with HIV infection aged &gt;50 years. Clin Infect Dis 2007; 45:654.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/20\">",
"      Girardi E, Sampaolesi A, Gentile M, et al. Increasing proportion of late diagnosis of HIV infection among patients with AIDS in Italy following introduction of combination antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/21\">",
"      Sanders GD, Bayoumi AM, Holodniy M, Owens DK. Cost-effectiveness of HIV screening in patients older than 55 years of age. Ann Intern Med 2008; 148:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/22\">",
"      Qaseem A, Snow V, Shekelle P, et al. Screening for HIV in health care settings: a guidance statement from the American College of Physicians and HIV Medicine Association. Ann Intern Med 2009; 150:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/23\">",
"      Fagnoni FF, Vescovini R, Passeri G, et al. Shortage of circulating naive CD8(+) T cells provides new insights on immunodeficiency in aging. Blood 2000; 95:2860.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/24\">",
"      Negoro S, Hara H, Miyata S, et al. Age-related changes of the function of T cell subsets: predominant defect of the proliferative response in CD8 positive T cell subset in aged persons. Mech Ageing Dev 1987; 39:263.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/25\">",
"      Bestilny LJ, Gill MJ, Mody CH, Riabowol KT. Accelerated replicative senescence of the peripheral immune system induced by HIV infection. AIDS 2000; 14:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/26\">",
"      Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS 2002; 16:1859.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/27\">",
"      Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008; 47:542.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/28\">",
"      Negoro S, Hara H, Miyata S, et al. Mechanisms of age-related decline in antigen-specific T cell proliferative response: IL-2 receptor expression and recombinant IL-2 induced proliferative response of purified Tac-positive T cells. Mech Ageing Dev 1986; 36:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/29\">",
"      Lederman MM, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS 2000; 14:2635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/30\">",
"      Douek DC, McFarland RD, Keiser PH, et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396:690.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/31\">",
"      Ho Tsong Fang R, Colantonio AD, Uittenbogaart CH. The role of the thymus in HIV infection: a 10 year perspective. AIDS 2008; 22:171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/32\">",
"      Ribeiro RM, de Boer RJ. The contribution of the thymus to the recovery of peripheral naive T-cell numbers during antiretroviral treatment for HIV infection. J Acquir Immune Defic Syndr 2008; 49:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/33\">",
"      Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis 2007; 13:1417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/34\">",
"      Cao W, Jamieson BD, Hultin LE, et al. Premature aging of T cells is associated with faster HIV-1 disease progression. J Acquir Immune Defic Syndr 2009; 50:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/35\">",
"      Decrion AZ, Varin A, Drobacheff C, et al. A subset of functional effector-memory CD8+ T lymphocytes in human immunodeficiency virus-infected patients. Immunology 2007; 121:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/36\">",
"      Stone, SF. HIV Med 2005; 6:399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/37\">",
"      Goedert JJ, Kessler CM, Aledort LM, et al. A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia. N Engl J Med 1989; 321:1141.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/38\">",
"      Phillips AN, Lee CA, Elford J, et al. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr 1991; 4:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/39\">",
"      Gardner LI Jr, Brundage JF, McNeil JG, et al. Predictors of HIV-1 disease progression in early- and late-stage patients: the U.S. Army Natural History Cohort. Military Medical Consortium for Applied Retrovirology. J Acquir Immune Defic Syndr 1992; 5:782.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/40\">",
"      Operskalski EA, Stram DO, Lee H, et al. Human immunodeficiency virus type 1 infection: relationship of risk group and age to rate of progression to AIDS. Transfusion Safety Study Group. J Infect Dis 1995; 172:648.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/41\">",
"      Rothenberg R, Woelfel M, Stoneburner R, et al. Survival with the acquired immunodeficiency syndrome. Experience with 5833 cases in New York City. N Engl J Med 1987; 317:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/42\">",
"      Ship JA, Wolff A, Selik RM. Epidemiology of acquired immune deficiency syndrome in persons aged 50 years or older. J Acquir Immune Defic Syndr 1991; 4:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/43\">",
"      Skiest DJ, Rubinstien E, Carley N, et al. The importance of comorbidity in HIV-infected patients over 55: a retrospective case-control study. Am J Med 1996; 101:605.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/44\">",
"      Ferro S, Salit IE. HIV infection in patients over 55 years of age. J Acquir Immune Defic Syndr 1992; 5:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/45\">",
"      Blaxhult A, Granath F, Lidman K, Giesecke J. The influence of age on the latency period to AIDS in people infected by HIV through blood transfusion. AIDS 1990; 4:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/46\">",
"      Sutin DG, Rose DN, Mulvihill M, Taylor B. Survival of elderly patients with transfusion-related acquired immunodeficiency syndrome. J Am Geriatr Soc 1993; 41:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/47\">",
"      Bacchetti P, Osmond D, Chaisson RE, et al. Survival patterns of the first 500 patients with AIDS in San Francisco. J Infect Dis 1988; 157:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/48\">",
"      Glynn JR, Sonnenberg P, Nelson G, et al. Survival from HIV-1 seroconversion in Southern Africa: a retrospective cohort study in nearly 2000 gold-miners over 10 years of follow-up. AIDS 2007; 21:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/49\">",
"      Ewings FM, Bhaskaran K, McLean K, et al. Survival following HIV infection of a cohort followed up from seroconversion in the UK. AIDS 2008; 22:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/50\">",
"      Yamashita TE, Phair JP, Mu&ntilde;oz A, et al. Immunologic and virologic response to highly active antiretroviral therapy in the Multicenter AIDS Cohort Study. AIDS 2001; 15:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/51\">",
"      Goetz MB, Boscardin WJ, Wiley D, Alkasspooles S. Decreased recovery of CD4 lymphocytes in older HIV-infected patients beginning highly active antiretroviral therapy. AIDS 2001; 15:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/52\">",
"      Manfredi R, Chiodo F. A case-control study of virological and immunological effects of highly active antiretroviral therapy in HIV-infected patients with advanced age. AIDS 2000; 14:1475.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/53\">",
"      Bhaskaran K, Hamouda O, Sannes M, et al. Changes in the risk of death after HIV seroconversion compared with mortality in the general population. JAMA 2008; 300:51.",
"     </a>",
"    </li>",
"    <li>",
"     Centers for Disease Control and Prevention. HIV/AIDS Surveillance Report, 2007. Vol. 19. Atlanta: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention; 2009:30. file://www.cdc.gov/hiv/topics/surrveillance/resources/reports/ (Accessed on January 01, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/55\">",
"      Perez JL, Moore RD. Greater effect of highly active antiretroviral therapy on survival in people aged &gt; or =50 years compared with younger people in an urban observational cohort. Clin Infect Dis 2003; 36:212.",
"     </a>",
"    </li>",
"    <li>",
"     Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. file://www.aidsinfo.nih.gov/guidelines/html/1/adult-and-adolescent-treatment-guidelines/0/ (Accessed on April 06, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/57\">",
"      Thompson MA, Aberg JA, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society-USA panel. JAMA 2010; 304:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/58\">",
"      Althoff KN, Justice AC, Gange SJ, et al. Virologic and immunologic response to HAART, by age and regimen class. AIDS 2010; 24:2469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/59\">",
"      Grabar S, Kousignian I, Sobel A, et al. Immunologic and clinical responses to highly active antiretroviral therapy over 50 years of age. Results from the French Hospital Database on HIV. AIDS 2004; 18:2029.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/60\">",
"      Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis 2001; 183:1290.",
"     </a>",
"    </li>",
"    <li>",
"     Shaefer, M, Demarest, J, Zhao, H, et al. Effect of age on baseline CD4+ and CD8+ cells and response to antiretroviral therapy (ART) over 48 weeks in a large clinical trial database. First International Workshop on HIV and Aging. October 4-5, 2010. Baltimore. Abstract O_05.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/62\">",
"      Wellons MF, Sanders L, Edwards LJ, et al. HIV infection: treatment outcomes in older and younger adults. J Am Geriatr Soc 2002; 50:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/63\">",
"      Wutoh AK, Brown CM, Kumoji EK, et al. Antiretroviral adherence and use of alternative therapies among older HIV-infected adults. J Natl Med Assoc 2001; 93:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/64\">",
"      Wutoh AK, Elekwachi O, Clarke-Tasker V, et al. Assessment and predictors of antiretroviral adherence in older HIV-infected patients. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/65\">",
"      Silverberg MJ, Leyden W, Horberg MA, et al. Older age and the response to and tolerability of antiretroviral therapy. Arch Intern Med 2007; 167:684.",
"     </a>",
"    </li>",
"    <li>",
"     Guaraldi, G, Menozzi, M, Zona, S, et al. CD4 nadir and antiretroviral exposure predict premature polypathology onset. First International Workshop on HIV and Aging. October 4-5, 2010. Baltimore. Abstract O_15.",
"    </li>",
"    <li>",
"     Sauvageon-Matre, H, Bannie, F, Tabah, I, et al. Pharmacokinetics of zidovudine in AIDS patients: influence of age and hepatic disorders [abstract no M.B.P. 323]. In: Program and abstracts of the 5th International Conference on AIDS (Montreal). Ottawa: International Development Research Centre, 1989.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/68\">",
"      Sotaniemi EA, Arranto AJ, Pelkonen O, Pasanen M. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther 1997; 61:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/69\">",
"      Knobel H, Guelar A, Valldecillo G, et al. Response to highly active antiretroviral therapy in HIV-infected patients aged 60 years or older after 24 months follow-up. AIDS 2001; 15:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/70\">",
"      Lodwick RK, Smith CJ, Youle M, et al. Stability of antiretroviral regimens in patients with viral suppression. AIDS 2008; 22:1039.",
"     </a>",
"    </li>",
"    <li>",
"     Flexner, C. the effect of aging on human pharmacology. Presented at the 15th Conference on Retroviruses and Opportunistic Infections, Boston, MA, February, 3-6, 2008; abstract #106.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/72\">",
"      Adler WH, Baskar PV, Chrest FJ, et al. HIV infection and aging: mechanisms to explain the accelerated rate of progression in the older patient. Mech Ageing Dev 1997; 96:137.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/73\">",
"      Shah SS, McGowan JP, Smith C, et al. Comorbid conditions, treatment, and health maintenance in older persons with human immunodeficiency virus infection in New York City. Clin Infect Dis 2002; 35:1238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/74\">",
"      Arnsten JH, Freeman R, Howard AA, et al. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection. AIDS 2007; 21:617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/75\">",
"      Klein RS, Lo Y, Santoro N, Dobs AS. Androgen levels in older men who have or who are at risk of acquiring HIV infection. Clin Infect Dis 2005; 41:1794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/76\">",
"      Wilkie FL, Goodkin K, Khamis I, et al. Cognitive functioning in younger and older HIV-1-infected adults. J Acquir Immune Defic Syndr 2003; 33 Suppl 2:S93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/77\">",
"      Valcour V, Shikuma C, Shiramizu B, et al. Higher frequency of dementia in older HIV-1 individuals: the Hawaii Aging with HIV-1 Cohort. Neurology 2004; 63:822.",
"     </a>",
"    </li>",
"    <li>",
"     Moore, DJ, Arce, M, Moseley, S, et al. The influence of family history of dementia on neuropsychological functioning among HIV-infected persons across the lifespan. First International Workshop on HIV and Aging. October 4-5, 2010. Baltimore. Abstract LB_03.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/79\">",
"      Evans SR, Ellis RJ, Chen H, et al. Peripheral neuropathy in HIV: prevalence and risk factors. AIDS 2011; 25:919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/80\">",
"      Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998; 338:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/81\">",
"      Mocroft A, Vella S, Benfield TL, et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998; 352:1725.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/82\">",
"      Grunfeld C, Kotler DP, Hamadeh R, et al. Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989; 86:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/83\">",
"      Hommes MJ, Romijn JA, Endert E, et al. Insulin sensitivity and insulin clearance in human immunodeficiency virus-infected men. Metabolism 1991; 40:651.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/84\">",
"      Geffner ME, Yeh DY, Landaw EM, et al. In vitro insulin-like growth factor-I, growth hormone, and insulin resistance occurs in symptomatic human immunodeficiency virus-1-infected children. Pediatr Res 1993; 34:66.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/85\">",
"      Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/86\">",
"      Carr A, Samaras K, Chisholm DJ, Cooper DA. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet 1998; 351:1881.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/87\">",
"      Adeyemi O, Rezai K, Bahk M, et al. Metabolic syndrome in older HIV-infected patients: data from the CORE50 cohort. AIDS Patient Care STDS 2008; 22:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/88\">",
"      Heath KV, Hogg RS, Chan KJ, et al. Lipodystrophy-associated morphological, cholesterol and triglyceride abnormalities in a population-based HIV/AIDS treatment database. AIDS 2001; 15:231.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/89\">",
"      Behrens G, Schmidt H, Meyer D, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/90\">",
"      Gallet B, Pulik M, Genet P, et al. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351:1958.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/91\">",
"      Vittecoq D, Escaut L, Monsuez JJ. Vascular complications associated with use of HIV protease inhibitors. Lancet 1998; 351:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/92\">",
"      Huang MB, Hunter M, Bond VC. Effect of extracellular human immunodeficiency virus type 1 glycoprotein 120 on primary human vascular endothelial cell cultures. AIDS Res Hum Retroviruses 1999; 15:1265.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/93\">",
"      Huang MB, Khan M, Garcia-Barrio M, et al. Apoptotic effects in primary human umbilical vein endothelial cell cultures caused by exposure to virion-associated and cell membrane-associated HIV-1 gp120. J Acquir Immune Defic Syndr 2001; 27:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/94\">",
"      Park IW, Ullrich CK, Schoenberger E, et al. HIV-1 Tat induces microvascular endothelial apoptosis through caspase activation. J Immunol 2001; 167:2766.",
"     </a>",
"    </li>",
"    <li>",
"     Nkhoma, E, Vannappagari, V, Mynepalli, L, Logie, J. Comorbidities and coinfections among HIV patients 50 years and older. First International Workshop on HIV and Aging. October 4-5, 2010. Baltimore. Abstract O_16.",
"    </li>",
"    <li>",
"     Berry, S, Moore, R, Gebo, K. Reasons for hospitalization differ among older and younger HIV-infected persons. First International Workshop on HIV and Aging. October 4-5, 2010. Baltimore. Abstract O_11.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/97\">",
"      Friis-M&oslash;ller N, Worm SW. Can the risk of cardiovascular disease in HIV-infected patients be estimated from conventional risk prediction tools? Clin Infect Dis 2007; 45:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/98\">",
"      Shiels MS, Pfeiffer RM, Engels EA. Age at cancer diagnosis among persons with AIDS in the United States. Ann Intern Med 2010; 153:452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?25/44/26313/abstract/99\">",
"      Crothers K, Huang L, Goulet JL, et al. HIV infection and risk for incident pulmonary diseases in the combination antiretroviral therapy era. Am J Respir Crit Care Med 2011; 183:388.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3735 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-122.72.76.133-2959C7380A-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26313=[""].join("\n");
var outline_f25_44_26313=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Risk groups",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      UNDERDIAGNOSIS OF HIV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMMUNOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      MORBIDITY AND MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Immunologic recovery and viral suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Adherence",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Safety and tolerability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      GENDER-SPECIFIC ISSUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Osteoporosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Menopause",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Hypogonadism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      NEUROLOGIC COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3509420\">",
"      Neurocognitive issues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3509427\">",
"      Peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      CARDIOVASCULAR DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5271826\">",
"      MALIGNANCY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25408154\">",
"      PULMONARY DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      PREVENTIVE MEDICINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3735\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3735|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?34/32/35333\" title=\"figure 1\">",
"      Survival after AIDS diagnosis in US 1998 to 2005",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/40/32398\" title=\"figure 2\">",
"      Survival in HIV not exposed to ART",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?32/40/33422\" title=\"figure 3\">",
"      Survival in HIV exposed to ART",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3735|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/5/33884\" title=\"table 1\">",
"      Predictors of survival in HIV patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/35/32313?source=related_link\">",
"      Bone and calcium disorders in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/61/12249?source=related_link\">",
"      Dementia and delirium in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/55/20345?source=related_link\">",
"      Diagnostic assays for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/29/12759?source=related_link\">",
"      Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/1/26650?source=related_link\">",
"      Epidemiology of cardiovascular disease and risk factors in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/56/29577?source=related_link\">",
"      Epidemiology, clinical manifestations, diagnosis, and treatment of HIV-associated peripheral neuropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/1/35864?source=related_link\">",
"      Epidemiology, pathogenesis and clinical features of HIV-associated neuropathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/35/16954?source=related_link\">",
"      HIV and women",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/34/5674?source=related_link\">",
"      Immunology of HIV-1 infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/3/49?source=related_link\">",
"      Management of dyslipidemia and cardiovascular risk in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/4/37962?source=related_link\">",
"      Overview of preventive medicine in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?15/31/15861?source=related_link\">",
"      Patient information: Initial treatment of HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/44/22210?source=related_link\">",
"      Patient information: Starting treatment for HIV (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/17/38167?source=related_link\">",
"      Patient monitoring during HIV antiretroviral therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/50/22312?source=related_link\">",
"      Pituitary and adrenal gland dysfunction in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/34/10793?source=related_link\">",
"      Serologic screening for HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/54/7014?source=related_link\">",
"      Tetanus-diphtheria toxoid vaccination in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/35/9786?source=related_link\">",
"      When to initiate antiretroviral therapy in HIV-infected patients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f25_44_26314="EPS tracing VT initiation termination";
var content_f25_44_26314=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F60903%7ECARD%2F60435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F60903%7ECARD%2F60435&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 590px\">",
"   <div class=\"ttl\">",
"    Electrophysiology study (EPS) in a patients showing the initiation and termination of ventricular tachycardia (VT)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 570px; height: 648px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Shown are three surface ECG leads (1,2,and V1) and electrogram from the coronary sinus (CS), bundle of His (HBE) and right ventricular apex (RVA). During ventricular pacing (S1) two premature ventricular beats (S2,S3) induce a sustained monomorphic ventricular tachycardia (VT) with a cycle length (CL) of 340 msec; the HBE tracing shows AV dissociation and the left atrial (LA) electrograms occur at a slower rate than those from the left ventricle (LV) (panel A). Panel B shows termiantion of the VT by the addition of a four beat train of rapid ventricular pacing (RVP), using a cycle length (230 msec) that is shorter than than of the VT (330 msec). The resumption of normal sinus rhythm (NSR) is indicated by the presence of the normal sequence of electrograms, ie, atrial (A), bundle of His (H) and ventricular (V).",
"    <div class=\"footnotes\">",
"     S: stimulus artifact.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Intracardiac electrograms during ventricular tachycardia",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 283px; height: 345px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    During an episodes of sustained monomorphic ventricular tachycardia (VT) a recording from the left ventricle (LV) shows complex, fragmented local electrograms. One of the components is a low amplitude, high frequency mid-diastolic potential (MDP) (arrows), which are isolated from the other components by isoelectric segments. The presence of this MDP identifies a target for radiofrequency ablation, although validation with other mapping techniques is necessary.",
"    <div class=\"footnotes\">",
"     V: ventricular electrogram.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26314=[""].join("\n");
var outline_f25_44_26314=null;
var title_f25_44_26315="Mnemonic for tracheal intubation preparation";
var content_f25_44_26315=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79150&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Mnemonic for tracheal intubation preparation",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        <strong>",
"         S",
"        </strong>",
"        : Suction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         T",
"        </strong>",
"        : Tools for intubation (laryngoscope blades, handle, other devices such as video laryngoscope)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         O",
"        </strong>",
"        : Oxygen source for preoxygenation and ongoing ventilation",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         P",
"        </strong>",
"        : Positioning",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         M",
"        </strong>",
"        : Monitors, including ECG, pulse oximetry, blood pressure, end-tidal CO",
"        <sub>",
"         2",
"        </sub>",
"        , and esophageal detectors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         A",
"        </strong>",
"        : Assistant; Ambu&reg; bag with face mask; Airway devices (endotracheal tubes, syringe, stylets, LMA); Airway assessment",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         I",
"        </strong>",
"        : Intravenous access",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <strong>",
"         D",
"        </strong>",
"        : Drugs, including induction agent, neuromuscular blocking agent, and desired adjuncts",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     ECG: electrocardiogram; LMA: laryngeal mask airway",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26315=[""].join("\n");
var outline_f25_44_26315=null;
var title_f25_44_26316="Beta-lactams against PRP";
var content_f25_44_26316=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F76028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F76028&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Efficacy of higher concentrations of beta-lactams against penicillin-resistant pneumococci",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tbody>",
"      <tr>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            More effective",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Penicillins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Penicillin, amoxicillin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Piperacillin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Cephalosporins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_single\">",
"            Second generation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cefuroxime",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_single\">",
"            Third generation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cefotaxime",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Ceftriaxone",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cefpodoxime",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_single\">",
"            Fourth generation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cefepime",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Carbapenems",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Imipenem-cilastatin",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"       <td class=\"container\">",
"        <table cellspacing=\"0\">",
"         <tbody>",
"          <tr>",
"           <td class=\"subtitle1_single\">",
"            Less effective",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Penicillins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent1\">",
"            Ticarcillin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle2_single\">",
"            Cephalosporins",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_single\">",
"            First generation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cefazolin, cephalexin",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_single\">",
"            Second generation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cefaclor",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"subtitle3_single\">",
"            Third generation",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Ceftazidime",
"           </td>",
"          </tr>",
"          <tr>",
"           <td class=\"indent2\">",
"            Cefixime",
"           </td>",
"          </tr>",
"         </tbody>",
"        </table>",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26316=[""].join("\n");
var outline_f25_44_26316=null;
var title_f25_44_26317="Limited efficacy of TID ISDN";
var content_f25_44_26317=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F79122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F79122&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Limited efficacy of three times daily isordil dinitrate",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 235px; background-image: url(data:image/gif;base64,R0lGODlhjAHrANUAAP///4CAgAAAAEBAQMDAwP+AgPDz+YCZzAAzmUBms/8AABBAn3BwcNDQ0CBNpsDN5rDA3yAgIBAQEODm86CgoDAwMP/AwP8QEPDw8FBQUP9AQP/Q0ODg4P9QUP+QkGBgYLCwsGCAv1BzuZCQkP9gYNDZ7KCz2ZCm0//g4P+goDBZrHCNxv/w8P8gIP8wMP9wcP+wsAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAACMAesAAAb/QIBwSCwaj8ikcslsOp/QqHRKrVqv2Kx2y+16v+CweEwum8/otHrNbrvf8Lh8Tq/b7/i8fs/v+/+AgYKDhIWGh4iJiouMjY6PkJGSk5SVlpeYmZqbnJ0MAQ0SERidpaanTBIUGRISDKiwsacCBBEZAQOyuruXtgIBDLm8w8SNIwISHBGvUxgUASOkxdPUbA0cGATSURgVAgPI29Xj5F8YwQ0ZIFMEAhUA4ATl8/RZGQK0HxnN3hURH0YIBBhIUN4cEybqKRQkYMQAgcK4fRDlThwAgQRxBaDjwIGBhSD7CADxcMA+Kcc23tuoZOBBBwkOhJyZZyJFClMouCPgDWdL/5ZxHJgogWACzaN0MNxzVYWBBAERgCZxGceECiErEiDdCueaEK9kqMJx8ECIgQVluapVM4AlrjJi3ZzQOsSEg7V4yzQYIGoA34hi4rI5m3ZIzLyIwbTDh0/CurBS2RygS+TBAqOJM3Nh4POMYDWEj4QIobl0lmcEOweOrGYyktCmY08BxxhwmM9oYB85cVW27ycNCAhXBZc1GtdKHJz4zfyJyeJtzpZYYvlj8+tFUDP4Bl0yaSYivmMfTxvf4zG4y0y43GT99PHYgwvnYCY9mdFPkJtCCL+NfAINdJfGBEVBIZQpZ3nUnxrb1SYgGvhBAcEC1nES3mELooFMag+aQf8gZlAksEInJ3j0YYZnRJWGfWFEGMWJmqyXln4ojhGMcACKgVFbAxY4BY2XiDiEAQ5AUCMZ5XEXxo7GiRGCTFQQaSQmB/Q2BAQKHhkGagOpdluTYKxX4RR2jTkJUe8RgaGWirDoxZpVwDmJClAWASObWwzQQDB+DcAMemB6UR0WJbBHSVZJAInnFbQkaRsYbnIhZxUriECJZSAaIeWih0SqxaBZ6PYIkcspgaWZnFaBwQgcQmbGpFaUKEkIljIBa6pSRMCYkoCWAeoWdEIyIapH3IkrFQJkgGOArpJxqxW/LnLWlE0oeiwUDACEhqdXPHDXFy4uEh4Um16b066PfsH/rRUJJPSFqIiUSKypWZoLBTJ9/rnaGHaJUeUiMk7xrL1IqLhtoFkcKIZyigg5hbEEL8FAVF122EW/Y0RLyL9VWBvxEY5azIXCY4gwoiFoWlHux0r8l2OzX2BMhnuGBHvFqSzXsa4UJJPhcR+IZjFwzlo4E+nOUFiVW89/YKoFxERzEco3ETCB9BNkpYEzIKRy8XPUV+jKrNUIUzHXGkPbQWsXK4NNRAMUWOREA1DpehIRGBHEI9torQF1HsN6sbXbQ7QjQQByL9FOBTwJ4GXeA+3tNWVqBM3HtGCk/TFEZRdBdy4B/LLE1UvAm9sC1Ooxbpg+Eo6FriB4Y9BUnUPx/3UZMuchr7+UE03BU/ik20QD3hA3eu1OmK6G5m0ELEbbOUegK1/a9rrF7WYUmmkdDo8xeM4jCQBAtiJHuUCab6x9B8dlMM8pLRUEkIHwXZCOxAHiwaH8Gyl72DrLFfhA6ASgry89zVBykFUdbHYG7F1rBCOoD/KWEC45qKBUcrDcGaBHsFW1ynpX+NsbNNYGp6nhewQLGcysUME5tHANXWOD+7S0E+GMbV8h/B8dnOcG9bFBhLiK34omiIQXzsGBYgicG5AoiQk84IlpmcAJDnACozjxiSAywBOF4MR5hWFiH8RhFYAoB6adLnWDKZIpDoCANiIAACZAAEwW8EY2uv8xAR95QBuXw8bCmEGFIKTCk/hAQjOsDg4o1IQe6dJG68iEjTI5AQK0okcEUKiPaXDZDQ04Rgr1oXto2J0cZviIRQrBAXIMgQk+AslTIqAEi0SACDA5CfsJgZTNe+WA+jYHMl5qkkIoQQLcqAIDtBIAw3wiAvA3SQT4cQyNQlf5mlBIPDBRC6CUwzUBAQE0HsGUAPiIAbDkzGOi0onLPEsbnykGPfHJLwWEFBHVVKc+EOkA7AQD++jAwUMYQASoW4IUEaCCsixgBQ+Y0CUREIIHiAABI9LjI9dJCftVE3AhUAFBZ/kAL1qhf3ZIZCEmJAKPCsGObQRACFApy+mg1AH/UJKoK/Mphnf6JYKKidw8b1lPQTzgBCEYpgM4atInMPAOuLzDPwM6iSThw0tbYNIULiqIEpggK5aMCQS29wQN3sGXfCBpURPBOCEI0C+BfEJS/WDVySxgAVpFnxJMqIdt8hOg3oxEQ4QQjLeI8QneusQEIODWSa5gKK9h2OXUKAixYgIcA/DGB4KR1ia0ixNOPIAIUCmiExTGh2Gtlz3xqom94CMDzpidPKOQu1JoUbOoVAFAxzqHta7BsZpBmhlh8dO86gGs+iMtJ37noBUyobVRs6vWFlDSUjwlX9M8QjddF07G2mGpvsUEUw4mhw1YoAApYIFvRPoG3JqCfNxV/4MFYFAAEmjgAgpogQZe4IILkGADsrHtu4SLCkD+9QsssEAKCtCB9yrABRoogAcsgF8ioOAFF3CBB8SrGeCWwbyosGk81bXTJKDAAh4gsAYUoAANdEDBFkDBE1LQAQWQwAKaUS7b+HsdW3o3xBpwgQIuYGLwWoDCVkBBAVrQggKoOC/3lCsaMByLdEDXuEuwwAs00IIda4AEBYABjMUAAxIooAMwwMMGQlyAMpv5zGhOs5rV7IEGfwECK53kASBAWyxglxjeKG5llfBdBrOBBR5owQVecOQ3jLkDF7jAidfM6EavGdGKbjMYxjmZVJ5AyVtgsi4cJz4BRjcPGyABj//Dq4ZDJ7oDkj6DqSPtZi+UAKicnXOdS0fjYdAiAgSgLJT/wIIU1Pe+ZFg1qlvNBmGn+l2EFWoILl0FTfMiKh84rRWCQ5/jIeLBEZ5wF4xN7DlwWwyvjrNWaXvncTSgAUpBbRWmVjZb2oHFLt5yFb79B3pPOtmWxrQQnJ2ZPLe7w3kQMpGNDAV7F8LgXwh3rOlsllqjwQIQl/d8qbABDaTgDwFwheiKADmNQKLLXw5zEhC+CJKzDd8OCAFzZ+0FEpP4AvgtMRUsoIAC+IFuIAgdazouuUcAWtCEHoLJIzF0LpRgznAgMQA88GUAyBwF7p0vhVksdRYUwMRhpvkL3Cv/8lBLnQ4DZAzC3F1vUZv41MfuhLALkGJJKJ3mGnB63C2QYC+TAAAF+PKQLVDfAujYu/H1uwI2gIIIFyDCXHCIOqjAAeFE+wPVpt0lep12WYzZvSS+MtsLDeo+M4HEgr+4zAGQAszH/QItEEKAS9zemtPc5jCoOdPD/ILBa6FB5rGCzslGXS18uL0jLjGW2+6G9QIfvvJ9gbyTkHmLC0HmtVe+zEcPALibGeI1r37N8w5j7mtBdEqhHxfI3nsk/B7zwt98GAI84ALDF8Eo7vYSlE4EmY8YBimQeYsX3AELJDoFIAaA8fZ3G/BlFiBoWzASfCV+W0B+5ccE5xd8mkd8/1LwYSFWYJl3YgvGeVRAf0MgcxsAXyMWdywgavGFAhvQYvGlZTu2YxdHelXmAvJHBfcQWXu1aw8oBhGYecPHgUJwY1enYzx2YgAIZKigFMiwYRyWg26wg8I3ZVXGY1imZdQAFmCxZ0zIBr/HdjM4DXvjV1iYheayF33xF58mhqmyGIzhGGeIhqnCGUPkhnLYgAA3h3YoBA54h2iYh3qYhXzYh6ZBPLeGU2EIiFpSAa2QawyoBX9oiJkxEg8Bhv/liHgiAQ4BAv+gIzpFibgSdrSgiR7HiamieOdRiKLYh+sCApskC6pYDK0IEiMAPLwyiUnwCcRgi7dYh6iAL/DUhv9CUAGL2AnAWAzDCBIG4xm1wwH4MAzKKD7MuIwgUQthxElMoBMKuAvWWIqykI0gkWfB44vRRkC8EI5KeArkCBLJsiy+qCvu8Gz48A7u2I4LgV7IODy7EnmwQDeMgY/5eI8L4V/UqATHwBhQZQoD+VS7cJCOM4994idteA+MUT2wAJH4IJETuSsWuSieIotQoQscWTUeuSsgOQ/aoEm+CACNyAgpqZK6WArRpGe0iAQr2SYtKQkzWQkBwAFcEgAF6QXrcpOIAJRBWZOlQAEGAQLauFpOIJSGwJRNSZSdsDe6JgUcwCrRwHtLCZWO4JSFwJWPoIaMcTdRUB7w+BNP4JX/goCWaamVmUCGEeAXGbCKTgACGIABuqJaR/CTbMmSxaCWjmCUW6Ar/MhzyOOXGLeXfNkfxxBPhHmWiEmTffmY9LAdGZmXhSmZQxmZ8HEPFIOXRqCXxGCYhzkTOccBoIAsuzJ2lxmamJmZINEgBJABlemTqzkMoukHt6kIEvABjCOJAWltttmanSKck9AoBPABwYgFoBmcmgkSkeULhBiTlsmazbkQU1MRJ5mbe6Cd20mclPAy2emdg8CdekCehvAJoTAK4Umd7LkQqsAK22WKRGCed0Cf9SmekHBrt5CcV7CcvGCfdgCgguALwMCfuleb/4mfaxkSx5AMy7CezNme/9aJDdoAoQlanfRQkjgCntL5mQoKCAIKdh+6CC/5jTh4BBzAj7KQosXAogqRkzvZk/UzoqdYDvIDABwwAEm5hDXKJsaDnKDYcz2KIp+IkgYqBVI1pEdSARWAlPHZoUraHCCwhirKo1GKIqY5AlVqpVfaHwxQjkrZpf0BpOklpvARi9MYpmaKHQCppmvaHCZ5om8aG6V5mnI6p5oBm7J5kni6FrvZm0dKBSHap5ZgnGQqn4SKF895D9H5m4laGtdZAYlDm4/qG6SQI5M6o5UqG8oiBCAglo66qYixEqEDqk9gNHGDlaJaGg0CpkvgDeBQlpK3qprBAXlWAVu6BFO6D//3sKPzSaO0mgl8MRyBipKis3t4kxG40BbK2qzO+qzQGq3SOq3UWq3Weq3Ymq3auq3c2q3euq2emQcMUG3nMAW7h6yFo6x+8a3Ruq7s+qzu+q7NGq/ymhH0Wq+Rw6z4qjf6uq/L6q96A6xrsJjjc4Oz6qaaGqp0CKX9iZlAOajZkQsUgBNfOgXKiGuCCZwIO34O27EMe6AfWwUQO5/ig1ZolRO6EgEyOgQP67EKy4guu7EL+7JgV7K5cLKIKrIxy6WUSrPKubM9u53f0ApmeKcNG7KCCrQJK7Mwi7Ru4IkmOgbCoSPhGlVVqwVTuyRXmwVZqxhbiwVd+wVhmweNt6H/HBqsaJu2aru2mWE0V+kFRuOrV3C2Z8u1cpkFVQkNmYoF1AYGRrOX2bChe7sW3fAN4dAFhesNrhoFDRA6EdG4s8i3jgsGZAkG7PYFUzMAIxlVu1KkprE48OC5WkCwGasFtBERp8sFqfsFdGmXorsF/vYFYuO3wmGNuYoXiZuJ9SOO8cAF7QAYv9sFwSsGpTt+GreXdCM9yRIGj2epE6ErktoFzcgXrzu3szi8nFusT0CwXYBz6Mq5jNMTX9CMt4sXKQEAK+EFjUsBuiK81xu5YAu/W0CZ6tK5bPk5xoqYzesbOhG+C9kFRnkPiwsFDXAMjEMKBbwTgwscBlyhXcCZ/wPxtVTpeAIAeV4AO7LjBYtRvnnhFFCBmPhwjKa7K/KQJBLsBCbsBfYLKRvXvcWzslUADgPMtjRcwzZ8wzicwzq8wzzcwz78w0AcxEI8xERcxIviMgBCAXrSBSSxxEbgkEYsC04ViRwMBcoYP1Uqv1HcCcHxeAAiEPTxDCTBABiAnMwSm35iEZ86ADgVbQPgJbjgxgCgxCaxDqU5x4izxZeArKFTwnWDLx25q9shloIsjt7woEMwyJObAZ8gmDoRQaKgx3u8cX0cuhchOuCAvr8QAO07BPdACoh4yZERyQDAHaapubSAARLQpAYrybVEyZ+Yye2wEZkMDhlBBJlsyXSzXARK8g0csMoUEG3yEG3esMCunAh8HMvis8uZfAzKAgISmRK7KspFAA4goBMPkY69uximesyPkMx+TM25zMnSRgQerG67/DbTwx3RtspFCjvefB0Y0JHx3BznW8/4nM/6vM/83M/+/M8AHdACPdAETQxBAAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Mean duration of exercise time to angina at different hours during days on which eight men with stable angina were given isosorbide dinitrate (ISDN) or placebo at 8 AM, 1 PM, and 6 PM (arrows). A signficant increase in exercise duration occurred after each dose of ISDN; however, the total duration of benefit was only about six hours.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Bassan MM. J Am Coll Cardiol 1990; 16:936.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26317=[""].join("\n");
var outline_f25_44_26317=null;
var title_f25_44_26318="Contents: Lipid disorders";
var content_f25_44_26318=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?1/56/1934\">",
"       Endocrinology and Diabetes",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Lipid disorders",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Lipid disorders",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/31/31222\">",
"           Measurement of serum lipids and lipoproteins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/29/33241\">",
"           Screening guidelines for dyslipidemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Pathophysiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/39/17015\">",
"           Effects of exercise on lipoproteins and hemostatic factors",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18149\">",
"           Hypercholesterolemia and atherosclerosis in primary biliary cirrhosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37274\">",
"           Inherited disorders of LDL-cholesterol metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/54/29546\">",
"           Lipid abnormalities after renal transplantation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33430\">",
"           Lipid abnormalities in nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6248\">",
"           Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/56/28550\">",
"           Lipid abnormalities in thyroid disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/45/18138\">",
"           Lipoprotein classification; metabolism; and role in atherosclerosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43621\">",
"           Secondary causes of dyslipidemia",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Treatment",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/23/10613\">",
"           ATP III guidelines for treatment of high blood cholesterol",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/39/44659\">",
"           Antihypertensive drugs and lipids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/47/35578\">",
"           Approach to the patient with hypertriglyceridemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33656\">",
"           Cholesterol lowering after an acute coronary syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/50/19240\">",
"           Clinical trials of cholesterol lowering for primary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/38/43626\">",
"           Clinical trials of cholesterol lowering in patients with coronary heart disease or coronary risk equivalents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/42/19111\">",
"           Compliance with lipid altering medications and recommended lifestyle changes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/34/2601\">",
"           Dietary fat",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/2/39978\">",
"           HDL metabolism and approach to the patient with abnormal HDL-cholesterol levels",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/25/37274\">",
"           Inherited disorders of LDL-cholesterol metabolism",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/59/3002\">",
"           Intensity of lipid lowering therapy in secondary prevention of coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/41/33430\">",
"           Lipid abnormalities in nephrotic syndrome",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/6/6248\">",
"           Lipid abnormalities in patients with chronic kidney disease not requiring dialysis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/51/28474\">",
"           Lipid lowering with diet or dietary supplements",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/14/42217\">",
"           Lipid lowering with drugs other than statins and fibrates",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/39/7800\">",
"           Lipid lowering with fibric acid derivatives",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/19/40248\">",
"           Lipoprotein(a) and cardiovascular disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/2/32\">",
"           Mechanisms of benefit of lipid-lowering drugs in patients with coronary heart disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/36/29258\">",
"           Postmenopausal hormone therapy and cardiovascular risk",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33802\">",
"           Statin myopathy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/56/24453\">",
"           Statin therapy in patients with heart failure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/35/32314\">",
"           Statins: Actions, side effects, and administration",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/63/10230\">",
"           Statins: Possible noncardiovascular benefits",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/5/10329\">",
"           Treatment of drug-resistant hypercholesterolemia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/32/10760\">",
"           Treatment of dyslipidemia in the older adult",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/32/14856\">",
"           Treatment of lipids (including hypercholesterolemia) in primary prevention",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/32/26122\">",
"           Treatment of lipids (including hypercholesterolemia) in secondary prevention",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F77CDC95E0-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f25_44_26318=[""].join("\n");
var outline_f25_44_26318=null;
var title_f25_44_26319="Chest stretch";
var content_f25_44_26319=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F64188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F64188&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Flexibility exercise: Chest",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 369px; height: 297px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This exercise, which stretches the chest muscles, is also good for your posture.",
"    <ol>",
"     <li>",
"      You can do this stretch while standing or sitting in a sturdy, armless chair.",
"     </li>",
"     <li>",
"      Keep your feet flat on the floor, shoulder-width apart.",
"     </li>",
"     <li>",
"      Hold arms to your sides at shoulder height, with palms facing forward.",
"     </li>",
"     <li>",
"      Slowly move your arms back, while squeezing your shoulder blades together. Stop when you feel a stretch or slight discomfort.",
"     </li>",
"     <li>",
"      Hold the position for 10 to 30 seconds.",
"     </li>",
"     <li>",
"      Repeat at least three to five times.",
"     </li>",
"    </ol>",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Go4Life. National Institute on Aging at the National Institutes of Health. Available at: file://go4life.niapublications.org (Accessed December 2, 2011).",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f25_44_26319=[""].join("\n");
var outline_f25_44_26319=null;
         